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Abbreviations  
 
Abl Abelson tyrosine kinase 
aFGF  Acidic fibroblast growth factor 
ATP Adenosine triphosphate  
bFGF Basic fibroblast growth factor 
BOP-Cl Bis(2-oxo-3-oxazolidinyl)phosphinic chloride 
BT-474 Human breast tumor cell line 
CML Chronic myeloid leukemia  
CPT Camptothecin  
CTCL Cutaneous T-cell lymphoma 
CuAAC Copper(I) catalyzed alkyne-azide cycloaddition 
DCC N,N′-Dicyclohexylcarbodiimide 
DFT Density functional theory 
DIBAL Diisobutylaluminum hydride 
DIC N,N′-Diisopropylcarbodiimide 
DIPEA N,N-Diisopropylethylamine  
DMAP 4-(Dimethylamino)pyridine 
DMC 2-Chloro-1,3-dimethylimidazolinium chloride 
DMP Dess-Martin periodinane  
DMF N,N-Dimethylformamide  
DMSO Dimethylsulfoxide  
DNA Deoxyribonucleic acid  
ECs Endothelial cells  
EDC N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide 
EGF Epidermal growth factor 
EGFR Epidermal growth factors receptor 
ERG Electron releasing group 
EWG Electron withdrawing group 
FBS Fetal bovine serum  
FDA Food and drug administartion 
FGF Fibroblast growth factor 
GTL-16  Human gastric carcinoma cell line 
HATU O-(7-Azabenzotriazol-1-yl)-N,N,N′,N′tetramethyluroniumhexafluorophosphate 
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HepG2 Human hepatocellular liver carcinoma  
HGF Hepatocyte growth factor 
HOBt 1-hydroxybenzotriazole  
MCF7 Human breast cancer cell line 
MDA-MB231 Human breast cancer cells 
MDCK Madin darby canine kidney cell line 
MDR Multidrug resistance  
MeOH Methanol  
Met Hepatocyte growth factor receptor or scatter factor receptor 
MHz Mega Hertz  
MMPs  Matrix metalloproteinases 
MW Microwave 
NCI National cancer institute  
NMR  Nuclear magnetic resonance  
NOEs  Nuclear overhauser effects  
NP  Natural product  
NRTK Non receptor tyrosine kinase 
NSCLC  Non-Small cell lung carcinoma  
PDGF  Platelet derived growth factor  
PDGFR Platelet derived growth factor receptor 
PTK Protein tyrosine kinase  
RNA  Ribonucleic acid 
RTK  Receptor tyrosine kinase 
SF Scatter factor 
SPR Surface plasmon resonance 
TEA  Triethylamine 
T-cells  Thimus cells 
TCR  Thimus cell antigen receptor 
THF  Tetrahydrofuran 
TK Tyrosine kinase 
TKI Tyrosine kinase inhibitor 
TLC  Thin-layer chromatography 
TSP-1 Thrombospondin-1   
VEGF  Vascular endothelial growth factor  
VEGFR Vascular endothelial growth factor receptor 
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1.1  Cancer 
Cancer is one of the most studied diseases in the world. Its mortality rates are second 
only to cardiovascular diseases. After a quarter century of rapid advances, cancer 
research has generated a rich and a complex body of knowledge, revealing that cancer is 
a disease involving dynamic changes in the genome.[1] Cancer can be defined as a disease 
caused by a series of cumulative genetic changes that occur in a normal cell. These 
genetic mutations cause cellular transformations and evolutions, which can lead to an 
uncontrolled growth of abnormal cells.[2] Moreover, these mutated cells can invade 
nearby tissues and spread to distant sites using bloodstream and lymphatic system. 
Actually we can define two different kind of tumors classified by their aggressiveness: the 
benigns, which featured by only local growth, and the maligns, in which the most 
important characteristics are the invasiveness and the potential occurrence of 
metastasis.[3] 
 
 
Figure 1: Cancer Cells. 
 
1.2  Anticancer drugs 
Most of the antitumoral drugs which used nowadays for cancer treatment are referred as 
cytotoxic agents because of their ability to kill directly the cancer cells. They are usually 
used in combination with other treatments like radiotherapy or surgery to increase the 
efficiency but they show their cytotoxic activity also in healthy cells. The selectivity and 
the efficiency of these drugs on tumoral cells are usually due to the faster growth 
compared to normal cells.[4]  
                                                           
[1]  D. Hanahan, R.A. Weinberg, The hallmarks of cancer, Cell 2000, 100, 57-70. 
[2]  G.C. Prendergast, E.M. Jaffee, Cancer immunologists and cancer biologists: Why we didn't talk then 
 but need to now, Cancer Res. 2007, 67, 3500-3504.  
[3]  P. Vineis, Definition and classification of cancer- monothetic or polythetic, Theor. Med. 1993, 14, 249-
256.  
[4]  C. Leonetti, G. Zupi, Targeting different signaling pathways with antisense oligonucleotides 
 combination for cancer therapy, Current Pharmaceutical Design 2007, 13, 463-470.  
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However, some kind of normal cells, like the bone marrow ones, grow fast and they can 
easily interact with antitumoral drugs. This relevant problem causes some collateral 
effects that can weaken the immune system and make intolerable the therapy for the 
patients. Another problem of chemotherapy is the issue of multidrug resistance (MDR) 
Tabella 1. 
 
 
Table 1: Mechanism of drug resistance. 
 
MDR occurs when cells, which have been once destroyed by a particular drug, they no 
longer respond to the treatment. It can be intrinsic, referred to tumors that are naturally 
unaffected by such a kind of drugs, or acquired, when it appears after some treatments 
because of an evolution of the tumor cells. For this reason the activity of the drug 
decreases. A tumor cell can express this phenomenon in different ways such as a reduced 
uptake of the drug, an increase in the production of proteins that repair the DNA-drug 
adducts, a different metabolic pathway that activates the tumoral cell or a development 
of drug expulsion mechanisms.[5]  
 
 
                                                           
[5]  D.B. Zamble, S.J. Lippard, Cisplatin and DNA repair in cancer chemotherapy, Trends Biochem. Sci. 1996, 
21, 38-38. 
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For this reason the discovery of new targets for cancer therapies is very important, for 
instance: 
- DNA, 
- protein tyrosine kinases (PTKs) 
- tubulin and microtubules 
- enzymes like Topoisomerase II or Histone Deacetylases 
 
In the following Table 2 is summarized a recent classification of anticancer drugs based on 
their biological target.[6] 
 
 
Table 2: New proposed classification of anticancer drugs. 
 
                                                           
[6] X.Z. Wu, A new classification system of anticancer drugs - Based on cell biological mechanisms, 
Medical Hypotheses 2006, 66, 883-887.   
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Depending from the desired target, it can be appeared a different mechanism of action. 
Some drugs do not directly act with DNA and cause cell apoptosis by inhibiting other 
targets. Examples of these anticancer drugs are taxanes and Vinca alkaloids (for example 
Vinblastin and Vincristin), which interfere with the polymerization or depolymerization of 
microtubules. The consequence is the alteration of the mitotic spindle, causing inhibition 
of the cellular proliferation.[7] Other drugs act on particular enzymes that regulate the 
replication processes like Topoisomerase II or Histone deacetylase.[8] Finally, anticancer 
drugs can interact directly with the DNA in different ways. For example they can bind the 
nucleobases, like alkylating agents,[9] cisplatin and derivatives,[10] causing distortion and 
blocking the process of the DNA replication. Moreover, they can also cleave the DNA 
strands like some metals complexes such as Bleomycin,[11] Rutenium dimers[12] and so on. 
In the end, anticancer drugs can act on protein tyrosine kinases (PTKs), which are involved 
in several cellular functions leading to cancer. In particular they have a main role in new 
blood vessels formation, a phenomenon well known as angiogenesis. This is a 
fundamental key step in the formation and growth of solid tumors.       
 
1.3  Angiogenesis 
Angiogenesis, the sprouting of new capillaries from the pre-existing blood vessels, is a 
complex process involving many biological and cellular functions. Angiogenesis is a 
biological protocol that has a relevant role in many diseases. It happens in normal 
physiological processes, such as embryonic development, the female menstrual cycle, 
bone remodelling and wound healing. On the other hand, angiogenesis also plays a crucial 
role in many pathological conditions, including ocular diseases, such as diabetic 
retinopathy, retinopathy of prematurity and age-related macular degeneration; vascular 
diseases such as ischemic heart disease and atherosclerosis; chronic inflammatory 
disorders such as psoriasis and rheumatoid arthritis and tumor growth.[13] For all these 
reasons angiogenesis is an important biological target in drug discovery. 
 
 
                                                           
[7]  S. Sharma, T. Ganesh, D.G.I. Kingston, S. Bane,  Promotion of tubulin assembly by poorly soluble 
 taxol analogs,  Anal. Biochem. 2007, 360, 56-62. 
[8]  J.M. Mehnert, W.K. Kelly, Histone deacetylase inhibitors: Biology and mechanism of action, Cancer J. 
2007, 13, 23-29.  
[9]  J.T. Millard, R.J. Spencer, P.B. Hopkins, Effect of nucleosome structure on DNA interstrand cross-linking 
reactions, Biochem. 1998, 37, 5211-5219. 
[10]  D. Lebwohl, R. Canetta, Clinical development of platinum complexes in cancer therapy: an historical 
perspective and an update, Eur. J. Cancer 1998, 34, 1522-1534.  
[11]  R.M. Burger, Cleavage of nucleic acids by bleomycin, Chem. Rev. 1998, 98, 1153-1169.  
[12]  T.K. Janaratne, A. Yadav, F. Ongeri, F.M. MacDonnell, Preferential DNA cleavage under anaerobic 
conditions by a DNA-binding ruthenium dimer, Inorg. Chem. 2007, 46, 3420-3422. 
[13] L.K. Shawver, K.E. Lipson, T.A.T.  Fong, G. McMahon, G.D. Plowman, L.M. Strawn, Receptor tyrosine 
kinases as targets for inhibition of angiogenesis, DDT 1997, 2, 50-63.  
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1.3.1  Angiogenesis and cancer 
The role of angiogenesis in tumor growth was firstly described by Folkman (1971).[14] He 
found that in most cases solid tumors growth is accompanied by neovascularisation: new 
capillary growth is induced by diffusible growth factor generated by malignant tumor 
cells.[15] Results obtained in the 1970s have led to the conclusion that new blood vessel 
formation is essential for the growth and metastasis of solid tumors. Angiogenesis is a 
vital process in the progression of cancer from small and localized neoplasms to larger, 
growing and potentially metastatic tumors. To grow beyond 1 to 2 mm in diameter, a 
tumor needs an independent blood supply, which is acquired by expressing growth 
factors that recruit new vasculature from existing blood vessels and This process 
continues even the tumor matures. Thus, upregulation of angiogenesis is a key step in 
sustained tumor growth and may also be critical for tumor metastasis.[16] Folkman studies 
showed that angiogenesis depends on the tight regulation of factors that promote or 
inhibit this biological event (Table 3). 
 
Angiogenic factors Anti-angiogeic factors 
Basic fibroblast growth factor (bFGF) Plateled factor 4 
Acidic fibroblast growth factor (aFGF) Thrombospondin-1 
Transforming growth factor (TGF) Transforming growth factor-b 
Plateled-derived growth factor (PDGF) Interferon-a 
Insulin-like growth factor (IGF) Prolactin fragment 
Vascular endothelial growth factor (VEGF) Angiostatin 
Hepatocyte growth factor (HGF) Tissue inhibitors of metalloproteinases 
Angiogenin TIMP-1 
Prostaglandine E1 and E2 TIMP-2 
Tumor necrosis factor-a (TNF-a) TIMP-3 
Growth hormona bFGF soluble receptor 
 
Table 3: Angiogenic and anti-angiogenic factors. 
 
1.3.2  Angiogenic switch-on 
It has been proposed by Hanahan and Folkman[17] (1996) that there is a “switch” that 
perturbs the balance between pro-angiogenic and anti-angiogenic factors (Figure 2).  
 
                                                           
[14] J. Folkman, Tumor Angiogenesis: Therapeutic Implications, N. Engl. J. Med. 1971, 285, 1182-1186.  
[15]  J. Folkman, Anti-Angiogenesis: New Concept for Therapy of Solid Tumors, Ann. Surg. 1972, 175, 409-
416.  
[16]  N. Ferrara, K.J. Hillan, H.P. Gerber, W. Novotny, Discovery and development of bevacizumab, an anti-
VEGF antibody for treating cancer, Nat. Rev. Drug. Discov. 2004, 3, 391-400. 
[17]  J. Folkman, D. Hanahan, Patterns and emerging mechanisms of the angiogenic switch during 
tumorigenesis, Cell 1996, 86, 353-364. 
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Figure 2: The balance hypothesis for angiogenic switch-on.  
 
The angiogenic switch-on has been suggested to be a component of the tumor phenotype 
that is often activated during the preneoplasic step in tumor development. When the 
balance is perturbed, uncontrolled angiogenic factors, released from hypoxic tumor cells, 
migrate to nearby blood vessel endothelium, which signals the activation of biochemical 
events leading to the angiogenic process. Endothelial cells are stimulated to proliferate, 
migrate to the tumor site and form new capillaries to supply oxygen and nutrients to the 
growing tumor (Figure 3).  
 
 
Figure 3: To grow beyond 1 to 2 mm in diameter, a tumor needs an independent blood supply, which 
is acquired by expressing growth factors that recruit new vasculature from existing blood vessels. This 
process continues even as the tumor matures. 
An adequate supply of oxygen and nutrients is critical for homeostasis of virtually all 
human cells and tissues. This delivery of oxygen and nutrients, and the corresponding 
elimination of metabolic waste and carbon dioxide, depends on the vascular system. 
Accordingly, the formation of new tissues is systematically coordinated with the 
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formation of a new vasculature. In this process, endothelial cells, the primary building 
blocks of vasculature, must undergo four major steps (Figure 4): [18]   
- Breaking through of the basal lamina that envelopes existing blood vessels 
- Migration toward a source signal 
- Proliferation 
- Formation of tubes 
 
 
 
Figure 4: Angiogenesis is a complex mechanism involving several biological processes. a) small non-
angiogenic tumor; b) invasion and migration of endothelial cells through the basement membrane; c) 
extension of vessels into the tumor. 
 
A large number of pro-angiogenic growth factors have been identified, many of which are 
able to induce all the four of the above steps mentioned. One of the primary factors 
among them is a protein known as vascular endothelial growth factor (VEGF). 
                                                           
[18]  C. Sturk, D. Dumont, The Basic Science of Oncology - fourth edition 2005. 
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1.3.3  Angiogenesis inhibition 
Without the supplement of blood circulation and with the angiogenesis inhibition, tumor 
growth is dramatically impaired. With the absence of an adequate vascularisation, tumor 
cells become necrotic[19] and apoptotic[20]. Conversely, if a tumor becomes vascularised, its 
mass can rapidly expand. These newly formed vessels not only promote tumor growth, 
but also cause the tumor cells to become malignant and metastatic. Due to the reasons 
previously cited, the inhibition of angiogenesis has become an attractive target in 
anticancer treatment. The concept of the anti-angiogenic therapy of cancer is based on 
tumor growth prevention.[21] Subsequently, it was also recognized, that metastasis can be 
affected by angiogenesis. For these reasons, inhibitors of angiogenesis are expected to be 
valuable drugs for cancer therapy. Importantly, because endothelial cells have a stable 
genome, acquired drug resistance is not expected,[22] and, in addition, the possible side 
effects of an anti-angiogenic therapy should be limited. Inhibitors of angiogenesis may 
represent not only new anticancer agents but also may offer the possibility for 
therapeutic intervention in several diseases like rheumatic diseases, endometriosis, 
psoriasis and diabetic retinopathy. In this context, protein kinases (PKs) possessed a 
central role because they are involved in several genetic programs like: tumor growth, 
invasive growth, metastatic process, suppression of apoptosis and angiogenesis. 
Extensive efforts have been made to identify and develop small-molecule inhibitors of 
these central signalling proteins. Some of these compounds have already been approved 
or are currently in clinical trials to examine their applicability as anticancer drugs (Table 
4). In particular the angiogenesis inhibitors have an important role in combined 
anticancer therapies. They show their maximum effect in combination with classical 
anticancer agents or others techniques like radiotherapies or surgeries.  
 
 
 
 
 
 
                                                           
[19]  S. Brem, H. Brem, J. Folkman, D. Finkelstein, A. Patz, Prolonged Tumor Dormancy by Prevention of 
Neovascularization in the Vitreous, Cancer Res. 1976, 36, 2807-2812. 
[20]  L. Holmgren, M.S. Oreilly, J. Folkman, Dormancy of Micrometastases - Balanced Proliferation and 
Apoptosis in the Presence  of Angiogenesis Suppression, Nat. Med. 1995, 1, 149-153.  
[21]  R. Kerbel, J. Folkman, Clinical translation of angiogenesis inhibitors, Nat. Rev. Cancer. 2002, 2, 727-739. 
[22]  R. Karbel, A cancer therapy resistant to resistance, Nature 1997, 390, 335-336. 
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With this double approach, the use of an angiogenesis inhibitor combined with a 
chemotherapic treatment is possible to maximize the inhibition of cancer growth and 
metastasis. 
 
Generic name Brand name Number Date approved Known targets Disease 
Fasudil - HA-1077 1999 ROCK 
Cerebral 
vasospasm 
Imatinib Gleevec STI-571 2001 
Abl, ARG, 
PDGFR, Kit 
CML, 
gastrointestinal 
stromal tumors 
Nilotinib Tasigna AMN107 2007 
Abl, ARG, Kit, 
PDGFR 
CML with resi 
stance to imatinib 
or intolerance 
Dasatinib Sprycel 
BMS-
354825 
2007 
Abl, ARG, Kit, 
PDGFR, Src and 
oth. 
CML with resi 
stance to imatinib 
or intolerance 
Gefitinib Iressa ZO-1839 2004 EGFR 
Non-small-cell 
lung cancers 
(especially 
adenocarcinomas) 
Erlotinib Tarceva OSI-774 2004 EGFR 
Non-small-cell 
lung and 
pancreatic 
carcinomas  
Lapatinib Tykerb GW572016 2007 
EGFR (Erb8-1, 
Erb8-2) 
Breast cancer, 
Her2-positive 
Sorafenib Nexavar BA 43-9006 2006 
8-Raf, VEGFR, 
PDGFR, FLT3, c-
Kit 
Renal cell 
carcinoma 
Sunitinib Sutent SU11248 2006 
VEGFR, PDGFR, 
FLT3, c-Kit 
Renal cell 
carcinoma, 
gastrointestinal 
stromal tumors 
Temsirolimus Torisel CCI-779 2007 mTOR 
Renal cell 
carcinoma 
 
Table 4: small-molecule inhibitors of PKs approved by FDA. 
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1.4  Judah Folkman  
Moses Judah Folkman: 1933 - 2008 
 
Born in Cleveland in 1933, Folkman graduated cum laude 
from The Ohio State University, Columbus, Ohio, in 1953. He 
continued his education at Harvard Medical School, where he 
graduated magna cum laude in 1957. Folkman began his 
surgical residency at the Massachusetts General Hospital and 
served as chief resident in surgery from 1964-1965. 
As a student, Folkman co-authored papers describing a new method of hepatectomy for 
liver cancer and developed the first atrio-ventricular implantable pacemaker for which he 
received the Boylston Medical Prize, Soma Weiss Award and Borden Undergraduate 
Award in Medicine. 
While serving as a lieutenant in the U.S. Navy from 1960-1962, Folkman and a colleague 
at the National Naval Medical Center, Bethesda, MD, first reported the use of silicon 
rubber implantable polymers for the sustained release of drugs. Their findings became 
the basis for development of Norplant, the contraceptive used internationally, and 
initiated the field of controlled release technology. At this time, Folkman also began to 
grow tumors in isolated perfused organs, which led to the idea that tumors are 
angiogenesis-dependent. 
In 1971 Folkman published a seminal paper in the New England Journal of Medicine, 
proposing the hypothesis that all tumor growth is angiogenesis-dependent. This founded 
the field of angiogenesis research and opened a field of investigation now pursued by 
scientists in many fields worldwide. Folkman's laboratory purified the first angiogenic 
protein from a tumor, discovered the first angiogenesis inhibitors and initiated clinical 
trials of antiangiogenic therapy. Today, angiogenesis inhibitors have received FDA 
approval in the U.S. for cancer and for the treatment of macular degeneration and are 
also approved in 27 other countries. Largely because of Folkman's research, the 
possibility of antiangiogenic therapy is now on a firm scientific foundation, not only in the 
treatment of cancer, but of many non-neoplastic diseases as well. 
Folkman is the author of 389 original peer-reviewed papers and 106 book chapters and 
monographs. He also holds honorary degrees from fifteen universities and is the recipient 
of numerous national and international awards. He has been elected to the National 
Academy of Sciences, the American Academy of Arts and Sciences, the American 
Philosophical Society and the Institute of Medicine of the National Academy of Sciences. 
In addition to his distinguished accomplishments in research, Folkman has served as a 
surgeon and teacher. He began his career as an instructor in surgery for Harvard's Surgical 
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Service at Boston City Hospital Boston, was promoted to Professor of Surgery at Harvard 
Medical School, and became the Julia Dyckman Andrus Professor of Pediatric Surgery in 
1968. From 1967 he served as Surgeon-in-Chief at the Children's Hospital Boston for 14 
years. Dr. Folkman is also a Professor of Cell Biology at Harvard Medical School and is 
currently Director of the Vascular Biology Program at Children's Hospital Boston. 
Angiogenesis inhibitors are now approved by the FDA in the U.S., for cancer and for 
macular degeneration and have received approval in 27 other countries. They have 
developed specific and sensitive angiogenesis-based biomarkers in blood and urine 
capable of detecting microscopic human cancers in mice. In pre-clinical studies, 
antiangiogenic therapy of these mice is guided by biomarkers until the biomarkers decline 
to normal levels. These results suggest the possibility of treating human cancer years 
before it becomes symptomatic, and before it can be anatomically located. 
 
1.5  Aim of the project 
The topic of this thesis is part of a multidisciplinary project that regards the preparation of 
selective anticancer compounds. In particular we faced the design, synthesis and 
biological exploitation of new tyrosine kinase inhibitors (TKIs). We focused our 
attemption and two different TKs:  
- Met (chapter III); 
- Abl (chapter IV). 
The importance of Abl and Met against cancer and angiogenesis led several research 
groups to look for small molecules able to interact and block the dangerous activity of 
these kind of TKs. 
In both cases we considered the situations of well known inhibitors and the three-
dimensional structure of the biological targets. We designed new scaffolds to be decored 
to generate different quality collections of possible inhibitors. 
The biological evaluation was developed in strict collaboration with different research 
groups. The activity toward cancer cells was considered as first instance. Then we moved 
to evaluate the activity toward single biological targets. The compounds with appreciable 
performance were selected for in vivo tests. For this reason the preparation in grams 
scale of the selected compounds was developed. 
The biological studies were faced to confirm the activity of any new compound and to 
ascertain the biological mechanism of action. Further, the biological evaluation resulted 
useful to confirm the reliability of the modelling study.  
24 
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Chapter II: Tyrosine kinases 
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2.1  Tyrosine kinases (TKs) 
Over 500 human genes encode protein kinases, and these can be grouped into a number 
of subsets based primarily on sequence and structural similarities.[23] In general, protein 
kinases catalyze the transfer of the terminal phosphoryl group of ATP to specific hydroxyl 
groups of serine, threonine or tyrosine residues of their protein substrates. The protein 
phosphorylation controls a wide range of cellular and pathogenic processes, thus even 
subtle changes in protein kinase activity can lead to a variety of diseases, including 
cancer.[24] In this family, protein tyrosine kinases (PTKs) have a relevant place, because 
they play an essential role in signalling pathways involved in the control of cellular 
proliferation and growth. Figure 5 shows the six hallmarks which lead to cancer.[25] 
Biologists suggest that the most part of cancers have acquired the same set of functional 
capabilities during their development, although through various mechanistic strategies. 
PTKs have a relevant role in the most part of these functions. 
 
 
Figure 5: Six hallmarks leading to cancer. 
 
PTKs function is the transmission of extracellular signals through a complex signalling 
pathway, to induce a specific genetic program like growth and migration. TKs can be 
subdivided into two large families: receptor tyrosine kinases (RTKs) and non-receptor 
tyrosine kinases (NRTKs). RTKs span the plasma membrane and contain an extracellular 
portion, which binds the ligands, and an intracellular portion, which possesses the 
                                                           
[23]  G. Manning, D.B. Whyte, R. Martinez, T. Hunter, S. Sudarsanam, The protein kinase complement of the 
human genome, Science 2002, 298, 1912-1934. 
[24]  M.A. Bogoyevitch, D.P. Fairlie, A new paradigm for protein kinase inhibition: blocking phosphorylation 
without directly targeting ATP binding, DDT 2007, 12, 622-633.  
[25] D. Hanahan, R.A. Weinberg, The hallmarks of cancer, Cell 2000, 100, 57-70. 
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residues responsible for catalytic activity and some regulatory sequences (Figure 6). The 
RTKs family includes the insulin receptor and the receptors for many growth factors such 
as epidermal (EGF), platelet-derived (PDGF), fibroblast (FGF) and vascular endothelial 
(VEGF). On the other hand, NRTKs are cytoplasmic proteins, without an extracellular or 
transmembrane portion but with modular domains that are responsible for subcellular 
targeting and regulation of the catalytic activity. The NRTK family includes Src, Abl, FAK 
and many others. 
 
Figure 6: Receptor tyrosine kinase (RTK). 
 
 
2.1.1  Receptor tyrosine kinases (RTKs) 
More than 16 distinct RTKs families are known and the members are grouped on the base 
of their structure (Figure 7). The RTKs can be broadly divided into two groups depending 
on the covalent organization of the receptor. Most RTKs possess a single polypeptide 
chain and are monomeric in the absence of a ligand. Members of the insulin receptor 
subfamily, which includes insulin-like growth factor-1 receptor, are disulfide-linked dimers 
of two polypeptide chains, forming a heterotetramer.  
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The ligand which binds to the extracellular portion of RTKs leads to the dimerization of 
the monomeric receptors or to a rearrangement within the quaternary structure of the 
heterotetrameric receptors, resulting in auto-phosphorylation of specific tyrosine 
residues in the cytoplasmic portion. 
 
 
Figure 7: RTKs families. 
 
In every case each RTKs has a comparable skeleton that could be classified as below: [26] 
- extracellular domain 
- transmembrane domain 
- juxtamembrane domain 
- catalytic domain 
- C-terminal domain 
 
The extracellular domain region contains the high-affinity binding site for the growth 
factor proteins. This domain diverges among the different receptor families, and appears 
with various structural motifs which have two basic functions. Some motifs participate in 
the formation of tridimensional configurations to ensure binding site stability and 
specificity for growth factors and others mediate receptor dimerization, which is critical 
for kinase activation and signal transduction. Every receptor family has a corresponding 
growth factor and each receptor generally binds one single factor with high affinity. 
                                                           
[26]  P. Longati, P.M. Comoglio, A. Bardelli, Receptor tyrosine kinases as therapeutic targets: The model of 
the MET oncogene, Curr. Drug Targets 2001, 2, 41-55. 
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The Transmembrane Domain region contains about twenty-five hydrophobic residues 
which included in the cellular lipid bilayer. Single point mutations in this domain can 
dramatically alter the tyrosine kinase activity of the receptor. 
Juxtamembrane Domain region is located in the cytoplasm. This region is involved in the 
modulation of receptor activity by adjacent signalling molecules, receptors or 
transducers. 
The Catalytic Domain region is responsible for the tyrosine kinase activity and it is 
composed of about 250 aminoacids. The kinase domain is composed of two lobes 
delimiting a central cleft. In the central cleft, the protein substrate and the complex ATP-
Mg++ ions are brought together and the phosphotransfer reaction takes place. The N-
terminal lobe contains a glycine-rich motif and the lysine residue critical for ATP binding. 
Protruding onto the central cleft is the catalytic loop, in which an aspartic residue is the 
catalytic base and other residues allow recognition of tyrosine substrate. The C-terminal 
lobe contains a second loop, known as the activation loop, frequently including 1 to 3 
tyrosine residues with regulatory functions. Mutations in the kinase activation loop are 
responsible for the kinase activity switch on in the absence of ligands.     
C-Terminal Tail includes up to 200 aminoacid residues. Its length and function are variable 
in different receptors. This segment binds the intracellular signal transducer after the 
receptor activation.  
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2.1.2  RTKs activation
[27] and signal transduction  
The activation loop of RTKs is relatively mobile and probably adopts numerous 
conformations (Figure 8). In the absence of a ligand, such as a growth factor, the steric 
hinderance around the catalytic site inhibits the tyrosine(s) phosphorylation mediated by 
ATP. This conformation (Figure 8 in red) prevents the binding of protein substrates and 
ATP.  
 
Figure 8: RTK activation mechanism. 
 
But when a ligand binds to the extracellular domain, induces the dimerization of the 
receptor and changes in the conformation of the activation loop (Figure 8 in green) which 
lead to the redaction of the catalytic site steric hinderance. Then ATP is able to get into 
the activation loop and the transphosphorylation can be occured. Transphosphorylation 
of the activation-loop tyrosine(s) residues shifts the receptor from inactive to the active 
state. Once an RTK is activated it triggers the signal transduction. This downstream signal 
(recruitment and activation of cytoplasmic signalling molecules) induces the appropriate 
cellular response: tumor growth, invasive growth, metastatic process, apoptosis 
inhibition, angiogenesis and so on. The knowledge of the RTKs activation mechanism can 
be used for the design of three different approaches to block the signal transduction: 
- inhibition of ligand binding with a specific receptor-binding antagonist, 
- interference with the RTKs activation loop to prevent the transphosphorylation,  
- interference with the downstream signal on cytoplasmic signalling molecules. 
                                                           
[27]  S.R. Hubbard, M. Mohammadi, J. Schlessinger, Autoregulatory mechanisms in protein-tyrosine kinases, 
J. Biol. Chem. 1998, 273, 11987-11990. 
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A number of RTKs are also involved in angiogenesis, directly or indirectly. Of particular 
interest is the vascular endothelial growth factor receptor (VEGFR), which plays a relevant 
and direct role in angiogenesis. Other RTKs of potential interest in angiogenesis are: the 
epidermal growth factor receptor (EGFR), the platelet derived growth factor receptor 
(PDGFR) and hepatocyte growth factor receptor HGFR) better known as Met receptor. 
These last three RTKs play an indirect role for the production of VEGF.   
 
2.2  Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) 
In the last thirty years a number of inducers of angiogenesis have been detected. The first 
which discovered in 1982 was the basic fibroblast growth factor (bFGF or FGF-2) followed 
shortly by the acid analogues[28] (aFGF or FGF-1). At about the same time, a secreted 
protein was identified by its ability to elicit vascular permeability. Subsequently this 
factor, called vascular endothelial growth factor[29] (VEGF), showed to be the most potent 
inducer of angiogenesis. VEGF is commonly expressed in a wide variety of human and 
animal cancer. Recently, two related endothelial growth factors, VEGF-B and VEGF-C, 
have been identified. An important point to take into consideration is that VEGF 
production and subsequent angiogenesis can be triggered by a number of factors in the 
cellular microenvironment but hypoxia (Figure 9) remains one of the most important 
trigger of VEGF expression even once a tumor becomes vascularized.  
 
 
Figure 9: This image illustrates hypoxic conditions in a tumor: cells closest to vasculature have a 
sufficient supply of oxygen, whereas oxygen supply diminishes further from blood vessels. As the 
oxygen supply decreases, cells become hypoxic (light purple areas) and later necrotic (grey areas).
 
 
 
                                                           
[28]  J. Folkman, Y. Shing, Angiogenesis, J. Biol. Chem. 1992, 267, 10931-10934. 
[29]  N. Ferrara, Vascular Endotelial Growth-Factor, Trends. Cardiovasc. Med. 1993, 3, 244-250. 
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Without an independent blood supply, tumors must depend on diffusion to obtain oxygen 
and other nutrients and typically cannot proliferate. Thus, a growing tumor without 
sufficient vasculature will be in hypoxic state, which is the lack of oxygen. In response to 
hypoxic conditions, tumors secrete, with several strategies involving PKs and VEGF in 
order to recruit new vasculature, which then provides a supply of oxygen.[30] As the tumor 
grows, continually outgrows its existing blood supply, leaving an area of necrotic and 
hypoxic tissue. Due to its main and direct role in vascularization processes VEGF and its 
receptors are one on the key targets against angiogenesis. Particularly, the inhibition 
occurs with the use of small molecules which blocks the receptor signal transduction 
(Figure 10). 
 
 
Figure 10: VEGFR small molecule inhibitors. 
 
 
                                                           
[30] M.A. Gimbrone, S.B. Leapman, R.S Cotran, J. Folkman, Tumor Dormancy in vivo by Prevention of 
Neovascularization, J. Exp. Med. 1972, 136, 261-276. 
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2.3  Met receptor 
Met receptor (Figure 11) is a RTK based on a dimeric molecule composed of a 50 kDa α-
chain disulfide linked to a 145 kDa β-chain in an α-β complex of 190 kDa.[31] Met is 
activated by its corresponding ligand hepatocyte growth factor (HGF), that triggers 
specific program leading to invasive growth, cell migration, cell survival, embryogenesis, 
organ regeneration, and neoplasia.[32] 
              
Figure 11: Met receptor. 
 
In addition, it was demonstrated that HGF-Met is a powerful inducer of angiogenesis,[33] 
which is mediated through their mitogenic effect on endothelial cells. HGF-Met is also 
able to stimulate the expression of pro-angiogenic factors like VEGF (Figure 12) and to 
downregulate angiogenesis inhibitors like thrombospondin-1 (TSP-1).[34] HGF is a heparin 
binding glycoprotein that consists of a 60 kDa α-chain and 30-kDa β-chain linked by 
disulfide bonds. In particular HGF, also known as scatter factor (SF), has the main function 
to induce cellular migration. This cellular spreading is a fundamental requirement for the 
metastatic process and for angiogenesis. The overexpression[35] of Met has been 
demonstrated in several malignant tumors such as breast, esophagus, prostate, pancreas, 
                                                           
[31]  E.M. Rosen, I.D. Goldberg, Scatter factor and angiogenesis. Adv. Cancer Res. 1994, 67, 257-279. 
[32] E.M. Rosen, S.K. Nigam, I.D. Goldberg, Scatter factor and the c-Met receptor: a paradigm for 
mesenchymal-epithelial interaction, J. Cell. Biol. 1994, 127, 1783-1787.  
[33]  S. Wagatsuma, R. Konno, S. Sato, A. Yajima, Tumor angiogenesis, hepatocyte growth factor, and c-Met 
expression in endometrial carcinoma, Cancer 1998, 82, 520-530. 
[34] G. Dong, Z. Chen, Z.Y. Li, N.T. Yeh, C.C. Bancroft, C. Van Waes, Hepatocyte growth factor/scatter factor-
induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic 
cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell 
carcinoma, Cancer Res. 2001, 61, 5911-5918. 
[35] S. Patane, N. Pietrancosta, H. Hassani, V. Leroux, B. Maigret, J.L. Kraus, R. Dono, F. Maina, A new Met 
inhibitory-scaffold identified by a focused forward chemical biological screen, Biochem. Biophys. Res. 
Commun. 2008, 375, 184-189. 
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kidney and bon.[36] Also, in in vivo models Met has showed to induce invasiveness and 
metastasizing capacity. For all these reasons and in particular for its over expression, the 
use of selective Met inhibitors, could lead to new anticancer therapies with more 
selectivity then the classic chemotherapy and, consequently, with less side effects for the 
patients.  
 
 
 
Figure 12: Dose dependent induction of VEGF and Gro-1/KC by HGF-Met in Pam 212 and LY cell lines.  
 
 
 
 
 
 
 
                                                           
[36] C. Kuhnen, T. Muehlberger, M. Honsel, E. Tolnay, H.U. Steinau, K.M. Muller, Impact of c-Met 
expression on angiogenesis in soft tissue sarcomas: correlation to microvessel-density, J. Cancer Res. 
Clin. Oncol. 2003, 129, 415-422. 
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2.4  Abelson tyrosine kinase (Abl) 
Abelson Tyrosine Kinase (Abl)[37] is a non-receptor of about 1150 residues. The N-terminal 
half (about 530 residues) contains two peptide binding units (the SH2 and SH3 domains) 
followed by a tyrosine kinase domain, whereas the C-terminal half contains DNA-binding 
domains interspersed with sites of phosphorylation and other short recognition motifs 
(Figure 13). 
 
 
Figure 13: Abl protein. 
 
The kinase domain presents a bilobal structure: the N-lobe contains a β-sheet and one 
conserved α-helix, the C-lobe is largely helical. At the interface between the two lobes, a 
highly conserved sequence of aminoacidic residues forms the ATP-binding pocket and the 
catalytic site. It was showed[38] that Abl is involved in the transduction of signals initiated 
by T-cell antigen receptor (TCR), a transmembrane receptor associated to T-cells (Thimus 
cells), a particular kind of lymphocytes. When an antigen is present inside a cell, it’s able 
to generate a pathogen-derived antigenic peptide, and this peptide is the ligand of a 
specific kind of TCR. When a TCR is engaged by its ligand, it initiates a signal cascade that 
results in the proliferation and activation of T-cells specific for the infectious agent and a 
consequent immune response. It was recognized that, as a consequence of the 
engagement of the TCR, a large number of phosphorylated tyrosine residues is 
accumulated in some cellular proteins. Nevertheless none of the component polypeptide 
chains of the TCR complex have intrinsic tyrosine kinase activity, so the TCR needs to 
recruit various non-receptor tyrosine kinases into the microenvironment.  
 
                                                           
[37] B. Nagar, W.G. Bornmann, P. Pellicena, T. Schindler, D.R. Veach, W.T. Miller, B. Clarkson, J. Kuriyan, 
Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors 
PD173955 and Imatinib, Cancer Res. 2002, 62, 4236-4243. 
[38] R.L. Wange, TCR signaling: another Abl-bodied kinase joins the cascade, Curr. Biol. 2004, 14, R562-
R564. 
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Besides Abl, other three non-receptors of the Src family are involved: Lck, Fyn e ZAP-70 
(Figure 14). 
 
              
Figure 14: Intracellular signal cascade involving Abl. 
 
Abl seems to act downstream of Lck and upstream of ZAP-70, although is not yet clear 
whether it acts exclusively through ZAP-70 or whether it might directly target other TCR 
signaling proteins downstream of ZAP-70. Under normal conditions, Abl exists in a highly 
regulated state with very low kinase activity. In most of the patients affected by chronic 
myeloid leukemia (CML), however, the accidental fusion of Bcr to the NH2 terminus of Abl 
results in the constitutive activation of Abl kinase activity: Bcr-Abl phosphorylates cellular 
proteins extensively and transforms cells, making them growth factor independent. 
Recently, some small-molecule tyrosine kinase inhibitors were discovered that are able to 
bind to the kinase domain at the interface between the two lobes, displacing ATP. The 
expansion of tumor cell populations must depend not only on the rate of proliferation but 
also on the rate of cell death. Abl protein tyrosine kinase activity provides hemopoietic 
cells with a survival advantage via the suppression of apoptosis. In the hemopoietic 
system, programmed cell death plays a key role in the maintenance of a homeostatic 
supply of mature blood cells from the bone marrow. There is, however, some evidence to 
suggest that cells from patients with CML exhibit an enhanced survival potential, in vitro, 
in the absence of hemopoietic growth factors. CML is associated with a chromosomal 
translocation which results in the formation of a fusion gene (bcr-Abl) which encodes a 
membrane associated, activated Abl protein tyrosine kinase. Reconstitution of the murine 
hemopoietic system with stem cells infected with the activated Abl tyrosine protein 
kinase has showed that there is a positive correlation between this oncogene and 
leukemogenesis. A possible role for activated Abelson tyrosine kinase on the suppression 
of apoptosis.[39] 
                                                           
[39] C.A. Evans, P.J. Owen-Lynch, A.D. Whetton, C. Dive, Activation of the Abelson Tyrosine Kinase Activity 
Is Associated with Suppression of Apoptosis in Hemopoietic Cells, Cancer Res. 1993, 53, 1735-1738. 
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3.1  Met inhibitors 
We have considered Met receptor, as a specific target for anticancer therapies because it 
is involved in several cellular functions leading to cancer. It is crucial for genetic program 
causing cellular scattering, angiogenesis and metastatic process. In particular, in cancer 
cells, oncogenic Met triggers the ‘‘invasive growth” program underlying cancer invasion 
and metastasis that occurs when neoplastic cells leave the primary tumor and infiltrate 
adjacent compartments to colonize distant organs.[40] For this reason Met inhibition is an 
important step in anti-cancer and also in anti-angiogenic therapy. Figure 15 shows few 
examples of known Met inhibitors.   
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Figure 15: Small molecules Met inhibitors. 
 
3.2  Modeling studies 
To find new inhibitors we screened a chemical library of bioactive molecules to identify 
distinct chemical scaffolds with inhibitory properties towards Met. Selected compounds 
included analogues with physical-chemical parameters in partial or total agreement with 
the Lipinski’s rule of five[41] and belonged to different families corresponding to 
heterocycles, peptides, polyamines and natural products. Seventeen crystallographic 
                                                           
[40] S. Corso, P.M. Comoglio, S. Giordano, Cancer therapy: can the challenge be MET?, Trends. Mol. Med. 
2005, 11, 284-292.  
[41] C.A. Lipinski, F. Lombardo, B.W. Dominy, P.J. Feeney, Experimental and computational approaches to 
estimate solubility and permeability in drug discovery and development settings, Adv. Drug. Deliv. Rev. 
2001, 46, 3-26. 
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complexes between Met tyrosine kinase domain and several structurally different 
inhibitors are available in Protein Data Bank. Such kinase complexes can be classified in 
three distinct conformational clusters.[42] 
 
Cluster 1 
Complexes 2RFS, 3I5N, 3CCN, 3CD8, 3F66, 2WGJ, 1R0P and 3A4P[43] show the so called 
active conformation of Met that is the conformation adopted by the protein when binds 
the ATP. As an example, Figure 16 a shows the binding mode of compound AM8 within 
the binding site (PDB code: 2RFS). AM8 makes favorable hydrogen bond contacts with 
residues Met1160 and Pro1158 belonging to the “hinge region” (residues 1159-1164). 
Furthermore, the m-chloro-phenyl portion of the ligand interacted with the activation 
loop (residues 1221-1251) establishing a π-π interaction with Tyr1230. In this 
conformation of Met, the phenylalanine of the DFG motif (residues 1222-1224) makes 
several hydrophobic interactions with residues Phe1200, Phe1134, Met1131, Leu1195 
and Val1220 (Figure 16 a-b).  
 
 
Figure 16 a-b: Binding mode of AM8 (reported as in stick with the carbon atoms in purple) in the 
active conformation of Met (2RFS). 
                                                           
[42] Asses, .Y, Leroux, V., Tairi-Kellou, S., Dono, R., Maina, F., Maigret, B. Analysis of c-Met kinase domain 
complexes: a new specific catalytic site receptor model for defining binding modes of ATP-competitive 
ligands. Chem. Biol. Drug Des., 2009, 74, 560-70. 
[43] a) S.F. Bellon et. al., c-Met inhibitors with novel binding mode show activity against several hereditary 
papillary renal cell carcinoma-related mutations, J. Biol. Chem. 2008, 283, 2675-2683. b) A.A. Boezio et. 
al., Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors, 
Bioorg. Med. Chem. Lett., 2009, 19, 6307-6312. c) J. Porter et. al., Discovery of 4-azaindoles as novel 
inhibitors of c-Met kinase. Bioorg. Med. Chem. Lett., 2009, 19, 2780-2784. d) B.K. Albrecht et. al., 
Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met 
kinase, J. Med. Chem., 2008, 51, 2879-2882. e) J. Porter et. al., Discovery of a novel series of 
quinoxalines as inhibitors of c-Met kinase. Bioorg. Med. Chem. Lett., 2009, 19, 397-400. f) N. Schiering 
et. al., Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met 
and its complex with the microbial alkaloid K-252a. Proc. Natl. Acad. Sci. USA, 2003, 100, 12654-12659. 
g) H. Nishii et. al., Discovery of 6-benzyloxyquinolines as c-Met selective kinase inhibitors. Bioorg. Med. 
Chem. Lett., 2010, 20, 1405-1409. 
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Cluster 2 
Complexes 3C1X, 3CE3, 3CTH, 3CTJ, 3F82[44] present the activation loop of the protein in 
an inactive, DFG-out conformation. In all these complexes, the DFG motif, which is 
conserved among kinases and marks the beginning of the activation loop (Asp1222-
Leu1245), is observed in the structure, but most of the remaining loop is undefined. The 
activation loop folds back toward the ATP-binding pocket opening in this way a 
hydrophobic pocket (Phe1134, Phe1200, Met1131, Leu1195 and Val1220), herein called 
DFG pocket. Within this cluster, the DFG pocket is always occupied by a p-F-phenyl ring of 
the co-crystallized inhibitor 320. In addition, because of the displacement of the 
activation loop, the C-helix (Asp1117-Phe1134) is shifted toward the DFG pocket. In this 
way, the C-helix pocket, defined by hydrophobic residues Phe1124, Val1155, Leu1142, 
Ile1145, and Gly1128 and existing because of the movement of the C-helix away from the 
small domain, is closed (Figure 16 c-d).  
 
 
 
Figure 16 c-d: Binding mode of 320 (reported as in stick with the carbon atoms in purple) in the 
inactive conformation of Met (3CTJ). 
 
 
 
 
                                                           
[44] a) G.M. Schroeder et. al., Identification of pyrrolo[2,1-f][1,2,4]triazine-based inhibitors of Met kinase, 
Bioorg. Med. Chem. Lett., 2008, 18, 1945-1951. b) K.S. Kim et. al., Discovery of pyrrolopyridine-
pyridone based inhibitors of Met kinase: synthesis, X-ray crystallographic analysis, and biological 
activities, J. Med. Chem., 2008, 51, 5330-5341. c) Z.W. Cai et. al., Discovery of orally active 
pyrrolopyridine- and aminopyridine-based Met kinase inhibitors, Bioorg. Med. Chem. Lett., 2008, 18, 
3224-3229. d) G.M. Schroeder et. al., Discovery of N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-
fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a 
Selective and Orally Efficacious Inhibitor of the Met Kinase Superfamily, J. Med. Chem., 2009, 52, 1251-
1254. 
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Cluster 3 
Complexes 2RFN, 3EFK and 3EFJ[45] show the activation loop of the protein in an inactive 
conformation, but, on the contrary to cluster 2, the C-helix pocket is open and able to 
receive the hydrophobic moiety of the co-crystallized ligand MT4 (Figure 16 e-f). 
 
 
Figure 16 e-f: Binding mode of MT4 (reported as in stick with the carbon atoms in white) in the 
inactive conformation of Met (3EFK). 
 
The docking studies and the molecular dynamic simulations previously reported showed 
the generic scaffold 1 (Figure 17) as potential Met inhibitors. Figure 17 shows also the 
possible interaction between ligand and protein.  
 
 
Figure 17: Interaction between Met and the generic structure 1 suggested by modeling.  
                                                           
[45] D`Angelo, N. D., Bellon, S. F., Booker, S. K., Cheng, Y., Coxon, A., Dominguez, C., Fellows, I., Hoffman, D., 
Hungate, R., Kaplan-Lefko, P., Lee, M. R., Li, C., Liu, L., Rainbeau, E., Reider, P.J., Rex, K., Siegmund, A., 
Sun, Y., Tasker, A. S., Xi, N., Xu, S., Yang, Y., Zhang, Y., Burgess, T. L., Dussault, I., Kim, T. S. Design, 
synthesis, and biological evaluation of potent c-Met inhibitors. J. Med. Chem, 2008, 51, 5766-5779 
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This class of compounds bind within the Met ATP-binding pocket in the inactive, DFG out 
conformation (see claster 2), with the thiazole moiety at the entrance of the binding 
pocket, near the residues forming the hinge region (Pro1158, Tyr1159 and Met1160). The 
disubstitued-benzene occupied the DFG hydrophobic pocket and the R1 residue occupied 
the C-helix hydrophobic pocket. The ligand was also involved in hydrogen bond 
interaction with the Lys62 side chain. Taking into consideration the binding mode of such 
hit compound, the available crystallographic structures of Met in complex with different 
inhibitors and all the known anticancer compounds reported in IMS and Becker's data 
banks, we design a new collection of compounds based on this characteristics:  
- presence of tetrahydropyridine, benzene or a cyclohexyl ring condensed on the 
thiazole moieties. The aromatic ring of Tyr1159, belong to hinge region, could 
favorably interact with the aromatic portion of the benzothiazole. 
- introduction of a second hydrophobic group R1 on the pseudo-peptide chain large 
enough to occupy the activation loop pocket making these compounds able to 
simultaneously interact with the two hydrophobic pockets. 
We planned the preparation of four series of compounds characterized by a different 
tricyclic scaffold and using a convergent approach (Scheme 1).  
 
3.3  Chemistry 
In our approach, we took into consideration the information deriving from molecular 
modeling studies and we designed a synthetic path with a convergent approach. The 
retro-synthetic strategy, showed in Scheme 1 proceeds through the separated 
preparation of the thiazole 2 and pseudo-dipeptide 3 portions bonded with an amide 
bound to afford analogues of generic structure 1. 
 
 
Scheme 1: Convergent retrosynthetic approach. 
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3.3.1  Thiazole portion synthesis 
Following the molecular modeling guideline we have synthesize four different thiazole 
scaffolds (Scheme 2) based on the skeleton 2:   
 
 
Scheme 2: Thiazoles portion synthesized. 
 
Each of these was synthesized starting from the corresponding 2-aminothiazole 4a-d, 
commercially available, with the exception of 2c. In this case the starting 2-
aminotetrahydro benzothiozole 4c was obtained by reaction of cyclohexanone with 
thiourea in the presence of iodine (Scheme 3).[46] This particular reaction is solvent free 
and leads to 4c without any purification. 
 
 
Scheme 3: Synthesis of 2-Amino-4,5,6,7-tetrahydrobenzothiazole 4c. 
 
Reaction of 4 with 2-bromo-4’-nitroacetophenone in EtOH or i-PrOH provided the 
corresponding nitro-derivatives 5 by alkylation of the ring nitrogen and successive 
dehydration.[47] The use of a polar solvent secured the successive second step while the 
                                                           
[46] A. Singh, J. Mohan, H.K. Pujari, Heterocyclic systems containing a bridgehead nitrogen atom: Part XXV. 
Syntheses of imidazo[2,1-b]benzothiazoles and quinoxalino[2,3:4’,5’]imidazo-[2’,1’-b] benzothiazoles, 
Indian J. Chem. 1976, 14B, 997-998. 
[47] M. Amat, A. Kövér, D. Jokic, O. Lozano, M. Pérez, N. Landoni, F. Subrizi, J Bautista, J. Bosch, Synthesis of 
a tetrahydroimidazo- [2’,1’:2,3]thiazolo[5,4-c]pyridine derivative with Met inhibitory activity, ARKIVOC 
2010, 3, 145-151. 
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use of toluene induces only the first step of the reaction (Scheme 4) that lead to 
compounds 6.  
 
 
 
Scheme 4: Synthesis of 5. 
 
The following reduction of the nitro group presents some problems. We tried with 
hydrogenation catalyzed by palladium using both THF and acetic acid as solvent but only 
the starting reagent was recovered. No reaction was detected probably due to the 
presence of sulfur that poisons the catalyst. The next attempt was done with SnCl2 in 
MeOH and concentrated HCl. In this case we isolated 2 in a variable yields (Scheme 5).  
 
 
 
Nome Thiazole 
a 
 
b 
 
c 
 
d 
 
 
Scheme 5: Synthesis of compounds 2a-d. 
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The reason is the presence of a secondary reaction (Scheme 6) that led to a chlorine 
insertion at position 3 of the tricyclic core (compounds 7).  
 
 
 
Scheme 6: Formation of side products 7 in the reduction of 5 using SnCl2. 
 
This side reaction was acceptable in the 2a-b synthesis because it is slower than the 
reduction. But in the case of 2c-d the chlorine insertion was faster and that gave an 
unsatisfactory yield, lower than 50%. This problem was overcome using Fe-powder in the 
presence of H2SO4 concentrated that leads to 2c-d in good yields and without any further 
purification (Scheme 7).  
 
 
Scheme 7: Reduction of 5c-d using iron. 
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3.3.2  Pseudo-dipeptide portion synthesis   
Glycine, R- and S-alanine, R- and S-phenylalanine, and S-tyrosine were selected for the 
generation of the pseudo-dipeptidic chain (Scheme 8) that was subsequently condensed 
with the tricyclic scaffolds. The methyl esters of the aminoacids were reacted with 3,5-
dimetylphenyl-, 3,5-difluorophenyl- and 3,5-ditrifluorometylphenyl-acetic acids in the 
presence of DCC or DCI to give the methyl esters 8. The hydrolysis of 8 (LiOH, MeOH, 0°C, 
1h) took place without any racemization[48] as reported in literature, and permitted to 
obtain the desired acids 3 (Table 5) that was recovered without any further purification. 
 
 
 
Scheme 8: Generic synthesis of pseudo-dipeptide 3.  
 
 
 
 
Compound R
1
 R
2
 
a (S)-Bn CH3 
b (R)-Bn CH3 
c (S)-Bn CF3 
d (R)-Bn CF3 
e (S)-Bn F 
f H CH3 
g (S)-pOH-Bn CH3 
h (S)-Me F 
i (R)-Me F 
 
Table 5: Pseudo-dipeptide 3 synthesized.  
                                                           
[48]  a) C. Benhaim, L. Bouchard, G. Pelletier, J. Sellstedt, L. Kristofova, S. Daigneault, Enantioselective 
Synthesis of beta-Trifluoromethyl alpha-Amino Acids Org. Lett. 2010, 12, 2008-2011; b) J.E. Green, 
D.M. Bender, S. Jackson, M.J. O'Donnell, J.R. McCarthy, R. James, Mitsunobu Approach to the 
Synthesis of Optically Active alpha,alpha-Disubstituted Amino Acids Org. Lett. 2009, 11, 807-810; c) L. 
Gentilucci, L. Cerisoli, R. De Marco, A. Tolomelli, A simple route towards peptide analogues containing 
substituted (S)- or (R)-tryptophans Tetrahedron Lett. 2010, 51, 2576-2579.     
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3.3.3  Synthesis of compounds 1 
We synthesized four families with scaffold 1 classified by the thiazole building block 2a-d 
employed (Scheme 9).  
 
 
Scheme 9: Convergent retrosynthetic approach. 
 
In the first approach we tried to form the acyl chloride of dipeptides 3 using firstly thionyl 
chloride and then with oxalyl chloride but in both cases we had a rapid degradation of 3 
that made impossible them employs. Reject this strategies we decided to follow the 
condensating agents way. For this purpose we tried several conditions. The first coupling 
agents employed, DCC, DIC, EDC and DMC (Figure 18) gave back 1 in a very low yield, 
lower than 20%, and with a complex profile of side products that make hardly the 
purification of the desired product. Then we tried with a stronger agent named BOP-Cl. In 
this case we obtain the series of compounds 1 with a quite good yield of 45-70% but again 
with a bad profile of side products.  
51 
Not pleased with these results we tried again the coupling using HATU. These last 
conditions led to final products in good yields (70-90 %). 
 
 
Figure 18: Condensing agents employed in the synthesis of final compounds 1.   
 
The building blocks 2a and 2b were used for the formation of the corresponding 
compounds 9 and 10 using HATU or BOP-Cl as condensing agent.  
 
 
Compound R
1
 R
2
 
9a (S)-Bn CH3 
9b (R)-Bn CH3 
10a (S)-Me F 
10b (R)-Me F 
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The use of 2c and 2d permitted the obtainment of 11 and 12 respectively. In these cases 
only HATU was used due to its high reaction yields. All the obtained compounds resulted 
stable as solid and in solution (DMSO, CHCl3, MeOH). All the structures were confirmed 
on the base of the NMR and MS spectra. 
 
 
 
Compound Code R
1
 R
2
 
11 CF054 (S)-Bn CH3 
12a CF022 (S)-Bn CH3 
12b CF056 (R)-Bn CH3 
12c CF052 (S)-Bn CF3 
12d CF081 (R)-Bn CF3 
12e CF082 (S)-Bn F 
12f CF083 H CH3 
12g CF023 (S)-pOH-Bn CH3 
 
 
Each compound was synthesized in hundreds milligrams scale except 12a and 12c that, 
for their high activity, were synthesized in grams scale necessary for in vivo biological 
trials.  
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3.3.4  Importance of central chain 
Till this point we tried to change the different R1 and R2 residues and the thiazole scaffold 
but no affords was done to check the importance of the central chain conformation 
(Figure 19).  
 
 
Figure 19: In red is showed the central pseudo-dipeptide chain. 
 
We took as a candidate our lead compound CF052 (12c, see biological section, scattering 
test pag 69) and we introduced some modification in the central portion of the molecule. 
Ever following the prediction of molecular modeling studies, we synthesized the 
corresponding benzylamine of 2d, compound 14, using the procedure reported below in 
Scheme 10. 
 
 
 
Scheme 10: Synthesis of modified analogues 15. 
 
The modeling showed that the analogue 15 has a worse binding affinity compared to 12c. 
But our idea was to check the importance of central chain and the program prediction 
ability. Furthermore a chemical diversity is fundamental for the improvement of the 
molecular model.  
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Following the same idea we synthesized two different analogs (18 and 19) using a 
pseudo-peptide portion based on β-alanine (Scheme 11).  
 
  
  
Scheme 11: Synthesis of modified analogues 18 and 19 based on β-alanine. 
 
3.4  BIACORE: Surface plasmon resonance (SPR) 
Working on TKIs an important point is to know the selectivity of our compounds, in 
particular if they are able to interact significantly only with the prefixed biological target 
or with a more number of targets. To do this kind of screening several tests are available 
but BIACORE: Surface Plasmon Resonance (SPR) seemed particularly interesting (Figure 
20). 
 
 
Figure 20: BIACORE Surface Plasmon Resonance (SPR) instrument. 
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The surface plasmon resonance (SPR) phenomenon occurs when polarized light, under 
conditions of total internal reflection, strikes an electrically conducting gold layer at the 
interface between media of different refractive index: the glass of a sensor surface (high 
refractive index) and a buffer (low refractive index). A wedge of polarized light, covering a 
range of incident angles, is directed toward the glass face of the sensor surface. Reflected 
light is detected within a Biacore system. An electric field intensity, knowed as an 
evanescent wave, is generated when the light strikes the glass. This evanescent wave 
interacts with, and is absorbed by, free electron clouds in the gold layer, generating 
electron charge density waves called plasmons and causing a reduction in the intensity of 
the reflected light. The resonance angle at which this intensity minimum occurs is a 
function of the refractive index of the solution close to the gold layer on the opposing 
face of the sensor surface. As molecules are immobilized on a sensor surface, the 
refractive index at the interface between the surface and a solution flowing over the 
surface changes, altering the angle at which reduced-intensity polarized light is reflected 
from a supporting glass plane. The change in angle, caused by binding or dissociation of 
molecules from the sensor surface, is proportional to the mass of bound material and is 
recorded in a sensorgram. When sample is passed over the sensor surface, the 
sensorgram shows an increasing response as molecules interact. The response remains 
constant if the interaction reaches equilibrium. When the sample is replaced by buffer, 
the response decreases as the interaction partners dissociate. Complete profiles of 
recognition, binding and dissociation are generated in real time. From these profiles, data 
such as specificity, affinity, kinetic behavior and sample concentration can be determined. 
For most applications, a dextran matrix covering the gold layer enables molecules to be 
immobilized to a sensor surface and provides a hydrophilic environment for interactions. 
Surface specificity is determined by the nature of the immobilized molecule. Since light 
does not penetrate the sample, interactions can be followed in colored, turbid or opaque 
samples. No labels are required and detection is instantaneous. 
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3.5  Selectivity on Met receptor 
To carry out SPR screening it is necessary to support the under examination compound on 
a surface. Following this aim we synthesized the bromo-derivatives 20. The presence of 
bromine on the benzothiazole ring could be an important anchor point for the 
introduction of a spacer, conveniently functionalized, necessary for the binding with the 
surface.   
 
 
 
Firstly we tried directly with a direct halogenation on 12c using both bromine and NBS. 
Unluckily both attempts failed. That forced us to restart a new synthesis as showed in 
Scheme 12.     
 
N
S
NH2
N
S
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Br
O
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21
Br
Br
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H
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CF3
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O H
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CF3
CF3
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NH2
3c
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THF, N2, rt, 16h
48%
EtOH
Reflux, 90min
34%
EtOH, Reflux, 90min
92%
Fepowder, H2SO4 12N
 
 
Scheme 12: Synthesis of bromine derivatives 20. 
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The construction of the benzothiazole derivative 21 proceeded through the o-position of 
p-bromoaniline bromination followed by potassium thiocyanate nucleophilic-substitution 
of bromine in o-position. Finally, it took place the second heterocycle formation induced 
by aniline nitrogen (Scheme 13). 
 
 
Scheme 13: Reaction mechanism in the synthesis of 21.   
 
The synthesis of 20 proceeded as showed previously (Scheme 12) through the reaction of 
21 with 2-bromo-4’-nitroacetophenone in EtOH, a reduction catalyzed by Fe-powder and 
the final condensation with pseudo-dipeptide 3c using HATU. Reached 20, we tried to 
functionalize it played on bromine just inserted. We employed different reaction 
conditions like Suzuki coupling, Stille coupling, Heck reaction but no trace of 
functionalized product was detected. We tried also with the insertion of a nitrile moiety 
using following conditions: 
- Zn(CN)2, Pd(PPh3)4, DMF, MW, 150 °C; 
- CuCN, DMF, 140 °C; 
Even in these last two attempts no trace of desired product was obtained. The bromine 
seems unreactive. This consideration was confirmed by the same results obtained using 
identical reaction conditions on the precursors 22 and 23. The only way for the 
introduction of the spacer seems the directly functionalization of p-bromoaniline.    
 
3.6  1,2,3-Triazole and amide bioisosterism 
Bioisosterism is a widely accepted principle in medicinal chemistry used to make changes 
in a lead structure with the aim of achieving various goals such as improved chemical 
stability or better pharmacokinetic properties while maintaining or even enhancing 
biological activity.[49] In relation to the recent widespread use of the copper(I)-catalyzed 
azide-acetylene cycloaddition reaction for the regioselective formation of 1,4-
disubstituted 1,2,3-triazole derivatives, a lot of examples show the similarity of the amide 
moiety and the 1,2,3-triazole ring (Figure 21). The similitudes of the two moieties can be 
                                                           
[49] E.D. Chrysina, E. Bokor, K. Alexacou, M. Charavgi, G.N. Oikonomakos, S.E. Zographos, D.D. Leonidas, 
N.G. Oikonomakos, L. Somsàk, Amide-1,2,3-triazole bioisosterism: the glycogen phosphorylase case, 
Tetrahedron:Asymmetry 2009, 20, 733-740. 
58 
seen in the size (distance between substituents 3.8–3.9 Å in amides, 5.0–5.1 Å in 
triazoles), the dipolar character (amide: 4 Debye, triazole: 5 Debye) and the H-bond 
acceptor capacity (lone pairs of the amide oxygen as well as of the triazole nitrogens): 
 
 
Figure 21: Bioisosterism between amide bond and 1,2,3-triazole.  
 
The triazole C(5)-H can act as a H-bond donor, in a similar manner to the hydrogen of the 
amide, as it was showed by X ray crystallography, in which the 1,2,3-triazole can 
participate in the H-bond network of an α-helical peptide. These findings raise the 
possibility of a broader use of the 1,2,3-triazole moiety as a bioisosteric replacement for 
the amide group. This is also supported by the high chemical stability of the 1,2,3-triazole 
ring, especially under hydrolytic as well as reductive and oxidative conditions. However, 
the outcome of such a replacement may depend on the biological target, that is, this kind 
of isosterism may not be considered to be obvious and it should be verified in each case. 
 
3.6.1  Click reaction 
Looking at the environment around us, all synthetic chemists can easily understand 
nature’s greatness: using carbonyl chemistry, nature was, and still is, able to create about 
35 simple “building blocks” and to assemble them into biopolymers. But to do that, 
nature could rely on a whole planet and a few billion years: it means that mimicking 
nature’s carbonyl chemistry doesn’t suit a rapid discovery of new molecules with desired 
properties. For this reason one of synthetic organic chemists’ goals is to develop an 
expanding set of powerful, selective and modular reactions that work reliably in both 
small- and large-scale applications. Sharpless and coworkers[50] termed this approach 
“click chemistry” and defined a set of stringent criteria that a process must meet to be 
useful in this context. The reaction must be modular, wide in scope, give very high yields, 
generate only inoffensive byproducts that can be removed by non-chromatographic  
methods, and be stereospecific (but not necessarily enantioselective).  
 
                                                           
[50] a) H.C. Kolb, M.G. Finn, K.B. Sharpless, Click chemistry: diverse chemical function from a few good 
reactions Angew. Chem. Int. Ed. 2001, 40, 2004-2021. b) M. Colombo, I. Peretto, Chemistry strategies in 
early drug discovery: an overview of recent trends D.D.T. 2008, 13, 677-684. c) J.E. Moses, A.D. 
Moorhouse, The growing applications of click chemistry Chem. Soc. Rev. 2007, 36, 1249-1262. 
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The required process characteristics include simple reaction conditions (ideally, the 
process should be insensitive to oxygen and water), readily available starting materials 
and reagents, the use of no solvent or a solvent that is benign (such as water) or easily 
removed, and simple product isolation. Purification, if required, must be by non-
chromatographic methods, such as crystallization or distillation, and the product must be 
stable under physiological conditions. It is important to recognize that click reactions 
achieve their required characteristics by having a high thermodynamic driving force, 
usually greater than 20 kcal mol-1. Click chemistry ideals are beautifully represented 
among cycloaddition reactions involving heteroatoms, such as hetero-Diels-Alder and, 
especially, 1,3-dipolar cycloadditions. These modular reactions unite two unsaturated 
reactants and provide fast access to an enormous variety of interesting five- and six-
membered heterocycles. In this family of reactions, the most useful in organic chemistry 
are Huisgen dipolar cycloadditions of azides and alkynes.[51] Concerns about the safety of 
azide moiety have always been an obstacle to a wide use of these reactions, but the azide 
group is by far the most convenient of the 1,3-dipolar components to introduce and 
probably the only one which is stable toward dimerization and/or hydrolysis. In addition, 
a wide variety of alkynes can participate to this reaction, with the EWG-substituted 
terminal alkynes being the most reactive. 
 
3.6.2  Huisgen cycloaddition 
The Huisgen cycloaddition reactions products are 1,2,3-triazoles and they are very 
interesting moieties in medicinal chemistry since they can act like rigid linkers mimicking 
the atom placement and electronic properties of a peptide bond, but without the same 
liability in hydrolytic cleavage. The drawback of these reactions is that a mixture of 
regioisomers is obtained:  
 
 
 
In 2002 Sharpless’ and Meldal’s groups reported independently the advantages of Cu(I)-
catalyzed alkyne-azide cycloaddition (CuAAC). Copper(I) catalysis improves the 
regioselectivity, affording exclusively the 1,4-regioisomer, and increases the reaction rate 
up to a 107 factor, thus avoiding also the necessity of high temperatures.  
                                                           
[51] M. Meldal, C.W. Tornoe, Cu-Catalyzed Azide-Alkyne Cycloaddition Chem. Rev. 2008, 108, 2952-3015. 
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Since copper(I) salts are quite labile, the active catalytic species is usually generated in 
situ. Two are the most used protocols: 
- Copper(II)/ascorbate system: the active catalyst is generated from the Cu(II) salts 
(0.25-2.0 mol %) via reduction with sodium ascorbate or ascorbic acid (5-10 mol %). A 
slight excess of ascorbate is generally used in order to prevent the formation of the 
oxidative coupling products that are often observed when a Cu(I) source is used 
directly: 
 
 
 
 
- Copper metal system: the active Cu(I) catalyst is formed via comproportionation of the 
Cu(II)/Cu(0) couple: 
 
 
 
 
This procedure is especially convenient in parallel synthesis applications or when the 
substrates do not tolerate ascorbate or its oxidation products. 
 
3.6.3  Mechanism 
Density functional theory (DFT) calculations[52] revealed that the reaction proceeds 
through a stepwise mechanism and not through a concerted one. 
- Concerted pattern (uncatalyzed) 
 
 
 
The activation barriers for the concerted reaction leading to both 1,4- and 1,5-
regioisomers of the 1,2,3-triazole are 25.7 and 26.0 kcal/mol, respectively. Both reactions 
are highly exothermic, -60.8 and -60.6 kcal/mol, for the 1,4- and 1,5-regioisomers, 
respectively. 
                                                           
[52] F. Himo, T. Lovell, R. Hilgraf, V. V. Rostovtsev, L. Noodleman, K. B. Sharpless, V.V. Fokin, Copper(I)-
catalyzed synthesis of azoles. DFT study predicts unprecedented reactivity and intermediates  J. Am. 
Chem. Soc. 2005, 127, 210-216. 
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- Stepwise pattern (Cu(I)-catalyzed, regiospecific) 
Conversion of the alkyne 24 to the acetylide 26 is known to be involved in many C-C 
bond-forming reactions. In this case the initial coordination of acetylene leads to the 
formation of a π-complex 25 that lowers the pKa of alkyne C-H by up to 9.8 units. This 
makes the second step (25-->26) accessible in an aqueous environment (Scheme 14). 
 
  
Scheme 14: Formation of copper(I) acetylide 
 
A mechanism in which coordination of the acetylene to the copper(I) (without its 
deprotonation) activates it toward a 1,3-dipolar cycloaddition is not realistic since the 
calculated barrier for this process is 27.8 kcal/mol, even higher than that without the 
copper catalyst. The concerted cycloaddition of acetylide 26 has a high activation barrier 
too, 23.7 kcal/mol. In the most likely hypothesis (Scheme 15), it doesn’t happen a 
concerted cycloaddition: the azide replaces one of the Cu ligands forming intermediate 
27. After that, the distal nitrogen of the azide in 27 attacks the C-2 carbon of the 
acetylide, forming the unusual six-membered copper(III) metallacycle 28: the calculated 
barrier is 14.9 kcal/mol, considerably lower than the barrier for the uncatalyzed reaction 
(26.0 kcal/mol).  
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This explains the enormous rate acceleration of the copper(I)-catalyzed process, 7 to 8 
orders of magnitude, as compared to the purely thermal cycloaddition. 
 
 
Sheme 15: Cycloaddition in Sharpless conditions mechanism. 
 
From 28, the barrier for ring contraction, which forms the triazolyl-copper derivative 29, is 
very low (3.2 kcal/mol). Proteolysis of 29 releases the triazole product, thereby 
completing the catalytic cycle. 
 
3.6.4  1,2,3-Triazole analogues of CF052 
Knowing the bioisosterism between 1,2,3-triazole and amide bond we considered 
interesting the synthesis of compound 30 (Figure 22). It is based on the structure of our 
lead compound CF052 (12c), the most active compound in our quality collection.  
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The excellent relationship between these two groups was also confirmed by molecular 
modeling studies.     
 
 
Figure 22: Lead compound CF052 (12c) and its 1,2,3-triazole analogue 30. 
 
To reach 30 our affords were focused on the design of a new synthesis based on our 
knowledge in the field of these kind of analogues. In Scheme 16 is showed the 
retrosynthetic approach. We hypothesized a key step based on a cycloaddition reaction in 
Sharpless conditions to afford 30 starting from azide 31 and alkyne 32.    
 
 
 Scheme 16: Retrosynthetic approach for the synthesis of 1,2,3-triazole analogue 30. 
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The synthesis of azide 31 proceeded through the in situ formation of the diazonium salt 
33, using sodium nitrite in acid conditions and water, and subsequent reaction with 
sodium azide. 
 
 
 
The synthesis of 32 resulted more complicated. In this case we decided to start from the 
methylester 8c for its analogies with 32. The main problem following this kind of 
approach was the necessity to synthesize an alkyne homologue of 8c. Took into 
consideration this aspect we designed the synthesis as show below, which has a Bestmann-Ohira 
reaction as a key step (Scheme 17). 
      
 
Scheme 17: Synthesis of alkyne 32. 
 
The Bestmann-Ohira reaction allows the conversion of an aldehyde to the homologues 
alkyne in mild conditions using Bestmann-Ohira reagent 35. To obtain the desired 
aldehyde 34 (necessary for the Bestmann-Ohira key step), we tried firstly different 
reductive conditions on ester 8c. We tried using NaBH4 but the reduction agent was too 
weak. Surely, the employment of LiAlH4 should lead to the reduction of both esters and 
amide groups contained in structure 8c. For this reason we used LiBH4 in THF that gave 
the alcohol 33 in a very good yield (92 %). The reduction was followed by alcohol re-
oxidation using Dess-Martin periodinane (DMP) in DCM that afford 34 in good yield (78 
65 
%). Finally the alkyne 32 was reached with the employment of Bestmann-Ohira reaction 
using the homonym reagent 35 and K2CO3 in methanol for 16 h at room temperature. 
Unluckily despite the mild conditions of this last step we observed the racemization of 
alkyne 32 due to the contemporary presence of a base and a protic solvent. The final step 
in the synthesis of 30 is a cyclocondensation in Sharpless conditions using azide 31 and 
alkyne 32 as showed in Scheme 18.  
 
 
 Scheme 18: Synthesis of 30 through cycloaddition in Sharpless conditions. 
 
 
3.6.5  Bestmann-Ohira reaction 
Terminal alkynes are extremely valuable synthetic intermediates and their formation 
from aldehydes is a widely used preparative procedure. Initially, the Corey-Fuchs[53] 
sequence has been employed, consisting in the formation of a terminal alkyne by an 
homologation of the corresponding aldehyde through a 1,1-dibromo alkenyl 
intermediate:  
 
 
 
The first step is comparable to a Wittig reaction and leads to a dibromoalkene. In the 
formation of the ylide from CBr4, two equivalents of triphenylphosphine are used.  
 
                                                           
[53] E.J. Corey, P.L. Fuchs, A synthetic method for formyl→ethynyl conversion (RCHO→RC CH or 
RC CR′), Tetrahedron Lett. 1972, 13, 3769-3772. 
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One equivalent forms the ylide while the other acts as reducing agent and bromine 
scavenger: 
 
 
 
By treatment with BuLi the corresponding bromoalkyne is generated, which undergoes 
metal-halogen exchange and yields the terminal alkyne after work-up: 
 
 
 
The need for a strong base like BuLi for the dehydrohalogenation of the intermediate 1,1-
dibromoalkenes can limit the applicability of this procedure. 
The Seyferth-Gilbert[54] homologation has been revealed as a very effective alternative to 
this method. It consists in the base-promoted reaction of dialkyl 
diazomethylphosphonates with aldehydes and arylketones at low temperatures to give 
alkynes: 
 
 
 
                                                           
[54] D. Seyferth, R.S. Marmor, P. Hilbert, Reactions of dimethylphosphono-substituted diazoalkanes. 
(MeO)2P(O)CR transfer to olefins and 1,3-dipolar additions of (MeO)2P(O)C(N2)R, J. Org. Chem. 1971, 
36, 1379-1386. 
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The deprotonated Seyferth-Gilbert reagent adds to the carbonyl compound forming an 
alkoxide that closes to give an oxaphosphetane. Comparable to the Wittig reaction, a 
cycloelimination yields a stable dimethyl phosphate anion and a diazoalkene: 
 
 
 
Upon warming of the reaction mixture to room temperature, loss of nitrogen gives a 
vinylidene carbene that yields the desired alkyne after 1,2-migration of one of the 
substituents: 
 
 
 
The major disadvantage of this procedure is the fact that the Seyferth-Gilbert reagent is 
not commercially available and has to be prepared by a multistep procedure that requires 
a strong base for deprotonation, low temperatures and inert gas techniques. 
Recently, Bestmann and Ohira[55] reported a valuable procedure in which dimethyl-1-
diazo-2-oxopropylphosphonate 35 is employed:[56] 
 
 
 
                                                           
[55] S. Ohira, Methanolysis of dimethyl (1-diazo-2-oxopropyl) phosphonate - generation of dimethyl 
(diazomethyl) phosphonate and reaction with carbonyl-compounds, Synth. Commun. 1989, 19, 561-
564. 
[56] A.K. Gosh, A. Bischoff, J. Cappiello, Asymmetric total synthesis of the gatroprotective microbial agent 
AI-77-B, Eur. J. Org. Chem. 2003, 821-832. 
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The Bestmann-Ohira reagent is stable and readily prepared in high yields from 
commercially available precursors: 
 
 
 
In this way, it is possible to obtain the dimethyl(diazomethyl)phosphonate anion by mild 
acyl cleavage of dimethyldiazo-2-oxopropylphosphonate: 
 
 
 
These mild reaction conditions allow the conversion of even enolizable aldehydes.[57] 
Furthermore, a new procedure has been described in which the commercially available 
dimethyl-2-oxopropylphosphonate can directly be used as reagent:[58] 
 
 
 
Nevertheless, this simpler procedure gave the desired alkynes in lower yields. 
                                                           
[57] S. Muller, B. Liepold, G.J. Roth, H.J. Bestmann, An improved one-pot procedure for the synthesis of 
alkynes from aldehydes, Synlett. 1996, 521-522. 
[58] G.J. Roth, B. Liepold, S.G. Muller, H.J. Bestmann, Further improvements of the synthesis of alkynes 
from aldehydes, Synthesis 2004, 1, 59-62. 
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3.7  Biology 
 
3.7.1  Scattering test on MDCK cells 
Efficiency of newly synthetized thiazol-based inhibitors was primarily assessed by 
checking their ability to block HGF-induced madin darby canine kidney (MDCK) scattering 
(Figure 23).[59] MDCK are epithelial cells forming cohesive clusters which scatter in 
response to Hepatocyte Growth Factor/Scatter Factor (HGF/SF) and thus represent an 
interesting model to study the ability of compounds to inhibit Met activity.[60] This assay is 
the most widely used to screen for Met inhibitors because of the clear answers it 
provides. It allowed us to identify among our family of compounds those which are able 
to inhibit Met-driven scattering, and to compare their relative efficiency by calculating 
their IC50, corresponding to the compound concentration at which HGF-induced cell 
scattering was half that in the control condition. For these studies, the Met inhibitor 
SU11274 was used as a reference compound in all assays.[61] 
 
 
Figure 23: 12c (CF 052) scattering test on MDCK cell. 
 
Among around 20 new synthesised compounds (Scheme 19), we found that CF022, 
CF052, CF054, CF056 CF081, CF082, and CF120 elicited inhibitory activity on Met-
triggered cell scattering (Table 6).  
 
 
                                                           
[59] Patane, S.; Pietrancosta, N.; Hassani, H.; Leroux, V.; Maigret, B.; Kraus, J. L.; Dono, R.; Maina, F., A new 
Met inhibitory-scaffold identified by a focused forward chemical biological screen. Biochem Biophys 
Res Commun 2008, 375,  184-189. 
[60] Chan, G. K.; Lutterbach, B. A.; Pan, B. S.; Kariv, I.; Szewczak, A. A., High-throughput analysis of HGF-
stimulated cell scattering. J Biomol Screen 2008, 13, 847-854. 
[61] Schiering, N.; Knapp, S.; Marconi, M.; Flocco, M. M.; Cui, J.; Perego, R.; Rusconi, L.; Cristiani, C., Crystal 
structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its 
complex with the microbial alkaloid K-252a. Proc Natl Acad Sci U S A 2003, 100, 12654-12659. 
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Scheme 19: List of compounds tested on MDCK cells for HGF induced scattering test. 
 
Compound Code Thiazole R
1
 R
2
 IC50 (µM) 
9a - 
 
(S)-Bn CH3 Not active 
9b - 
 
(R)-Bn CH3 Not active 
10a - 
 
(S)-Me F Not active 
10b - 
 
(R)-Me F Not active 
11 CF054 
 
(S)-Bn CH3 0.8 
12a CF022 
 
(S)-Bn CH3 0.6 
12b CF056 
 
(R)-Bn CH3 0.6 
12c CF052 
 
(S)-Bn CF3 0.2 
12d CF081 
 
(R)-Bn CF3 0.2 
12e CF082 
 
(S)-Bn F 0.8 
12f CF083 
 
H CH3 Not active 
12g CF023 
 
(S)-pOH-Bn CH3 Not active 
15 CF070 
 
(S)-Bn CF3 Not active 
18 - 
 
- F Not active 
19 - 
 
- F Not active 
20 CF203 
 
(S)-Bn CF3 Not active 
30 CF120 
 
Bn CF3 0.6 
 
Table 6: Concentration of 50 % scattering inhibition on MDCK cells. Selected CF compounds tested for 
their action on HGF-induced scattering of MDCK cells. The IC50 value (µM) for the most active 
compounds is reported. R
1
 and R
2
 residues are referred to the positions showed on generic structure 
12a-g. 
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By evaluating the IC50 of the most active compounds, we found that CF052 and CF081 
impaired Met-triggered cell scattering at concentration comparable to SU11274 (CF052: 
0,17 µM; CF081: 0,20 µM; SU11274: 0,15 µM; Figure 24).  
 
 
Figure 24: HGF-induced scattering of MDCK cells is blocked by CF22, CF52, CF81, CF82, and not by 
CF83. SU11274 was used as positive control. The IC50 is indicated in µM. 
 
No toxic effects were observed at biologically active concentrations and they only 
appeared when the doses rang from 50 to 100 fold higher. The toxicity can be explained 
due to the presence of a little quantity of DMSO necessary for the first dissolution of the 
CF compounds. We could see that compound CF022 was indeed a good inhibitor of Met-
induced scattering. Dehydrogenation of the thiazol ring in compound CF054 slightly 
decreased its activity, as well as introduction of fluorine atoms in R2 positions in CF082, 
while the steriogenic center configuration doesn’t lead to variations in the activity as 
showed by CF052 and CF081. This last modification was conceived in order to use non-
natural aminoacids, which may be more resistant to proteolysis. Strikingly, the presence 
of CF3 groups in R
2 substituents (compound CF052) greatly improved the inhibition by our 
compounds of Met-triggered scattering. The benzyl group in R1 position proved to be 
critical for Met inhibition since attempts to replace it by hydrogen atom, CH3 group or p-
hydroxyl benzyl group resulted in inactive compounds. Further validations were obtained 
by testing CF compounds on human MCF10A breast cells and similar inhibitory properties 
on Met-triggered scattering were observed. 
 
3.7.2  Double mechanism of action 
Differently by the common Met inhibitors the interesting point of our CF series is the dual 
action mechanism: they impair Met signaling by interaction with the ATP binding pocket 
into the intracellular domain and, in addition to the classical inhibitors, prevent its 
restoration after degradation. This dual activity could lead to a synergic effect that makes 
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the CF family different by precedent Met inhibitors. In detail signalling by activated Met is 
attenuated through receptor endocytosis and proteasomal degradation in endosomal 
compartments. Subsequently, Met receptors are restored following gene transcription,[62] 
allowing fine tuning and delicate balance of Met functions. Upon HGF stimulation, Met is 
down-regulated after 6 h and its protein levels are restored after 24 h (Figure 25) 
 
 
Figure 25: Upon HGF stimulation, Met protein levels are down-regulated after 6 hours and restored 
by 24 hours in primary embryonic hepatocytes. 
 
Remarkably, CF series treatment impaired restoration of Met protein levels over time. In 
contrast to CF, SU11274 did not prevent up-regulation of Met protein levels (Figure 26), 
as previously showed.[63]  
 
 
Figure 26: restoration of Met protein levels in 293-T cells is impaired by the presence of CF052 (12c) 
at 5μM. In contrast, SU11274 does not prevent restoration of Met protein levels. 
 
3.7.3  Survival on HepG2 and GTL-16 cell lines 
We next investigated the ability of CF compounds to prevent Met-triggered survival of 
cancer cells. These studies were performed on human hepatocellular liver carcinoma 
HepG2 cells, which tumorigenesis is Met-dependent,[64] and on human GTL-16 gastric 
carcinoma cells, in which Met gene amplification results in high Met protein levels and its 
                                                           
[62] A.C. Porter, R.R. Vaillancourt, Tyrosine kinase receptor-activated signal transduction pathways which 
lead to oncogenesis, Oncogene 1998, 17, 1343–1352. 
[63] S. Arena, A. Pisacane, M. Mazzone, P.M. Comoglio, A. Bardelli, Genetic targeting of the kinase activity 
of the Met receptor in cancer cells, Proc. Natl. Acad. Sci. USA 2007, 104, 11412–11417. 
[64] Heideman, D. A.; Overmeer, R. M.; van Beusechem, V. W.; Lamers, W. H.; Hakvoort, T. B.; Snijders, P. 
J.; Craanen, M. E.; Offerhaus, G. J.; Meijer, C. J.; Gerritsen, W. R., Inhibition of angiogenesis and HGF-
cMET-elicited malignant processes in human hepatocellular carcinoma cells using adenoviral vector-
mediated NK4 gene therapy, Cancer Gene Ther. 2005, 12, 954-962. 
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ligand independent activation. As consequences, GTL-16 cells are “Met-addicted” for 
survival, anchorage-independent growth, and tumor formation when injected in nude 
mice.[65]  
 
 
Figure 27: (B and C) Survival of HepG2 (B) and GTL-16 (C) cells was reduced by CF052 (12c), in a dose 
dependent manner (µM). (D and E) Survival of BT474 (D) and MCF7-ErbB2 (E) cells, which are 
addicted to the ErbB oncogenes, was impaired by the ErbB inhibitor Gefitinib (Gefit), but not by CF052 
(µM). For survival assays (n=3), cells were serum-starved for 24 hrs and then incubated with CF052 or 
Gefitinib for 48 h. Values are expressed as means ± s.e.m. *P<0.05; **P<0.01; Student’s t-tests. 
 
We found that compounds CF022, CF052, CF081, and CF082 reduced survival of both 
HepG2 (Figure 27 B) and GTL-16 cells (Figure 27 C and 28) in a dose dependent manner.  
 
 
Figure 28: CF compounds block Met-triggered cell survival and anchorage-independent growth. 
Survival of GTL-16 cells was reduced by CF022, CF052, CF081 and CF082, in a dose dependent manner 
(µM). GTL-16 cells were serum-starved for 24 h and then incubated in the presence or not of CF 
compounds for 48 h. 
                                                           
[65] Zou, H. Y.; Li, Q.; Lee, J. H.; Arango, M. E.; McDonnell, S. R.; Yamazaki, S.; Koudriakova, T. B.; Alton, G.; 
Cui, J. J.; Kung, P. P.; Nambu, M. D.; Los, G.; Bender, S. L.; Mroczkowski, B.; Christensen, J. G., An orally 
available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy 
through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007, 67, 4408-4417. 
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In contrast, CF compounds did not restrain survival of cancer cell lines, such as BT474 and 
MCF7-ErbB2 (Figure 27 D-E), which are addicted to ErbBs oncogenes.[66]  
 
3.7.4  CFs interfere with Met-triggered in vitro tumorigenesis 
We next ascertained whether the identified CF compounds prevented also Met-triggered 
anchorage-independent growth, which is a hallmark of oncogenic transformation. Soft-
agar growth of HepG2 cells requires intact Met as it is impaired by the Met inhibitor 
SU11274.[65] We found that compounds CF022, CF052, CF081, and CF082 impaired 
tumorigenesis of HepG2 cells, in a dose dependent manner (Figure 29 A-B and 30 B).  
 
 
Figure 29: CF052 blocks in vitro tumorigenesis by Met. CF52 impairs anchorage-independent growth 
of HepG2 (A and B) and GTL-16 (C and D) cells, in a dose dependent manner (µM; n=3). Values are 
expressed as means ± s.e.m. *P<0.05; **P<0.01; Student’s t-tests. 
 
By evaluating the IC50 of the most active compounds, we found that CF052 and CF081 
impaired Met-triggered anchorage-independent growth at concentration lower than 
those required for SU11274 (CF052: 0,321 µM; CF081: 0,620 µM; SU11274: 1,561 µM; 
Figure 29 A-B and 30 B).  
 
 
 
 
                                                           
[66] K.M. Nicholson, C.H. Streuli, N.G. Anderson, Autocrine signalling through erbB receptors promotes 
constitutive activation of protein kinase B/Akt in breast cancer cell lines, Breast Cancer Res. Treat. 
2003, 81, 117–128. 
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CF compounds impaired effectively also tumorigenesis of GTL-16 cells addicted to the 
Met oncogene, in a dose dependent manner (Figure 29 C-D and 30 C).  
 
 
Figure 30: CF compounds block Met-triggered cell survival and anchorage-independent growth. CF 
compounds impaired anchorage-independent growth of HepG2 (B) and GTL-16 (C) cells, in a dose 
dependent manner (µM). Values are expressed as means ± s.e.m. (n=3) *P<0.05; **P<0.01; Student’s 
t-tests. 
 
The IC50 evaluation for the most active compounds revealed that CF052 and CF081 were 
also the most efficient to impair Met-triggered in vitro tumorigenesis (CF052: 0,811 µM; 
CF081: 1,194 µM; SU11274: 0,228 µM; Figure 29 C-D and 30 C). Altogether, these findings 
demonstrate that CF compounds restrain in vitro tumorigenesis of cells dependent or 
addicted to the Met oncogene. As CF052 appeared the most effective among all 
compounds, its properties were further investigated through a series of in vitro and in 
vivo assays. 
 
3.7.5  CF052 interferes with Met phosphorylation and signalling in living cells 
Activation of Met by HGF can be biochemically evaluated by following the 
phosphorylation levels of two tyrosine residues located in its kinase domain, namely 
Tyr1234 and Tyr1235. We therefore characterised the inhibitory properties of CF052 by 
following Met phosphorylation in HepG2 cells. High levels of phospho-Met were observed 
upon HGF stimulation, and phosphorylation levels progressively decreased overtime 
(Figure 31 A-B).  
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Met phosphorylation was reduced by CF052 of approximately 30 to 50% overtime when 
compared to controls (Figure 31A-B).  
 
 
Figure 31: CF052 interacts with Met (depending on in silico data) and interferes with Met 
phosphorylation. (A) Met phosphorylation following HGF stimulation in HepG2 cells was reduced in 
the presence of CF052. For western blot analyses, cells were treated with HGF for 30, 60, and 90 
minutes in the presence or not of CF052 (10µM). Total cell lysates were analyzed using α-
phosphoTyr1234/1235-Met (pMet) (upper panel). ERK protein levels were used as loading controls (lower 
panel). (B) Quantification of Met phosphorylation in the presence or not of CF052 (n=5). Values are 
expressed as means ± s.e.m. *P<0.05; **P<0.01; Student’s t-tests. (C) Met phosphorylation was also 
reduced by CF022 and CF052 applied at 3 and 10 µM in human MDA-MB231 breast cancer cells 
exposed to HGF stimulation for 15 minutes.  
 
Reduced Met phosphorylation by CF052 was observed also in other cell lines, such as in 
human MDA-MB231 breast cancer cells exposed to HGF stimulation (Figure 31C). 
Altogether, these results indicated that the new CF chemical scaffold interferes with Met 
phosphorylation. 
 
3.7.6  CF52 impairs in vivo tumor growth 
We next evaluated the ability of CF052 to impair tumor growth of cancer cells addicted to 
the Met oncogene. GTL-16 cells (106) were intra-peritoneally injected in nude mice and 
tumor growth was examined in mice treated with CF052 or vehicle alone. Intra-peritoneal 
injection of cancer cells leads to development of several nodules in the peritoneal cavity, 
offering the possibility to evaluate compound efficacy on tumor weight and nodule 
numbers. Notably, we found that both the total weight and the number of nodules were 
drastically reduced in mice injected with CF052, in a dose dependent manner (Figure 32 
A). In particular, when CF052 was administered to mice at a dose of 30 mg kg-1 every two 
days, we found (see Figure 32 B-C): 
- reduction in tumor weight of 60 % (control: 539,3 ± 209,6; CF052 injected: 214,3 ± 
148,1; P = 0,0004);  
- reduction of nodule numbers was 82 % for nodules smaller than 2 mm (control: 8,6 ± 
4,6; CF052 injected: 1,6 ± 1,6; P = 4,4E-05);  
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- reduction of nodule numbers was 76 % for nodules between 2 to 5 mm (control: 10,6 ± 
5,3; CF052 injected: 2,6 ± 1,8; P = 5,2E-05);  
- reduction of nodule numbers was 59 % for nodules bigger than 5 mm (control: 2,3 ± 
1,6; CF052 injected: 0,9 ± 0,6; P = 0,0099).  
Moreover, when GTL-16 cells were subcutaneously injected, tumor growth was also 
reduced by approximately 35 % in mice treated with CF052. 
 
 
Figure 32: CF052 interferes with growth of tumors triggered by cancer cells addicted to the Met 
oncogene. (A) Dose-response of CF052 (i.p. 10 or 30 mg kg
-1
 every 2 days) on tumor growth, 
evaluated by measuring tumor weight. (B) and nodule numbers (C) in nude mice injected intra-
peritoneally with GTL-16 cells. Values are reported as boxplots. Two independent experiments were 
performed and 8 mice per group were used. Values are expressed as means ± s.e.m. *P<0.05; 
**P<0.01; Student’s t-tests. 
 
Next was evaluated whether CF052 elicited toxic effects in vivo. As the body weight is a 
generic indicator of animal physiology influenced for example by body metabolism, 
activity and feeding behaviour, the weight of mice treated with CF052 was followed and 
no significant differences were found versus controls (P > 0.05; Figure 33 A). We 
measured also the weight of heart, spleen, kidney and liver of mice treated for 21 days 
with CF052. No differences were found between the two groups (P > 0.05; Figure 33 B). 
Taken together, these findings demonstrate that CF052 elicited in vivo tumor growth 
inhibition of cancer cells addicted to the Met oncogene. Moreover, the absence of side 
effects indicated that CF052 was well tolerated when injected in mice at doses required 
to elicit its anti-tumor effects.  
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Figure 33: In vivo administration of CF052 does not result in major side effects. (A) Evolution of the 
body weight in mice daily treated with CF052 (30 mg kg
-1
) or vehicle showed no significant 
differences. Body weight is expressed as weight evolution over the 21 day’s treatment. (B) The weight 
of heart, spleen, kidney and liver was evaluated in mice intra-peritoneally injected everyday with 
CF052 (30 mg kg
-1
) or vehicle. No significant differences were observed. Values are expressed as 
means ± s.e.m. P>0.05; Student’s t-tests. 
 
3.8  Modelling Studies  
Docking studies were performed on all the new hypothesized compounds in order to 
predict their binding mode inside the ATP binding pocket of the protein. Two different 
inactive conformations of Met kinase have been used for docking calculations. The active 
conformation was immediately discarded because of its inability to accommodate such 
bulky ligands. Among the inactive conformations, we chose the 3CTJ and the 3EFK as 
representative of the second and the third X-ray cluster, respectively. 
 
Docking on 3CTJ 
The docking calculations performed in 3CTJ (Figure 35) showed a common binding mode 
for the left part of all inhibitors. The benzothiazole (A-ring) is located at the entrance of 
the ATP binding site, in close proximity of the residues constituting the hinge region and 
partially superimposed to the pyrrolopyridine of the crystallographic inhibitor (Figure 34). 
 
 
Figure 34: General structure of the CF series of designed compounds. 
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The N-benzyl ring of compounds 9, 10, 18 and 19 and bromine of compound 20 are 
solvent exposed, outside of the binding pocket and does not make any favorable 
interactions. The central aromatic ring (B-ring) π-stacks with Phe1223 (DFG motif) and is 
flanked on the opposite face by gatekeeper residue Leu1157. The peptidic moiety could 
be involved in H-bonds with Asp1222 of activation loop or N of Lys1110. The placement of 
Hydrophobic I and Hydrophobic II moieties is the most interesting element about the 
binding mode of all the studied compounds.  
 
 
Figure 35: Binding mode of 320 (reported as in stick with the carbon atoms in purple) in the inactive 
conformation of Met (3CTJ). 
 
Molecules 9, 12a-e and 12g, having two hydrophobic residues bound to the peptidic 
moiety, occupy or with Hydrophobic I (9a, 12b, 12d and 12e) or with Hydrophobic II (9b, 
11, 12a, 12c and 12g) the DFG pocket. Since the C-helix is closed in this crystallographic 
complex, the other hydrophobic group (Hydrophobic I or II depending on the compound) 
is outside of the binding site and does not give any interaction with the protein.  
 
Docking on 3EFK 
The docking calculations performed in 3EFK (Figure 36) gave essentially the same results 
as the simulations carried out in 3CTJ. Again, the A-ring is in close proximity of hinge 
region. The B-ring is involved in lipophilic interactions with the side chain of Leu1157 and 
in the stacking with the side chain of Phe1089 that in 3EFK replaces Phe1223.  
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This replacement is extremely significant and demonstrates the flexibility of the binding 
pocket of Met.  
 
Figure 36: Binding mode of MT4 (reported as in stick with the carbon atoms in white) in the inactive 
conformation of Met (3EFK). 
 
In fact, while in 3CTJ the co-crystallized inhibitor is able to occupy the DFG pocket, in the 
3EFK the inhibitor MT4 occupies the C-helix pocket. In this way the activation loop shifts 
(see black arrow in Figure 37), with the Phe1223 that occupies the DFG pocket and cannot 
anymore interact with the inhibitor. However, the place of Phe1223 is taken by Phe1089 
that “comes down” to interact with the central aromatic ring of ligand, moving the P-loop 
(Figure 37).  
 
Figure 37: Superposition of X-ray crystal structures 3CTJ in purple and 3EFK in green. Binding mode of 
compound CF022 (12a) as found by docking simulation in both 3CTJ and 3EFK (blue carbon atoms for 
CF022 into 3CTJ and yellow carbon atoms for CF022 into 3EFK). Some relevant residues are reported 
as stick for both the structures. 
 
In addition, the peptidic moiety could be involved in H-bond with Lys1110. In this 
crystallographic structure, since the closing of DFG pocket, Hydrophobic I fit into the C-
helix pocket, while Hydrophobic II is outside the binding pocket, toward Glu1120. 
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3.9  Discussion 
The binding mode just now described for the inhibitors in both the crystallographic 
complexes is able to rationalize the inactivity of compounds 9, 10, 18, 19 and 20. In fact 
these compounds are characterized by the presence of a benzyl group or a bromine 
bound to A-ring that is outside of the binding pocket and solvent exposed, giving 
unfavorable interactions. Anyway, this binding mode is not able to explain the inactivity 
of 12f. Compound 12f occupies with its unique hydrophobic group the C-helix pocket in 
3EFK and the DFG pocket in 3CTJ. The only difference between 12f and 12a or 12b (two of 
the most active compounds) is the lacking of the second hydrophobic group that, 
however, seems not to be involved in favorable interactions with Met neither in 3CTJ, nor 
in 3EFK. Furthermore, compound 12g with a polar OH group in the Hydrophobic I is 
inactive against Met, demonstrating that two hydrophobic groups are necessary for the 
activity. 
Merge of 3CTJ and 3EFK 
The impossibility to rationalize the activity data using the X-ray complexes 3CTJ and 3EFK 
was overcome merging these two crystallographic structures. The new modelled protein 
(hereafter called Merge protein) had both the hydrophobic pockets open, with the DFG 
and the P-loop in the orientation of 3CTJ and the C-helix as 3EFK (Figure 38). 
 
Figure 38: (a) Superposition of 3CTJ (yellow cartoon) and Merge protein (blue cartoon). (b) 
Superposition of 3EFK (red cartoon) and Merge protein (blue cartoon). (c) The Merge protein showed 
as surface with DFG pocket in yellow and C-helix pocket in fuchsia. Inhibitors co-crystallized in 3CTJ 
and in 3EFK (white carbons and purple carbons, respectively) are also reported in stick 
representation. 
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3.10  Docking on Merge protein 
The docking calculations were repeated using the merge protein for all the prepared 
compounds. Each compound was found to bind Met in regular orientation, with A-ring 
toward the entrance of the binding site. The interactions and the binding mode of each 
compound are the same previously described in 3CTJ and 3EFK, with the only difference 
that in the Merge protein, since both the hydrophobic pockets are open, both 
Hydrophobic I and II give their contribution to the interactions with Met. In this context, it 
results clear the inactivity of 12f that having only the Hydrophobic II is not able to fit in 
the same time both the pockets.  
 
3.11  Conclusion 
A convenient and versatile synthesis of a new collection of potential Met inhibitors based 
on thiazole scaffold was realised. The synthesis resulted flexible and permits to obtain a 
series of analogues. The synthesis is also scalable and gives the possibility to produce 
compounds in grams scale.   
Biological evaluation showed interesting in vitro and in vivo activity for some compounds, 
in particular tetrahydro-benzothiazole and benzothiazole scaffolds resulted determinant 
for the activity on Met. 
The reported activity data clearly showed that the incorporation of phenylalanine in the 
pseudo-dipeptide chain is fundamental for the activity of this class of inhibitors. Any 
others attempt to replace phenylalanine with others amino acids led to inactive products.  
Biological tests and in silico studies confirmed also the bioisosterism between peptide 
bond and 1,2,3-triazole ring. The activity of our lead compound CF052 (12c) and the 
corresponding triazole derivatives CF120 (30) have  a comparable activity. 
Biological trials showed that the CF series compounds are able both to reduce Met 
phosphorylation and to prevent Met-triggered survival of Met-dependent HepG2 and 
GTL-16 cancer cell lines.  
The study on biological mechanism of action showed an important point for this thiazole 
based inhibitors: the double ability to reduce Met phosphorylation and to prevent its re-
synthesis. This dual mechanism of action could lead to more potent Met inhibitors. 
The obtained results showed the good ability of the prediction coming from the modelling 
studies and these results confirmed the importance of the in silico studies in drug 
discovery. 
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3.12 Experimental details 
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3.12.1  Modeling 
 
Building of merge protein 
The backbone of 3CTJ and 3EFK crystallographic complexes was superimposed using the 
software Pymol version 1.2[67] by the implemented Shindyalov and Bourne algorithm,[68] 
obtaining a RMSD value of 0.31 Å. The crystallographic complex 3CTJ was taken as 
template from the first residue (Val1051) to Ser1111, then, to be able to insert the C-helix 
of 3EFK, residues Leu1112-Phe1134 were removed, while residues Ile1118-Phe1134, 
constituting the C-helix in the intended 3EFK orientation, were added. The remaining 
residues (Ser1135-Lys1360) of 3CTJ were conserved in the Merge protein. This chimeric 
protein was subjected to minimization using Macromodel 8.5/Maestro and OPLS_2005 
force field (Polak-Ribiere conjugate gradient, 0.05 kJ/Å·mol convergence).[69-70] In 
particular, the backbone of the entire protein was frozen, while all the amino acid side 
chains were unconstrained during energy minimization to allow for reorientation and 
proper hydrogen-bonding geometries and van der Waals contacts. The obtained 
minimized Merge protein was used for the following docking calculation.  
 
Docking simulations 
Docking studies were performed on all the compounds by means of the GOLD 4.0 
software.[71] The Kinase Scoring Function was chosen as fitness function. This particular 
kind of Chemscore keeps into account weak CHO interactions calculating a contribution 
for weak hydrogen bonds. This term can be useful when dealing with particular proteins, 
like most kinases that contain weak N-heterocycle CH...O hydrogen bonds. The GA 
parameter settings of Gold were employed using the Search efficiency set to 100%. The 
reliability of the docking protocol was tested by simulations of the binding mode of Met 
inhibitors co-crystallized in 3CTJ and 3EFK by a comparison of the modeled complexes 
with the available 3D structures derived by X-ray crystallography. Structures of inhibitors 
were built using Maestro 3D-sketcher, minimized with OPLS_2005 force field, using the 
                                                           
[67] DeLano, W. L. The PyMOL Molecular Graphics System; DeLano Scientific LLC: San Carlos, CA; 
http://www.pymol.org. 
[68] Shindyalov, N., Bourne, P. E. Protein structure aligment by incremental combinatorial extension (CE) of 
the optimal path. Protein Eng., 1998, 11, 739–747. 
[69] Maestro, version 8.5; Schrodinger: New York, 2008. 
[70] Jorgensen, W. L.; Maxwell, D. S.; Tirado-Rives, J. Development and testing of the OPLS all-atom force 
field on conformational energetics and properties of organic liquids. J. Am. Chem. Soc. 1996, 118, 
11225– 11236. 
[71] (a) Jones, G., Willett, P., Glen, R. C. Molecular Recognition of Receptor Sites Using a Genetic Algorithm 
with a Description of Desolvation,  J. Mol. Biol.  1995, 245, 43-53; b) Jones, G., Willett, P., Glen, R. C., 
Leach, A. R., Taylor, R. Development and Validation of a Genetic Algorithm for Flexible Docking, J. Mol. 
Biol. 1997, 267, 727-748: c) Verdonk, M. L., Cole, J. C., Hartshorn, M. J., Murray, C. W., Taylor, R. D., 
Improved Protein-Ligand Docking Using GOLD, Proteins, 2003, 52, 609-623. 
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Polak-Ribiere conjugated gradient method (0.001 kJ/Å·mol convergence) and finally 
docked in the native protein. The experimental binding conformations of the reference 
compounds were successfully reproduced applying the already mentioned settings of 
GOLD, with 30 docking runs. In particular, the first ranked docked conformation was able 
to reproduce the X-ray conformation of 320 and MT4 (ligand of 3CTJ and 3EFK, 
respectively) with a root-mean-square deviation (rmsd) of 0.7 Å and 0.3 Å, respectively, 
calculated on all heavy atoms coordinates. With a reliable docking procedure in our 
hands, in the next step of the computational work we used the 3CTJ, 3EFK and the Merge 
protein to dock the synthesized compounds. 
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3.12.2  Biology  
 
Cell culture 
MDCK cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco BRL) 
containing 4mM L-glutamine and supplemented with 2% (v/v) foetal bovine serum (Gibco 
BRL), 100 U/mL penicillin, and 100 μg/mL streptomycin. Cells were plated at a density of 
1000 cells per well in 24-well microplates and allowed settling overnight at 37°C in a 
humidified atmosphere of 5% CO2 prior to treatments. Human MCF10A breast cells, 
human MDA-MB231 breast cancer cells, human GTL-16 gastric carcinoma cells, human 
HepG2 hepatocellular carcinoma cells, human U-87 glioblastoma-astrocytoma cells and 
human LLC Lewis lung carcinoma cells were grown in RPMI medium (Gibco BRL) 
containing 4mM L-glutamine and supplemented with 10% (v/v) foetal bovine serum 
(Gibco BRL), 100 U/mL penicillin, and 100 μg/mL streptomycin and kept at 37°C in a 
humidified atmosphere of 5% CO2. 
 
Compound treatments 
For scattering assays, MDCK cells were pre-incubated with compounds over-night at 0.1-
100 µM concentrations at 37 °C in a humidified atmosphere of 5 % CO2, followed by 24 
hours stimulation with 20 ng/ml HGF (R&D Systems), as previously described.[59] Cells 
were further incubated at 37 °C in an atmosphere of 5 % CO2 for 24-48 hours, washed 
with phosphate-buffered saline (PBS; Gibco BRL), and fixed with 4 % PFA (Sigma). The 
quantification of scattering response was performed by counting the number of cells with 
scattered morphology in 30 independent colonies. The IC50 corresponds to the 
concentration of compounds leading to a 50 % inhibition of Met-triggered cell scattering. 
Active compounds were assayed to impair scattering response also on MCF10A cells 
following the same procedure. For survival assays, GTL-16, HepG2 and U-87 cells were 
cultured in serum-free media for 24 hrs prior to compound addition for 48 hrs. Viability 
was assessed with the Cell Titer Glo Luminescent Assay (Promega). For in vitro 
tumorigenesis, soft agar growth assays were performed using GTL-16, HepG2, and U-87 
cells, as previously described.[59] Data on biological assays are representative of three 
independent experiments performed in duplicate. 
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Biochemical evaluation of Met inhibitors 
After starvation, cells were pretreated overnight with inhibitors, then stimulated with 
HGF, and total extracts were analyzed as described.[72] Antibodies used were anti-tubulin 
(Sigma), anti-phospho Y1234-1235-Met, anti-Akt, anti-phospho-Akt, anti-phospho-Gab1, anti 
phosphor-ErbBs, anti-phospho-PDGFR, anti-PDGFRs, anti-ERKs (Cell Signaling), anti-ErbBs, 
anti-Met (Santa Cruz). 
 
In vivo tumorigenesis assays 
Xenografts of GTL-16 cells were established by intraperitoneal (i.p.) or subcutaneous (into 
the flank/leg region) injection of cells (106) in nude mice (S/SOPF SWISS NU/NU; Charles 
River). When GTL-16 cell were intra-peritoneally injected, mice were treated with CF052 
(i.p. 10 or 30 mg kg-1) or vehicle at day 1 and treatment was repeated every two days. 
Alternatively, CF052 treatment was started 7 days after cell injection and treatment was 
daily performed. When GTL-16 cell were sub-cutaneously injected, CF052 administration 
(i.p. 30 mg kg-1) was daily performed starting from day 1. Mice were then sacrificed after 
21 days of treatment. Tumor nodules present in the peritoneal cavity were isolated and 
quantified according to their diameter and their total weight. Similarly, sub-cutaneous 
tumors were isolated after 21 days of treatment and quantified as above. For CF052 in 
vivo treatment, the drug was formulated in Cremophor EL (polyethoxylated castor oil) and 
DMSO (1:1, v/v) and diluted in sterile 0.9% (w/v) sodium chloride for administration at 
dose levels of 10 and 30 mg kg-1. Three independent tumorigenesis assays were 
performed (8 mice per group were used). Mice were kept at the IBDML animal facilities 
and all experiments were performed in accordance with institutional guidelines. 
 
Toxicity evaluation of compounds in vivo 
The weight of nude mice treated with CF52 compound (30 mg kg-1) or vehicle was 
measured before, during and after treatment. To evaluate the weight of heart, spleen, 
kidney and liver, mice were sacrificed after 21 days of CF52 or vehicle treatments, organs 
were dissected, rinsed in PBS, and their weight was measured. 
                                                           
[72] F. Maina, G. Pante, F. Helmbacher, R. Andres, A. Porthin, A.M. Davies, C. Ponzetto, R. Klein, Coupling 
Met to specific pathways results in distinct developmental outcomes, Mol Cell 2001, 7, 1293-1306. 
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3.12.3  Chemistry 
 
General 
All non-aqueous reactions were performed under inert atmosphere with dry, freshly 
distilled solvents using standard procedures. Drying of organic extracts during the work-
up of reactions was performed over anhydrous Na2SO4 or MgSO4. Evaporation of solvents 
was accomplished with a rotatory evaporator. Thin-layer chromatography (TLC) was 
performed on Merck precoated 60F254 plates. Reactions were monitored by TLC on silica 
gel, with detection by UV light (254 nm) or by charring with 1 % permanganate solution. 
Flash chromatography was performed using Silica gel (240–400 mesh, Merck). NMR 
spectra were recorded with Brucker 300 and 400 MHz spectrometers using chloroform-d 
(CDCl3), dimethylsolfoxide-d6 (DMSO-d6) and methanol-d4 (CD3OD). Chemical shifts are 
reported in parts per million (δ) downfield from tetramethylsilane (TMS). EI mass spectra 
were recorded at an ionizing voltage of 6Kev on a VG 70-70 EQ. ESI mass spectra were 
recorded on FT-ICR APEXII (Bruker Daltonics). All reactions were carried out in dry 
solvents. Specific rotations were misured by a polarimeter “P-1030 Jasco” with 10 cm of 
Optical path cells and 1 ml of capacity. The mesures were done between 18 and 22 °C at 
589 nm Wavelength (Na lamp). The melting point was determined by “Digital Melting 
Point IA9100 series - Electrothermal”.  
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General Procedure for Synthesis of (2) 
 
 
 
 
 
Procedure A:  
Fe powder (7 g, 120 mmol) and H2SO4 12 N (0.7 ml, 30 mmol) were added to a solution of  
5 (6 mmol) in  ethanol/water (5:1, 50-100 ml) and the mixture was stirred at 90 °C for 1 h. 
The hot solution was filtered through celite and washed with hot ethanol. The solvent 
was removed in vacuo and the crude materials was extracted by satured solution of 
NaHCO3 and AcOEt. The organic phase was dried with Na2SO4 anhydrous. Compound 2 
was obtained without any further purification.  
 
Procedure B:   
HCl (37 %, 100 ml) was slowly added to a mixture of 5 (3.4 mmol) and SnCl2 (13 mmol) in 
MeOH (100 ml). The crude mixture was refluxed for 30 min. A solution of K2CO3 (2 M) was 
slowly added to reach pH 9. The precipitate was filtered and purified by flash 
chromatography. 
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2-(4-Aminophenyl)-7-benzyl-5,6,7,8-tetrahydroimidazo[2’,1’:2,3]thiazolo[5,4-c]pyridine  
- (2a) 
ARKIVOC 2010, 3, 145-151. 
 
 
 
 
 
From 5a (1.92 g, 4.08 mmol) using procedure B. Crude material was purified by flash 
chromatography (AcOEt + 0.1 % NEt3) to afford 2a as pale yellow solid (0.38 g, yield 26 % 
over 2 steps). 
 
1H NMR (CDCl3, 400 MHz): δ 7.60 (2H, d, J = 8.4 Hz), 7.39 (1H, s), 7.25-7.36 (5H, m), 6.69 
(2H, d, J = 8.4 Hz), 3.73 (2H, s), 3.56 (2H, s), 2.95 (2H, t, J = 6.0 Hz), 2.71 (2H, t, J = 6.0 Hz).  
EIMS 360 [M]+. 
92 
2-(4-Aminophenyl)-6-benzyl-5,6,7,8-tetrahydroimidazo[2’,1’:2,3]thiazolo[4,5-c]pyridine 
- (2b) 
ARKIVOC 2010, 3, 145-151. 
 
 
 
 
 
From 5b using the procedure B. Crude material was purified by flash chromatography 
(CH2Cl2 to CH2Cl2:MeOH 98.5:1.5). to afford 2b as pale yellow solid (yield 23%). 
 
1H NMR (CDCl3 with drops of CD3OD, 400 MHz): δ 7.89 (1H, s), 7.52 (2H, d, J = 8.8 Hz), 
7.33-7.39 (5H, m), 6.73 (2H, d, J = 8.8 Hz), 3.80 (2H, s), 3.57 (2H, t, J = 1.5 Hz), 2.95 (2H, t, J 
= 5.2 Hz), 2.82 (2H, t, J = 5.2 Hz).  
13C NMR (CDCl3 with drops of CD3OD, 100.6 MHz): δ 148.22, 146.63, 145.77, 136.89, 
128.80 (2C), 128.33 (2C), 127.45, 125.96 (2C), 124.27, 124.08, 119.34, 115.22 (2C), 
104.16, 61.42, 49.94, 48.86, 24.27.  
EIMS 360 [M]+. 
93 
 2-(4-Aminophenyl)-5,6,7,8-tetrahydroimidazo[2,1-b]benzothiazole - (2c) 
Bioorg. Med. Chem. Lett. 2005, 15, 1561-1564. 
 
 
 
 
 
2c was prepared from 5c (2.00g, 6.69 mmol) using general procedure A for synthesis of 2. 
Yellow solid (1.58 g, yield 89 %).  
 
1H NMR (DMSO-d6, 300 MHz): δ  7.87 (1H, s), 7.50 (2H, d, J = 8.2 Hz), 6.58 (2H, d, J = 8.2 
Hz), 5.13 (2H, s), 2.69-2.64 (4H, m), 1.89-1.85 (4H, m).  
EIMS 269 [M]+. 
94 
2-(4-aminophenyl)imidazo[2,1-b]benzothiazole - (2d) 
J. Med. Chem. 1986, 29, 386-394. 
 
 
 
 
 
2d was prepared from 5d (2.00 g, 6.78 mmol) using general procedure A for synthesis of 
2. Pale yellow solid (1.63 g, yield 91 %).  
 
1H NMR (DMSO-d6, 300 MHz): δ 8.48 (1H, s), 8.05 (1H, d, J = 8.0 Hz), 7.93 (1H, d, J = 8.0 
Hz), 7.61-7.51 (3H, m), 7.42 (1H, t, J = 8.0 Hz), 6.64 (2H, d, J = 9.0 Hz), 5.23 (2H, s);   
EIMS 265 [M]+.  
95 
General Procedure for Synthesis of (3) 
 
 
 
 
 
Procedure C:  
A solution of a phenylacetic acid (3.7 mmol), DMAP (5.55 mmol) and DCC (5.55 mmol) in 
THF (40-70 ml) was stirred at rt for 30 min. The hydrochloride salt of the carboxy 
protected aminoacid (3.7 mmol) was added and the solution was stirred for 48 h at rt. 
The crude mixture was filtered over celite and the solvent was removed in vacuo. The 
product was purified by flash chromatography to afford the methylester of acid 8. The 
methylester (1 mmol) was dissolved in methanol. A solution of LiOH 1N (4 mmol) was 
added and the reaction mixture was stirred for 1 h at 0 °C. H2O was added and methanol 
only was evaporated under reduced pressure. The pH was reduced to 2 using HCl solution 
1N. The crude materials was extracted with ethyl acetate and the organic phase was dried 
with Na2SO4 anhydrous. The solvent was removed in vacuo to afford 3 without any 
further purification.  
 
Procedure D:  
A solution of phenylacetic acid (6 mmol), DMAP (3 mmol) and DCI (10 mmol) in THF was 
stirred for 14h at rt. The crude mixture was filtered over celite and the solvent was 
removed in vacuo. The product was purified by flash chromatography. The product was 
purified by flash chromatography to afford the methylester of acid 8. The methylester (1 
mmol) was dissolved in methanol. A solution of LiOH 1N (4 mmol) was added and the 
reaction mixture was stirred for 1 h at 0 °C. H2O was added and methanol only was 
evaporated under reduced pressure. The pH was reduced to 2 using HCl solution 1N. The 
crude materials was extracted with ethyl acetate and the organic phase was dried with 
Na2SO4 anhydrous. The solvent was removed in vacuo to afford 3 without any further 
purification.  
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(S)-2-[2-(3,5-dimethylphenyl)acetamido]-3-phenyl-propanoic acid - (3a) 
 
 
 
 
 
The methylester of acid 3a was prepared using L-Phenylalaninemethylester hydrochloride 
(0.80 g, 3.71 mmol) and 3,5-Dimethylphenylacetic acid (0.61 g, 3.71 mmol) using general 
procedure C for synthesis of 3. The crude mixture was purified by flash chromatography 
(Hex:AcOEt 2:1) to afford the methylester as white solid (0.85 g, yield 70 %).  
 
1H NMR (CDCl3, 400 MHz): δ 7.24-7.18 (3H, m), 6.94-6.91 (3H, m), 6.82 (2H, s), 5.83 (1H, d, 
J = 7.6 Hz), 4.91-4.83 (1H, m), 3.66 (3H, s), 3.52 (1H, d, J = 15.8 Hz), 3.48 (1H, d, J = 15.8 
Hz), 3.09 (1H, dd, J = 13.8, 5.5 Hz), 3.04 (1H, dd, J = 13.8, 5.5 Hz), 2.19 (6H, s).  
EIMS 325 [M]+.  
 
3a was prepared from the corresponding methylester (0.64 g, 1.96 mmol) using general 
procedure C for synthesis of 3. White solid (0.58 g, yield 95 %).  
 
m.p. 85-88°C,  
[α]20D = +35.12 (Na, c = 0.80 in CHCl3).  
1H NMR (CDCl3, 400 MHz): δ 10 (1H, s), 7.24-7.19 (3H, m),  6.97 (2H, dd, J = 7.2, 1.6 Hz), 
6.94 (1H, s), 6.78 (2H, s), 6.01 (1H, d, J = 7.6 Hz), 4.87-4.83 (1H, m), 3.52 (1H, d, J = 16.4 
Hz), 3.48 (1H, d, J = 16.4 Hz), 3.16 (1H, dd, J = 14.0, 5.6 Hz), 3.06 (1H, dd, J = 14.0, 5.6 Hz), 
2.3 (6H, s). 
 13C NMR (CDCl3, 100.6 MHz): δ 174.36, 172.18, 138.63 (2C), 135.44, 133.68, 129.67, 
129.24 (2C), 128.54 (2C), 127.26 (2C), 127.08, 53.17, 43.20, 36.99, 21.23 (2C).  
HR-EIMS Anal. Calcd for [C19H21NO3]
+ 311.1521; found 311.1523.  
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(R)-2-[2-(3,5-dimethylphenyl)acetamido]-3-phenylpropanoic acid - (3b) 
 
 
 
 
 
The methylester of acid 3b was prepared using D-Phenylalaninemethylester 
hydrochloride (0.80 g, 3.71 mmol) and 3,5-Dimethylphenylacetic acid (0.61 g, 3.71 mmol) 
using general procedure C for synthesis of 3. The crude mixture was purified by flash 
chromatography (Hex:AcOEt 2:1) to afford the methylester as white solid (0.82 g, yield 68 
%).  
 
1H NMR (CDCl3, 400 MHz): δ 7.24-7.18 (3H, m), 6.94-6.91 (3H, m), 6.82 (2H, s), 5.83 (1H, d, 
J = 7.6 Hz), 4.91-4.83 (1H, m), 3.66 (3H, s), 3.52 (1H, d, J = 15.8 Hz), 3.48 (1H, d, J = 15.8 
Hz), 3.09 (1H, dd, J = 13.8, 5.5 Hz), 3.04 (1H, dd, J = 13.8, 5.5 Hz), 2.19 (6H, s).  
EIMS 325 [M]+. 
 
3b was prepared from the corresponding methylester (0.75 g, 2.30 mmol) using general 
procedure C for synthesis of 3. White solid (0.70 g, yield 98 %).  
 
mp 85-88°C,  
[α]20D = -35.52 (Na, c = 1.28 in CHCl3).  
1H NMR (CDCl3, 400 MHz): δ 10 (1H, s), 7.24-7.19 (3H, m),  6.97 (2H, dd, J = 7.2, 1.6 Hz), 
6.94 (1H, s), 6.78 (2H, s), 6.01 (1H, d, J = 7.6 Hz), 4.87-4.83 (1H, m), 3.52 (1H, d, J = 16.4 
Hz), 3.48 (1H, d, J = 16.4 Hz), 3.16 (1H, dd, J = 14.0, 5.6 Hz), 3.06 (1H, dd, J = 14.0, 5.6 Hz), 
2.3 (6H, s).  
13C NMR (CDCl3, 100.6 MHz): δ 174.36, 172.18, 138.63 (2C), 135.44, 133.68, 129.67, 
129.24 (2C), 128.54 (2C), 127.26 (2C), 127.08, 53.17, 43.20, 36.99, 21.23 (2C).  
HR-EIMS Anal. Calcd for [C19H21NO3]
+ 311.1521; Found 311.1522. 
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(S)-2-[2-(3,5-bis(trifluoromethyl)phenyl)acetamido]-3-phenylpropanoic acid - (3c) 
 
 
 
 
 
The methylester of acid 3c was prepared using L-Phenylalaninemethylester hydrochloride 
(0.72 g, 3.34 mmol) and 3,5-Bis(trifluoromethyl) phenylacetic acid (0.91 g, 3.34 mmol) 
using general procedure C for synthesis of 3. The crude mixture was purified by flash 
chromatography (Hex:AcOEt 2:1) to afford the methylester as white solid (0.90 g, yield 63 
%).  
 
1H NMR (CDCl3, 400 MHz): δ 7.82 (1H, s), 7.72 (2H, s), 7.27-7.23 (3H, m), 7.01-6.98 (2H, 
m), 5.97 (1H, d, J = 7.2 Hz), 4.93-4.88 (1H, m), 3.79 (3H, s), 3.66 (1H, d, J = 15.6 Hz), 3.61 
(1H, d, J = 15.6 Hz), 3.17 (1H, dd, J = 13.6, 5.6 Hz), 3.09 (1H, dd, J = 13.6, 5.4 Hz).  
EIMS 433 [M]+. 
 
3c was prepared from the corresponding methylester (0.63 g, 1.46 mmol) using general 
procedure C for synthesis of 3. White solid (0.61 g, yield 99 %). 
 
mp 138-140 °C  
[α]20D = +10.17 (Na, c = 1.28 in MeOH).  
1H NMR (DMSO-d6, 400 MHz): δ 8.52 (1H, d, J = 8.2 Hz), 7.96 (1H, s), 7.88 (2H, s), 7.22-7.13 
(5H, m), 4.49-4.43 (1H, m), 3.65 (1H, d, J = 15.3 Hz), 3.57 (1H, d, J = 15.3 Hz), 3.09 (1H, dd, 
J = 13.8, 4.6 Hz), 2.86 (1H, dd, J = 13.8, 9.8 Hz). 
13C NMR (DMSO-d6, 100.6 MHz): δ 173.88, 169.96, 140.73, 138.55, 131.12 (2C, q, J = 32.8 
Hz), 130.94 (2C), 130.11 (2C), 129.10 (2C), 127.44, 124.50 (2C, q, J = 272.6 Hz), 121.25, 
54.60, 42.17, 37.90.  
HR-EIMS Anal. Calcd for [C19H15F6NO3]
+ 419.0956; Found 491.0952. 
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(R)-2-[2-(3,5-bis(trifluoromethyl)phenyl)acetamido]-3-phenylpropanoic acid - (3d) 
 
 
 
 
 
The methylester of acid 3d was prepared using D-Phenylalaninemethylester 
hydrochloride (0.600 g, 2.78 mmol) and 3,5-Bis(trifluoromethyl)phenylacetic acid (0.760 
g, 2.78 mmol) using general procedure C for synthesis of 3. The crude mixture was 
purified by flash chromatography (Hex:AcOEt 2:1) to afford the methylester as white solid 
(0.75 g, yield 62 %).  
 
1H NMR (CDCl3, 400 MHz): δ 7.82 (1H, s), 7.72 (2H, s), 7.27-7.23 (3H, m), 7.01-6.98 (2H, 
m), 5.97 (1H, d, J = 7.2 Hz), 4.93-4.88 (1H, m), 3.79 (3H, s), 3.66 (1H, d, J = 15.6 Hz), 3.61 
(1H, d, J = 15.6 Hz), 3.17 (1H, dd, J = 13.6, 5.6 Hz), 3.09 (1H, dd, J = 13.6, 5.4 Hz).  
EIMS 433 [M]+. 
 
3d was prepared from the corresponding methylester (0.26 g, 0.60 mmol) using general 
procedure C for synthesis of 3. White solid (0.25 g, yield 99 %).  
 
mp 138-140 °C 
[α]20D = -10.52 (Na, c = 0.21 in MeOH).  
1H NMR (DMSO-d6, 400 MHz): δ 8.52 (1H, d, J = 8.2 Hz), 7.96 (1H, s), 7.88 (2H, s), 7.22-7.13 
(5H, m), 4.49-4.43 (1H, m), 3.65 (1H, d, J = 15.3 Hz), 3.57 (1H, d, J = 15.3 Hz), 3.09 (1H, dd, 
J = 13.8, 4.6 Hz), 2.86 (1H, dd, J = 13.8, 9.8 Hz). 
13C NMR (DMSO-d6, 100.6 MHz): δ 173.88, 169.96, 140.73, 138.55, 131.12 (2C, q, J = 32.8 
Hz), 130.94 (2C), 130.11 (2C), 129.10 (2C), 127.44, 124.50 (2C, q, J = 272.6 Hz), 121.25, 
54.60, 42.17, 37.90.  
HR-EIMS Anal. Calcd for [C19H15F6NO3]
+ 419.0956; Found 491.0955. 
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(S)-2-[2-(3,5-difluorophenyl)acetamido]-3-phenylpropanoic acid - (3e) 
 
 
 
 
 
The methylester of acid 3e was prepared using L-Phenylalaninemethylester hydrochloride 
(0.80 g, 3.71 mmol) and 3,5-Difluorophenylacetic acid (0.64 g, 3.71 mmol) using general 
procedure C for synthesis of 3. The crude mixture was purified by flash chromatography 
(Hex:AcOEt 2:1) to afford the methylester as white solid (0.93 g, yield 75 %).  
 
1H NMR (CDCl3, 300 MHz): δ 7.25-7.23 (3H, m), 6.96-6.92 (2H, m), 6.74-6.70 (3H, m), 5.83 
(1H, d, J = 6.8 Hz), 4.88-4.82 (1H, m), 3.73 (3H, s), 3.50 (1H, d, J = 14.2 Hz), 3.47 (1H, d, J = 
14.2 Hz), 3.12 (1H, dd, J = 13.8, 5.6 Hz), 3.02 (1H, dd, J = 13.8, 5.9 Hz).  
EIMS 333 [M] +. 
 
3e was prepared from the corresponding methylester (0.73 g, 2.19 mmol) using general 
procedure C for synthesis of 3. White solid (0.63 g, yield 91 %).  
 
mp 182-184 °C.  
[α]20D = +33.63 (Na, c = 0.96 in MeOH:CHCl3 1:1).  
1H NMR (DMSO-d6, 400 MHz): δ 8.48 (1H, d, J = 8.2 Hz), 7.26-7.18 (5H, m), 7.09-7.03 (1H, 
m), 6.87-6.83 (2H, m), 4.48-4.42 (1H, m), 3.49 (1H, d, J = 14.2 Hz), 3.43 (1H, d, J = 14.2 Hz), 
3.09 (1H, dd, J = 13.8, 4.7 Hz), 2.86 (1H, dd J = 13.8, 9.8 Hz).  
13C NMR (DMSO-d6, 100.6 MHz): δ 173.38, 169.44, 162.53 (2C, dd, J = 245.5, 14.1 Hz), 
140.99 (t, J = 10.0 Hz), 137.91, 129.55 (2C), 128.55 (2C), 126.89, 112.57 (2C, d, J = 25.2 
Hz), 102.29 (2C, t, J = 25.2 Hz), 53.91, 41.81, 37.14.  
HR-EIMS Anal. Calcd for [C17H15F2NO3]
+ 319.1020; Found 319.1019. 
101 
2-[2-(3,5-dimethylphenyl)acetamido]acetic acid - (3f) 
 
 
 
 
 
The methylester of acid 3f was prepared using Glycinemethylester hydrochloride (0.80 g, 
6.37 mmol) and 3,5-Dimethylphenylacetic acid (1.05 g, 6.37 mmol) using general 
procedure C for synthesis of 3. The crude mixture was purified by flash chromatography 
(Hex:AcOEt 2:3) to afford the methylester as white solid (0.78 g, yield 52 %).  
1H NMR (CDCl3, 300 MHz): δ 6.92 (1H, s), 6.88 (2H, s), 5.92 (1H, d, J = 5.1 Hz), 3.99 (2H, d, J 
= 5.1 Hz), 3.72 (3H, s), 3.54 (2H, s), 2.30 (6H, s).  
EIMS 235 [M]+. 
 
3f was prepared from the corresponding methylester (0.74 g, 3.145 mmol) using general 
procedure C for synthesis of 3. White solid (0.66 g, yield 95 %).  
 
mp 129-131 °C.  
1H NMR (DMSO-d6, 400 MHz): δ 8.30 (1H, t, J = 5.7 Hz), 6.88, (2H, s), 6.85 (1H, s), 3.75 (2H, 
d, J = 5.7 Hz), 3.39 (2H, s), 2.23 (6H, s).  
13C NMR (DMSO-d6, 100.6 MHz): δ 171.79, 171.05, 137.47 (2C), 136.37, 128.19, 127.30 
(2C), 42.35, 41.21, 21.34 (2C).  
HR-EIMS Anal. Calcd for [C12H15NO3]
+ 221.1052; Found 221.1054. 
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(S)-2-[2-(3,5-dimethylphenyl)acetamido]-3-(4-hydroxyphenyl)propanoic acid - (3g) 
 
 
 
 
 
The methylester of acid 3g was prepared using L-Tyrosine methyl ester hydrochloride 
(0.47 g, 2.32 mmol) and 3,5-Dimethylphenylacetic acid (0.45 g, 2.32 mmol) using general 
procedure C for synthesis of 3. The crude mixture was purified by flash chromatography 
(Hex:AcOEt 2:3) to afford the methylester as white solid (0.34 g, yield 43 %).  
1H NMR (CDCl3, 400 MHz): δ 7.12-7.05 (3H, m), 6.80-6.78 (2H, m), 6.69 (2H, d, J = 9.0 Hz), 
5.71 (1H, d, J = 7.6 Hz), 4.85-4.79 (1H, m), 3.53 (3H, s), 3.41 (1H, d, J = 15.7 Hz), 3.34 (1H, 
d, J = 15.7 Hz), 2.98 (1H, dd, J = 13.8, 5.8 Hz), 2.96 (1H, dd, J = 13.8, 5.8 Hz), 2.07 (6H, s).  
EIMS 341 [M]+. 
 
3g was prepared from the corresponding methylester (0.22 g, 0.65 mmol) using general 
procedure C for synthesis of 3. White solid (0.21 g, yield 97 %). 
 
mp 145-148 °C.  
[α]20D = +22.12 (Na, c = 1.35 in MeOH).  
1H NMR (CDCl3, 400 MHz): δ 7.12-7.07 (3H, m),  6.91 (2H, dd, J = 7.1, 1.7 Hz), 6.68 (2H, d, J 
= 9.01 Hz), 5.86 (1H, d, J = 7.6 Hz), 4.91-4.85 (1H, m), 3.59 (1H, d, J = 16.4 Hz), 3.51 (1H, d, 
J = 16.4 Hz), 3.23 (1H, dd, J = 14.0, 5.6 Hz), 3.06 (1H, dd, J = 14.0, 5.6 Hz), 2.3 (6H, s).  
13C NMR (CDCl3, 100.6 MHz): δ 174.28, 172.18, 155.62, 138.63 (2C), 133.68, 130.27, 
129.67, 129.36 (2C), 127.26 (2C), 115.75 (2C), 53.17, 43.20, 36.99, 21.23 (2C).  
EIMS 327 [M]+
103 
(S)-2-[(3,5-Difluorophenyl)acetamido]propanoic acid - (3h) 
 
 
 
 
 
The methylester of acid 3h was prepared using L-alanine methyl ester hydrochloride and 
3,5-difluorophenylacetic acid using general procedure D for synthesis of 3. The crude 
mixture was purified by flash chromatography (Hex:AcOEt 1:1) to afford the methyl ester 
as white solid (yield 85 %).  
 
1H NMR (CDCl3, 400 MHz) δ: 6.83 (2H, tt, J = 6.6, 2.4 Hz), 6.73 (1H, tt, J = 11.2, 2.4 Hz), 6.26 
(1H, d, J = 5.2 Hz), 4.58 (1H, qd, J = 7.2, 5.2 Hz), 3.74 (3H, s), 3.55 (2H, s), 1.39 (3H, d, J = 
7.2 Hz).  
 
3h was prepared from the corresponding methyl ester using general procedure D for 
synthesis of 3. Amorphous solid (yield 72 %). 
 
[α]20D = +28.15 (Na, c = 0.64 in CHCl3).  
1H NMR (CDCl3, 300 MHz) δ: 6.82 (2H, tt, J = 6.6, 2.1 Hz), 6.75 (1H, tt, J = 9.3, 2.1 Hz), 6.03 
(1H, d, J = 6.0 Hz), 4.60 (1H, qd, J = 7.2 Hz), 3.57 (2H, s), 1.45 (3H, d, J = 7.2 Hz).  
13C NMR (100.6 MHz, CD3OD) δ: 175.95, 172.44, 163.69 (2C, dd, J = 247.9, 16.8 Hz), 
141.07 (t, J = 40.0 Hz), 113.22 (2C, d, J = 28.0 Hz), 102.95 (t, J = 102.0 Hz, CHAr), 48.26, 
42.71, 17.50.  
EIMS 243 [M]+
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(R)-2-[(3,5-difluorophenyl)acetamido]propanoic acid - (3i) 
 
 
 
 
 
The methylester of acid 3i was prepared using L-alanine methyl ester hydrochloride and 
3,5-difluorophenylacetic acid using general procedure D for synthesis of 3. The crude 
mixture was purified by flash chromatography (Hex:AcOEt 1:1) to afford the methyl ester 
as white solid (yield 82 %).  
 
1H NMR (CDCl3, 400 MHz) δ: 6.83 (2H, tt, J = 6.6, 2.4 Hz), 6.73 (1H, tt, J = 11.2, 2.4 Hz), 6.26 
(1H, d, J = 5.2 Hz), 4.58 (1H, qd, J = 7.2, 5.2 Hz), 3.74 (3H, s), 3.55 (2H, s), 1.39 (3H, d, J = 
7.2 Hz).  
 
3i was prepared from the corresponding methyl ester using general procedure D for 
synthesis of 3. Amorphous solid (yield 68 %). 
 
[α]20D = -27.89 (Na, c = 0.75 in CHCl3).  
1H NMR (CDCl3, 300 MHz) δ: 6.82 (2H, tt, J = 6.6, 2.1 Hz), 6.75 (1H, tt, J = 9.3, 2.1 Hz), 6.03 
(1H, d, J = 6.0 Hz), 4.60 (1H, qd, J = 7.2 Hz), 3.57 (2H, s), 1.45 (3H, d, J = 7.2 Hz).  
13C NMR (100.6 MHz, CD3OD) δ: 175.95, 172.44, 163.69 (2C, dd, J = 247.9, 16.8 Hz), 
141.07 (t, J = 40.0 Hz), 113.22 (2C, d, J = 28.0 Hz), 102.95 (t, J = 102.0 Hz, CHAr), 48.26, 
42.71, 17.50.  
EIMS 243 [M]+
105 
2-Amino-4,5,6,7-tetrahydrobenzothiazole - (4c) 
Bioorg. Med. Chem. Lett. 2005, 15, 1561-1564. 
 
 
 
 
 
A mixture of cycloexanone (3.00 g, 30.6 mmol), thiourea (4.65 g, 61.1 mmol) and iodine 
(7.76 g, 30.6 mmol) was stirred at 110°C for 12 h. The reaction mixture was cooled to 
room temperature. Hot water was then added to solubilize the crude material, and the 
resulting solution was stirred for 30 min. The aqueous solution was washed with diethyl 
ether and then neutralized by the addition of solid NaHCO3. The pale yellow crystals were 
collected by filtration. The hydroiodide salt was dissolved in a hot saturated aqueous 
solution of Na2CO3. After cooling, the aqueous solution was extracted with CH2Cl2. The 
organic layer was dried over anhydrous Na2SO4, filtered, and concentrated under reduced 
pressure. The compound 4c was obtained without any further purification as pale yellow 
solid (3.39 g, yield 72 %).  
 
1H NMR (DMSO-d6 300 MHz) δ 6.61 (2H, s), 2.52-2.48 (2H, m), 2.38-2.35 (2H, m), 1.72-
1.68 (4H, m).  
EIMS 154 [M]+. 
106 
General Procedure E for Synthesis of (5) 
 
 
 
 
 
A mixture of 4 (1 mmol) and 2-Bromo-4’-nitroacetophenone (1.1 mmol) was reflux in 
ethanol or iso-propanol for 50-90 min, then the mixture was cooled to 0 °C. The solid was 
collected by filtration and washed with ethanol to afford 5 without any further 
purification. 
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7-Benzyl-2-(4-nitrophenyl)-5,6,7,8-tetrahydroimidazo[2’,1’:2,3]thiazolo[5,4-c]pyridine - (5a) 
ARKIVOC 2010, 3, 145-151. 
 
 
 
 
 
2-amino-5-benzyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine 4a (1.0 g, 4.08 mmol) and 2-
bromo-4’-nitroacetophenone (1.09 g, 4.49 mmol) were dissolved in i-PrOH (6 ml). 5a was 
obtained following procedure E (1.67 g, yield 41 %).  
 
1H NMR (CDCl3, 400 MHz): δ 8.22 (2H, d, J = 8.8 Hz), 7.94 (2H, d, J = 8.8 Hz), 7.70 (1H, s), 
7.27-7.37 (5H, m), 3.78 (2H, s), 3.61 (2H, s), 3.01 (2H, t, J = 6.0 Hz), 2.81 (2H, t, J = 6.0 Hz).  
EIMS 390 [M]+. 
108 
6-Benzyl-2-(4-nitrophenyl)-5,6,7,8-tetrahydroimidazo[2’,1’:2,3]thiazolo[4,5-c]pyridine - (5b)  
ARKIVOC 2010, 3, 145-151. 
 
 
 
 
 
2-amino-5-benzyl-4,5,6,7-tetrahydrothiazolo[4,5-c]pyridine (4b, 3.9 g, 16.1 mmol) and 2-
bromo-4’-nitroacetophenone (4.7 g, 19.4 mmol) were dissolved in i-PrOH (80 ml). 5b 
(2.28 g, yield 45 %) was directly submitted to the next step without further purification 
109 
2-(4-Nitrophenyl)imidazo[2,1-b]-5,6,7,8-tetrahydrobenzothiazole - (5c) 
Bioorg. Med. Chem. Lett. 2005, 15, 1561-1564. 
 
 
 
 
 
5c was prepared from 2-amino-5,6,7,8-tetrahydrobenzothiazole 4c (3.00 g, 19.5 mmol) 
and 2-Bromo-4’-nitroacetophenone (5.24 g, 21.4 mmol) using general procedure E for 
synthesis of 5. Yellow solid (2.31 g, yield 40 %).  
 
1H NMR (DMSO-d6, 300 MHz): δ 8.52 (1H, s), 8.27 (2H, d, J = 8.8 Hz), 8.09 (2H, d, J = 8.8 
Hz), 2.73-2.69 (4H, m), 1.92-1.88 (4H, m).   
EIMS 299 [M]+. 
110 
2-(4-nitrophenyl)imidazo[2,1-b]benzothiazole - (5d) 
J. Med. Chem. 1986, 29, 386-394. 
 
 
 
 
 
5d was prepared from 2-aminobenzothiazole (1.00 g, 6.46 mmol) and 2-Bromo-4’-
nitroacetophenone (1.83 g, 7.10 mmol) using general procedure E for synthesis of 5. 
Yellow solid (0.495 g, yield 26 %).  
 
1H NMR (DMSO-d6, 300 MHz): δ 9.10 (1H, s), 8.34 (2H, d, J = 9.0 Hz), 8.12 (2H, d, J = 9.0 
Hz), 8.07 (1H, d, J = 8.0 Hz), 8.02 (1H, d, J = 8.0 Hz), 7.64 (1H, t, J = 8.0 Hz), 7.49 (1H, t, J = 
8.0 Hz). 
EIMS 295 [M]+. 
111 
General Procedures for Synthesis of 9-12 
 
 
 
 
Procedure F: 
Compound 3 (1.1 mmol) was dissolved in anhydrous CH2Cl2 that was activated with the 
addition of HOBt (1.1 mmol), BOP-Cl (1.1 mmol) and DIPEA (4.0 mmol) in the presence of 
activated MS 4ºA and stirred for 10 min at r.t. under argon. A solution of amine 2 (1.0 
mmol) in a small amount of CH2Cl2 was transferred to the  mixture. The reaction was 
further stirred at r.t. for 48 h and quenched with a saturated solution of NaHCO3 and the 
product was extracted with AcOEt, washed with water, brine and dried on MgSO4. The 
solvent was removed under reduced pressure and the crude was purified by flash 
chromatography to afford 9-12. 
 
Procedure G: 
Compound 3 (1.1 mmol) was dissolved in anhydrous THF under nitrogen and was added 
in order: HATU (1.1 mmol) and DIPEA (2 mmol) and stirred for 15 min at r.t. The mixture 
was added 2 (1 mmol) and stirred at room temperature overnight. The solvent was 
removed under reduced pressure and the crude was purified by flash chromatography to 
afford 9-12. 
112 
(S)-N-[4-(7-Benzyl-5,6,7,8-tetrahydroimidazo[2’,1’:2,3]thiazolo[5,4-c]pyridin-2-yl)phenyl]-
2-[2-(3,5-dimethylphenyl)acetamido]-3-phenylpropanamide - (9a) 
 
 
 
 
9a was prepared from 2a (0.12 g, 0.35 mmol) and 3a (0.11 g, 0.35 mmol) using general 
procedure F. The crude mixture was purified by Byotage chromatography (MeOH:CH2Cl2 
1:99) to afford 9a as a white solid (0.12 g, yield 55 %).  
 
[α]20D = +3.61 (Na, c = 0.23 in MeOH).  
1H NMR (CDCl3 with drops of CD3OD, 400 MHz): δ 9.37 (1H , brs), 7.69 (2H, d, J = 8.8 Hz), 
7.56 (1H, s), 7.47 (2H, d, J = 8.4 Hz), 7.38 (1H, s), 7.37 (1H, d, J = 1.6 Hz), 7.32-7.47 (3H, m), 
7.20-7.24 (3H, m), 7.10 (2H, dd, J = 7.2, 2.4 Hz), 6.91 (1H, s), 6.82 (1H, d, J = 8.0 Hz), 6.78 
(2H, s), 4.75 (1H, dt, J = 14.8, 7.2 Hz), 3.79 (2H, 2H), 3.62 (2H, s), 3.46 (2H, s), 3.09 (1H, dd, 
J = 14.0, 6.8 Hz), 3.02 (2H, t, J = 5.6 Hz), 2.98 (1H, dd, J = 14.0, 6.8 Hz), 2.80 (2H, t, J = 5.6 
Hz), 2.28 (6H, s).  
13C NMR (CDCl3 with drops of CD3OD, 100.6 MHz): δ 172.01, 169.29, 148.34, 145.89, 
138.21, 136.84, 136.83, 136.66, 135.95, 133.89, 129.91, 129.04, 128.98, 128.75, 128.37, 
128.24, 127.50, 126.82, 126.67, 125.34, 124.53, 120.23, 120.14, 118.88, 105.56, 61.01, 
54.72, 50.02, 48.48, 42.95, 38.02, 22.53, 20.90.  
HR-MS Anal. Calcd for [C40H39N5O2S+H]
+ 654.2902; Found 654.2898. 
113 
(R)-N-[4-(7-Benzyl-5,6,7,8-tetrahydroimidazo[2’,1’:2,3]thiazolo[5,4-c]pyridin-2-yl)phenyl]-
2-[2-(3,5-dimethylphenyl)acetamido]-3-phenylpropanamide - (9b) 
 
 
 
 
 
9b was prepared from 2a (0.15 g, 0.42 mmol) and 3b (0.13 g, 0.42 mmol) using general 
procedure F. The crude mixture was purified by Byotage chromatography (MeOH:CH2Cl2 
1:99) to afford 9b as a white solid (0.12 g, Yield 45 %).  
 
[α]20D = -3.40 (Na, c = 0.20 in MeOH).  
1H NMR (CDCl3 with drops of CD3OD, 400 MHz): δ 9.37 (1H , brs), 7.69 (2H, d, J = 8.8 Hz), 
7.56 (1H, s), 7.47 (2H, d, J = 8.4 Hz),  7.38 (1H, s), 7.37 (1H, d, J = 1.6 Hz), 7.32-7.47 (3H, 
m), 7.20-7.24 (3H, m), 7.10 (2H, dd, J = 7.2, 2.4 Hz), 6.91 (1H, s), 6.82 (1H, d, J = 8.0 Hz), 
6.78 (2H, s), 4.75 (1H, dt, J = 14.8, 7.2 Hz), 3.79 (2H, 2H), 3.62 (2H, s), 3.46 (2H, s), 3.09 
(1H, dd, J = 14.0, 6.8 Hz), 3.02 (2H, t, J = 5.6 Hz), 2.98 (1H, dd, J = 14.0, 6.8 Hz), 2.80 (2H, t, 
J = 5.6 Hz), 2.28 (6H, s).  
13C NMR (CDCl3 with drops of CD3OD, 100.6 MHz): δ 172.01, 169.29, 148.34, 145.89, 
138.21, 136.84, 136.83, 136.66, 135.95, 133.89, 129.91, 129.04, 128.98, 128.75, 128.37, 
128.24, 127.50, 126.82, 126.67, 125.34, 124.53, 120.23, 120.14, 118.88, 105.56, 61.01, 
54.72, 50.02, 48.48, 42.95, 38.02, 22.53, 20.90.  
HR-MS Anal. Calcd for [C40H39N5O2S+H]
+ 654.2902; Found 654.2908.  
114 
(S)-N-[4-(6-Benzyl-5,6,7,8-tetrahydroimidazo[2’,1’:2,3]thiazolo[4,5-c]pyridin-2-yl)phenyl]-2-
[2-(3,5-difluorophenyl)acetamido]propanamide - (10a)  
 
 
 
 
 
From 2b and 3h using procedure G. Flash chromatography (DCM:MeOH 99:1) to give 10a 
(yield 48 %).  
 
[α]20D = +4.18 (Na, c = 0.23 in MeOH);  
1H NMR (CDCl3 with drops of CD3OD, 400 MHz) δ: 9.54 (1H, brs), 7.67 (1H, dt, J = 8.8, 1.6 
Hz), 7.63 (1H, d, J = 7.6 Hz), 7.52 (1H, dt, J = 8.8, 1.6 Hz), 7.32-7.42 (6H, m), 6.84 (2H, tt, J = 
6.4, 2.4 Hz), 6.70 (1H, tt, J = 11.2, 2.4 Hz), 4.57 (1H, q, J = 7.2 Hz), 3.81 (2H, s), 3.58 (2H, s), 
3.54 (2H, s), 2.95 (2H, t, J = 5.6 Hz), 2.82 (2H, t, J = 5.6 Hz), 1.41 (3H, d, J = 6.8 Hz).  
13C NMR (CDCl3 with drops of CD3OD, 100.6 MHz) δ: 170.80, 170.24, 163.05 (d, J = 132.8 
Hz), 148.67, 145.84, 137.30 (t, J = 93.1 Hz), 136.97, 129.90, 128.87, 128.42, 127.51, 
125.38, 124.09, 120.14, 120.05, 119.89, 112.07 (d, J = 69.4 Hz), 105.32, 102.40 (t, J = 253 
Hz), 61.53, 50.02, 49.46, 48.93, 42.25, 24.45, 17.95.  
HR-MS Anal. Calcd for [C32H29F2N5O2S+H]
+ 586.2088; Found: 586.2075. 
115 
(R)-N-[4-(6-Benzyl-5,6,7,8-tetrahydroimidazo[2’,1’:2,3]thiazolo[4,5-c]pyridin-2-yl)phenyl]-
2-[2-(3,5-difluorophenyl)acetamido]propanamide - (10b)  
 
 
 
 
 
From 2b and 3i using procedure G. Flash chromatography (DCM:MeOH 99:1) to give 10b 
(yield 53 %). 
 
[α]20D = -4.02 (Na, c = 0.25 in MeOH);  
1H NMR (CDCl3 with drops of CD3OD, 400 MHz): δ 9.54 (1H, brs), 7.67 (1H, dt, J = 8.8, 1.6 
Hz), 7.63 (1H, d, J = 7.6 Hz), 7.52 (1H, dt, J = 8.8, 1.6 Hz), 7.32-7.42 (6H, m), 6.84 (2H, tt, J = 
6.4, 2.4 Hz), 6.70 (1H, tt, J = 11.2, 2.4 Hz), 4.57 (1H, q, J = 7.2 Hz), 3.81 (2H, s), 3.58 (2H, s), 
3.54 (2H, s), 2.95 (2H, t, J = 5.6 Hz), 2.82 (2H, t, J = 5.6 Hz), 1.41 (3H, d, J = 6.8 Hz).  
13C NMR (CDCl3 with drops of CD3OD, 100.6 MHz): δ 170.80, 170.24, 163.05 (d, J = 132.8 
Hz), 148.67, 145.84, 137.30 (t, J = 93.1 Hz), 136.97, 129.90, 128.87, 128.42, 127.51, 
125.38, 124.09, 120.14, 120.05, 119.89, 112.07 (d, J = 69.4 Hz), 105.32, 102.40 (t, J = 253 
Hz), 61.53, 50.02, 49.46, 48.93, 42.25, 24.45, 17.95.  
HR-MS Anal. Calcd. for [C32H29F2N5O2S+H]
+ 586.2088; Found 586.2094.  
116 
(S)-N-[4-(5,6,7,8-Tetrahydroimidazo[2,1-b]benzothiazol-2-yl)phenyl]-2-[2-(3,5-
dimethylphenyl)acetamido]-3-phenylpropanamide - (11 - CF054) 
 
 
 
 
 
11 was prepared from 2c (0.08 g, 0.30 mmol) and 3a (0.10 g, 0.33 mmol) using general 
procedure G. The crude mixture was purified by flash chromatography (EtOH:CH2Cl2 1:30) 
to afford 11 as a white solid (0.15 g, Yield 91 %).  
 
mp 225-228 °C. 
[α]20D = +5.79 (Na, c = 0.96 in CHCl3).  
1H NMR (DMSO-d6, 400 MHz): δ 10.14 (1H, s), 8.44 (1H, d, J = 8.2 Hz), 8.10 (1H, s), 7.77 
(2H, d, J = 8.6 Hz), 7.60 (2H, d, J = 8.6 Hz), 7.31-7.19 (5H, m), 6.81 (1H, s), 6.75 (2H, s), 
4.70-4.67 (1H, m), 3.39 (1H, d, J = 14.1 Hz), 3.32 (1H, d, J = 14.1 Hz), 3.07 (1H, dd, J = 14.2, 
4.9 Hz), 2.90 (1H, dd, J = 14.2, 9.6 Hz), 2.72-2.68 (4H, m), 2.20 (6H, bs), 1.89-1.85 (4H, m).  
13C NMR (DMSO-d6, 100.6 MHz): δ 171.31, 171.13, 148.12, 146.22, 138.74, 138.63, 
138.05, 137.11 (2C), 131.12, 131.97, 130.32 (2C), 129.15 (2C), 128.78, 127.88 (2C), 
127.45, 126.03 (2C), 121.57, 120.69 (2C), 107.97, 55.97, 43.09, 38.90, 24.91, 23.83, 23.28, 
22.30 , 21.97(2C).  
HR-EIMS Anal. Calcd for [C34H34N4O2S]
+ 562.2402; Found 562.2408. 
117 
(S)-N-[4-(Imidazo[2,1-b]benzothiazol-2-yl)phenyl]-2-[2-(3,5-dimethylphenyl)acetamido]-3-
phenylpropanamide - (12a - CF022) 
 
 
 
 
 
12a was prepared from 2d (0.54 g, 2.05 mmol) and 3a (0.70 g, 2.25 mmol) using general 
procedure G. The crude mixture was purified by flash chromatography (EtOH:CH2Cl2 1:30) 
and crystallization with CHCl3 to afford 12a as white solid (0.86 g, yield 75 %). 
 
mp 224-226 °C  
[α]20D = +4.42 (Na, c = 1.28 in CHCl3).  
1H NMR (CDCl3, 400 MHz): δ 8.60 (1H, s), 7.92 (1H, s), 7.79 (2H, d, J = 8.4 Hz), 7.70 (1H, d, J 
= 7.8 Hz), 7.61 (1H, d, J = 7.8 Hz), 7.48-7.44 (3H, m), 7.37 (1H, t, J = 7.8 Hz), 7.29-7.21 (3H, 
m), 7.12-7.10 (2H, m), 6.95 (1H, s), 6.78 (2H, s), 6.29 (1H, d, J = 7.6 Hz), 4.92-4.86 (1H, m), 
3.51-3.47 (2H, m), 3.14 (1H, dd, J = 14.0, 6.4 Hz), 3.05 (1H, dd, J = 14.0, 7.8 Hz), 2.30 (6H, 
s).  
13C NMR (CDCl3, 100.6 MHz): δ 172.60, 170.02, 148.34, 146.43, 139.19, 138.16, 137.08, 
134.73 (2C), 132.56, 131.01, 130.79, 129.91 (2C), 129.76, 129.22 (2C), 127.78 (2C), 
127.56, 127.16, 126.44 (2C), 125.91, 124.80, 121.00 (2C), 113.68, 107.62, 55.99, 44.11, 
38.48, 21.84 (2C).  
HR-EIMS Anal. Calcd for [C34H30N4O2S]
+ 558,2089; Found 558,2086. 
118 
(S)-N-[4-(Imidazo[2,1-b]benzothiazol-2-yl)phenyl]-2-[2-(3,5-dimethylphenyl)acetamido]-3-
phenylpropanamide - (12b - CF056) 
 
 
 
 
 
12b was prepared from 2d (0.54 g, 2.05 mmol) and 3b (0.70 g, 2.25 mmol) using general 
procedure G. The crude mixture was purified by flash chromatography (EtOH:CH2Cl2 1:30) 
and crystallization with CHCl3 to afford 12b as white solid (0.89 g, yield 78 %).  
 
mp 224-226 °C  
[α]20D = -4.28 (Na, c = 0.83 in CHCl3).  
1H NMR (CDCl3, 400 MHz): δ 8.60 (1H, s), 7.92 (1H, s), 7.79 (2H, d, J = 8.4 Hz), 7.70 (1H, d, J 
= 7.8 Hz), 7.61 (1H, d, J = 7.8 Hz), 7.48-7.44 (3H, m), 7.37 (1H, t, J = 7.8 Hz), 7.29-7.21 (3H, 
m), 7.12-7.10 (2H, m), 6.95 (1H, s), 6.78 (2H, s), 6.29 (1H, d, J = 7.6 Hz), 4.92-4.86 (1H, m), 
3.51-3.47 (2H, m), 3.14 (1H, dd, J = 14.0, 6.4 Hz), 3.05 (1H, dd, J = 14.0, 7.8 Hz), 2.30 (6H, 
s).  
13C NMR (CDCl3, 100.6 MHz): δ 172.60, 170.02, 148.34, 146.43, 139.19, 138.16, 137.08, 
134.73 (2C), 132.56, 131.01, 130.79, 129.91 (2C), 129.76, 129.22 (2C), 127.78 (2C), 
127.56, 127.16, 126.44 (2C), 125.91, 124.80, 121.00 (2C), 113.68, 107.62, 55.99, 44.11, 
38.48, 21.84 (2C).  
HR-EIMS Anal. Calcd for [C34H30N4O2S]
+ 558,2089; Found 558,2085. 
119 
(S)-N-[4-(Imidazo[2,1-b]benzothiazol-2-yl)phenyl]-2-[2-(3,5-bis(trifluoromethyl)phenyl) 
acetamido]-3-phenylpropanamide - (12c - CF052) 
 
 
 
 
 
12c was prepared from 2d (0.77 g, 2.91 mmol) and 3c (1.34 g, 3.20 mmol) using general 
procedure G. The crude mixture was purified by flash chromatography (Hex:AcOEt 1:1) 
and crystallization with CH2Cl2 to afford 12c as white solid (1.40 g, yield 72 %).  
 
mp 243-245 °C 
[α]20D = +1.54 (Na, c = 0.31 in DMSO).  
1H NMR (DMSO-d6, 400 MHz): δ 10.25 (1H, s), 8.71-8.69 (2H, m), 8.04 (1H, d, J = 8.0 Hz), 
7.98 (1H, d, J = 8.0 Hz), 7.96 (1H, s), 7.90 (2H, s), 7.82 (2H, d, J = 8.6 Hz), 7.66 (2H, d, J = 8.6 
Hz), 7.58 (1H, t, J = 8.0 Hz), 7.44 (1H, t, J = 8.0 Hz), 7.29-7.13 (5H, m), 4.75-4.70 (1H, m), 
3.74 (1H, d, J = 15.1 Hz), 3.70 (1H, d, J = 15.1 Hz), 3.10 (1H, dd, J = 13.8, 4.8 Hz), 2.89 (1H, 
dd, J = 13.8, 9.7 Hz).  
13C NMR (DMSO-d6, 100.6 MHz): δ 172.13, 169.45, 146.82, 145.91, 141.12, 139.44, 
138.87, 133.21, 131.98 (2C, q, J = 33.2 Hz) 131.80, 131.01 (2C), 130.51, 130.23 (2C), 
129.03 (2C), 127.79, 127.41, 126.23 (2C), 126.18, 126.10, 123.42 (2C, q, J = 271.0 Hz), 
121.79, 120.84 (2C), 114.37, 109.56, 56.04, 42.60, 38.65.  
HR-EIMS Anal. Calcd for [C34H24F6N4O2S]
+ 666.1524; Found 666.1527. 
120 
(R)-N-[4-(Imidazo[2,1-b]benzothiazol-2-yl)phenyl]-2-[2-(3,5-bis(trifluoromethyl)phenyl) 
acetamido]-3-phenylpropanamide - (12d - CF081) 
 
 
 
 
12d was prepared from 2d (0.10 g, 0.38 mmol) and 3d (0.17 g, 0.42 mmol) using general 
procedure G. The crude mixture was purified by flash chromatography (Hex:AcOEt 1:1) 
and crystallization with CH2Cl2 to afford 12d as white solid (0.18 g, yield 74 %).  
 
mp 243-245 °C 
[α]20D = -1.46 (Na, c = 0.34 in DMSO).  
1H NMR (DMSO-d6, 400 MHz): δ 10.25 (1H, s), 8.71-8.69 (2H, m), 8.04 (1H, d, J = 8.0 Hz), 
7.98 (1H, d, J = 8.0 Hz), 7.96 (1H, s), 7.90 (2H, s), 7.82 (2H, d, J = 8.6 Hz), 7.66 (2H, d, J = 8.6 
Hz), 7.58 (1H, t, J = 8.0 Hz), 7.44 (1H, t, J = 8.0 Hz), 7.29-7.13 (5H, m), 4.75-4.70 (1H, m), 
3.74 (1H, d, J = 15.1 Hz), 3.70 (1H, d, J = 15.1 Hz), 3.10 (1H, dd, J = 13.8, 4.8 Hz), 2.89 (1H, 
dd, J = 13.8, 9.7 Hz).  
13C NMR (DMSO-d6, 100.6 MHz): δ 172.13, 169.45, 146.82, 145.91, 141.12, 139.44, 
138.87, 133.21, 131.98 (2C, q, J = 33.2 Hz) 131.80, 131.01 (2C), 130.51, 130.23 (2C), 
129.03 (2C), 127.79, 127.41, 126.23 (2C), 126.18, 126.10, 123.42 (2C, q, J = 271.0 Hz), 
121.79, 120.84 (2C), 114.37, 109.56, 56.04, 42.60, 38.65.  
HR-EIMS Anal. Calcd for [C34H24F6N4O2S]
+ 666.1524; Found 666.1529. 
121 
(S)-N-[4-(Imidazo[2,1-b]benzothiazol-2-yl)phenyl]-2-[2-(3,5-difluorophenyl)acetamido]-3-
phenylpropanamide - (12e - CF082) 
 
 
 
 
 
12e was prepared from 2d (0.10 g, 0.38 mmol) and 3e (0.13 g, 0.42 mmol) using general 
procedure G. The crude mixture was purified by flash chromatography (Hex:AcOEt 1:1) 
and crystallization with isopropanol to afford 12e as white solid (0.13 g, yield 62 %).  
 
mp 242-243 °C  
[α]20D = -4.34 (Na, c = 0.27 in CH3OH:CHCl3 1:1).  
1H NMR (DMSO-d6, 400 MHz): δ 10.29 (1H, s), 8.73 (1H, s), 8.62 (1H, d, J = 8.3 Hz), 8.05 
(1H, d, J = 7.9 Hz), 7.99 (1H, d, J = 7.9 Hz), 7.83 (2H, d, J = 8.6 Hz), 7.67 (2H, d, J = 8.6 Hz), 
7.59 (1H, t, J = 8.0 Hz), 7.45 (1H, t, J = 8.0 Hz), 7.32-7.20 (5H, m), 7.05 (1H, tt, J = 9.5, 2.3 
Hz ), 6.86 (2H, dd, J = 8.4, 2.3 Hz), 4.75-4.70 (1H, m), 3.53 (1H, d, J = 14.1 Hz), 3.49 (1H, d, J 
= 14.1 Hz), 3.11 (1H, dd, J = 13.7, 4.8 Hz) 2.90 (1H, dd, J = 13.7, 9.8 Hz).  
13C NMR (DMSO-d6, 100.6 MHz): δ 170.56, 169.51, 162.53 (2C, dd, J = 244.5, 14.1 Hz), 
147.29, 146.32, 141.07 (t, J = 10.1 Hz), 138.46, 137.94, 132.27, 129.67 (2C), 129.40, 
129.32, 128.48 (2C), 127.21, 126.87, 125.61 (2C), 125.57, 125.52, 120.10 (2C), 113.80, 
112.62 (2C, d, J = 24.1 Hz), 109.01, 102.28 (t, J = 26.2 Hz), 55.39, 41.90, 38.31.  
HR-EIMS Anal. Calcd for [C32H24F2N4O2S]
+ 566,1588; Found 566,1584.  
122 
N-[4-(Imidazo[2,1-b]benzothiazol-2-yl)phenyl]-2-[2-(3,5-dimethylphenyl)acetamido] 
acetamide - (12f - CF083) 
 
 
 
 
 
12f was prepared from 2d (0.10 g, 0.38 mmol) and 3f (0.09 g, 0.42 mmol) using general 
procedure G. The crude mixture was purified by flash chromatography (MeOH/CH2Cl2 
1:30) and crystallization with CH3CN to afford 12f as white solid (0.13 g, yield 72 %).  
 
mp 250-252 °C.  
1H NMR (DMSO-d6, 400 MHz): δ 10.04 (1H, s), 8.71 (1H, s), 8.37-8.33 (1H, m), 8.05 (1H, d, J 
= 7.9 Hz), 7.98 (1H, d, J = 7.9 Hz), 7.82 (2H, d, J = 8.6 Hz), 7.66 (2H, d, J = 8.6 Hz), 7.59 (1H, 
t, J = 7.9 Hz), 7.44 (1H, t, J = 7.9 Hz), 6.92 (2H, s), 6.87 (1H, s), 3.92 (2H, d, J = 5.6 Hz), 3.34 
(2H, s), 2.26 (6H, s).  
13C NMR (DMSO-d6, 100.6 MHz): δ 171.83, 168.80, 147.93, 147.42, 139.14, 138.16 (2C), 
137.09, 132.99, 130.29, 130.21, 128.88, 128.02 (2C), 127.78, 126.29 (2C), 126.17, 126.08, 
120.53 (2C), 114.36, 109.48, 44.10, 43.19, 21.99 (2C).  
EIMS 468 [M]+.  
123 
(S)-N-[4-(Imidazo[2,1-b]benzothiazol-2-yl)phenyl]-2-[2-(3,5-dimethylphenyl)acetamido]-3-
(4-hydroxyphenyl)propanamide - (12g - CF023) 
 
 
 
 
12g was prepared from 2d (0.07 g ,0.28 mmol) and 3g (0.10 g, 0.31 mmol) using general 
procedure G. The crude mixture was purified by flash chromatography (IPA/CH2Cl2 95:5) 
to afford 12g as pale yellow (0.08 g, yield 52 %).  
 
mp 265-268 °C  
[α]20D = +2.76 (Na, c = 0.5 in DMSO).  
1H NMR (DMSO-d6, 400 MHz): δ 10.25 (1H, s), 8.73 (1H, s), 8.39 (1H, d, J = 7.8 Hz), 8.08 
(1H, d, J = 8.1 Hz), 7.98 (1H, d, J = 8.1 Hz), 7.81 (2H, d, J = 8.6 Hz), 7.67 (2H, d, J = 8.6 Hz), 
7.58 (1H, t, J = 8.1 Hz), 7.43 (1H, t, J = 8.1 Hz), 7.11 (2H, d, J = 7.5 Hz), 6.84 (1H, s), 6.78 
(2H, s), 6.67 (2H, d, J = 7.5 Hz),5.89 (1H, s), 4.65-4.54 (1H, m), 3.48-3.30 (2H, m), 2.98 (1H, 
dd, J = 14.2, 4.5 Hz), 2.81 (1H, dd, J = 14.2, 9.3 Hz), 2.53 (6H, s).  
13C NMR (DMSO-d6, 100.6 MHz): δ 171.64, 169.12, 154.75, 147.78, 146.05, 138.85, 
138.06, 134.65 (2C), 132.84 (2C), 132.24, 130.77, 130.61, 130.19, 129.12, 127.13 (2C), 
116.78 (2C), 127.02, 126.08 (2C), 125.34, 124.63, 120.53 (2C), 112.89, 107.41, 54.11, 
44.01, 35.21, 21.81 (2C).  
EIMS 574 [M]+.  
124 
2-(4-cyanophenyl)imidazo[2,1-b]benzothiazole - (13) 
 
 
 
 
 
To a solution of 2-aminobenzothiazole (0.930 g, 6.00 mmol) in ethanol (92 ml), 2-Br-4’-
cyanoacetophenone (1.50 g, 6.60 mmol) was added and the solution was refluxed for 90 
min. After the completion of the reaction, the solution was cooled to 0 °C. The resulting 
precipitate was filtered and washed with ethanol to provide 13 as foam (0.578 g, yield 35 
%).  
 
1H NMR (CDCl3 400 MHz): δ 8.09 (1H, s), 7.98 (2H, d, J = 8.2 Hz), 7.75 (1H, d, J = 8.0 Hz), 
7.70 (2H, d, J = 8.2 Hz), 7.66 (1H, d, J = 8.0 Hz), 7.51 (1H, t, J = 8.0 Hz), 7.41 (1H, t, J = 8.0 
Hz).  
13C NMR (CDCl3, 100.6 MHz): δ 149.75, 146.43, 138.91, 133.29 (2C), 132.65, 131.17, 
127.13, 126.29 (2C), 126.16, 125.26, 119.68, 113.53, 111.31, 109.18.  
EIMS 275 [M]+. 
125 
2-(4-benzylamine)imidazo[2,1-b]benzothiazole - (14) 
 
 
 
 
 
To a cooled at 0 °C mixture of 2-(4-cyanophenyl)imidazo[2,1-b]benzothiazole 13 (0.250 g, 
0.900 mmol) in dry toluene (5 ml) was added 1M diisobutylaluminum hydride solution in 
Hexane (4.5 ml, 4.50 mmol) and the solution was refluxed for 2 h. Then, the solution was 
poured into ice-water (50 ml), an aqueous NaOH 1N solution (15 ml) was added and the 
organic layer was extracted with Et2O. The combined organic layers were washed with 
brine, dried with Na2SO4 and evaporated in vacuum to dryness to provide 14 as yellow 
solid (0.224 g, yield 90 %).  
 
1H NMR (DMSO-d6, 400 MHz): δ 8.75 (1H, s), 8.03 (1H, d, J = 8.0 Hz), 7.98 (1H, d, J = 8.0 
Hz), 7.83 (2H, d, J = 8.1 Hz), 7.57 (1H, t, J = 8.0 Hz), 7.43 (1H, t, J = 8.0 Hz), 7.41 (2H, d, J = 
8.1 Hz), 3.78 (2H, s).  
13C NMR (DMSO-d6, 100.6 MHz): δ 147.95, 147.68, 143.12, 133.43, 133.08, 130.30, 128.72 
(2C), 127.86, 126.26, 126.11, 126.03 (2C), 114.41, 109.98, 46.18. 
EIMS 279 [M]+. 
126 
(S)-N-[4-(Imidazo[2,1-b]benzothiazol-2-yl)benzyl]-2-[2-(3,5-bis(trifluoromethyl)phenyl) 
acetamido]-3-phenylpropanamide - (15) 
 
 
 
 
 
Compound 3c (0.058 g, 0.138 mmol) was dissolved in anhydrous THF (10 ml) under 
nitrogen and was added in order: HATU (0.053 g, 0.138 mmol) and DIPEA (44 µl, 0.250 
mmol) and stirred for 15 min. at r.t. The mixture was added 14 (0.035 g, 0.125 mmol) and 
stirred at room temperature overnight. The solvent was removed under reduced pressure 
and the crude was purified by flash chromatography (Hex:AcOEt 3:7) to afford 15. White 
solid (0.026 g, yield 31 %).  
 
[α]20D = +4.09 (Na, c = 0.30 in DMSO) 
1H NMR (DMSO-d6, 400 MHz): δ 8.76 (1H, s), 8.63 (1H, t, J = 5.9 Hz), 8.58 (1H, d, J = 8.5 
Hz), 8.05 (1H, d, J = 7.7 Hz), 7.99 (1H, d, J = 7.7 Hz), 7.96 (1H, s), 7.87 (2H, s), 7.80 (2H, d, J 
= 8.2 Hz), 7.59 (1H, t, J = 7.7 Hz), 7.44 (1H, d, J = 7.7 Hz), 7.23 (2H, d, J = 8.2 Hz), 7.21-7.15 
(5H, m), 4.63-4.57 (1H, m), 4.35 (1H, dd, J = 15.3, 5.9 Hz), 4.30 (1H, dd, J = 15.3, 5.9 Hz), 
3.72 (1H, d, J = 14.4 Hz), 3.67 (1H, d, J = 14.4 Hz), 3.05 (1H, dd, J = 13.6, 5.2 Hz), 2.82 (1H, 
dd, J = 13.6, 9.5 Hz).  
13C NMR (DMSO-d6, 100.6 MHz): δ 171.37, 169.20, 147.34, 146.70, 140.15, 138.59, 
138.09, 132.98, 132.30, 130.55 (2C, q, J = 36 Hz), 130.37 (2C), 129.94, 129.58 (2C), 128.33 
(2C), 128.05 (2C), 127.16, 126.65, 125.61, 125.49, 125.05 (2C), 123.75 (2C, q, 268 Hz), 
120.64, 113.77, 109.36,54.65, 42.44, 41.61, 38.46. 
EIMS 680 [M]+. 
127 
3-[2-(3,5-difluorophenyl)acetamido]propanoic acid - (17) 
 
 
 
 
 
The methylester of acid 17 was prepared using β-alanine methyl ester hydrochloride (1.00 
g, 7.16 mmol) and 3,5-difluorophenylacetic acid (1.17 g, 6.823 mmol) using general 
procedure D for synthesis of 3 (page XX). The crude mixture was purified by flash 
chromatography (Hex:AcOEt 2:3) to afford the methyl ester as white solid (1.32 g, yield 75 
%). 
 
1H NMR (CDCl3, 400 MHz): δ 6.73 (2H, tt, J = 6.8, 2.4 Hz), 6.73 (1H, tt, J = 11.2, 2.4 Hz), 6.22 
(1H, brs), 3.67 (3H, s),  3.50 (2H, t, J = 6.0 Hz), 2.53 (2H, t, J = 6.0 Hz).  
HR-FABMS Anal. Calcd 258.0941 [M+H]+; Found 258.0946. 
  
17 was prepared from the corresponding methyl ester using general procedure D for 
synthesis of 3. White solid (0.96 g, yield 81 %). 
 
1H NMR (CDCl3, 400 MHz): δ 7.02 (1H, brs), 6.74 (2H, tt, J = 6.6, 2.4 Hz), 6.63 (1H, tt, J = 
11.2, 2.4 Hz), 3.40 (3H, s), 3.73 (2H, t, J = 6.0 Hz), 2.42 (2H, t, J = 6.0 Hz).  
13C NMR (CDCl3, 100.6 MHz): δ 172.48, 170.41, 162.09 (2C, d, J = 241,3 Hz), 138.43 (t, J = 
11.2 Hz), 112.06 (2C, d, J =  25.4 Hz), 102.37 (t, J = 27.2 Hz), 37.28, 35.05, 33.40.  
HR-MS Anal. Calcd for [C11H11F2NO3+H]
+ 244.0780; Found 244.0785. 
128 
(S)-N-[4-(7-Benzyl-5,6,7,8-tetrahydroimidazo[2’,1’:2,3]thiazolo[5,4-c]pyridin-2-yl)phenyl]-
2-[2-(3,5-difluorophenyl)acetamido]acetamide - (18) 
 
 
 
 
 
18 was prepared from 2a (0.15 g, 0.42 mmol) and 17 (0.11 g, 0.44 mmol) using general 
procedure F. The crude mixture was purified by flash chromatography (DCM:MeOH 99:1) 
to afford 18 as a white solid (0.17 g, Yield 70 %).  
 
1H NMR (CDCl3 with drops of CD3OD, 400 MHz): δ 9.48 (1H brs), 7.72 (2H, dt, J = 9.2, 1.6 
Hz), 7.58 (1H, s), 7.55 (1H, dt, J = 9.2, 1.6 Hz), 7.30-7.38 (5H, m), 6.82 (1H, tt, J = 6.4, 2.4 
Hz), 6.69 (1H, tt, J = 11.2, 2.4 Hz), 3.80 (2H, s), 3.64 (2H, s), 3.52 (2H, dd, J = 12.0; 6.4 Hz), 
3.48 (2H, s), 3.03 (2H, t, J = 5.6 Hz), 2.83 (2H, t, J = 5.6 Hz), 2.57 (2H, t, J = 6.4 Hz).  
13C NMR (CDCl3 with drops of CD3OD, 100.6 MHz): δ 172.96, 170.27, 163.97 (d, J = 123.7 
Hz), 161.52 (d, J = 132.8 Hz), 148.32, 145.90, 138.48 (t, J = 92.6 Hz), 137.13, 136.84, 
129.61, 128.94, 128.32, 127.45, 124.58, 119.93, 118.92, 111.90 (d, J = 70.4 Hz), 111.72 (d, 
J = 69.4 Hz), 105.56, 102.21 (t, J = 253.0 Hz), 61.00, 50.06, 48.46, 42.41, 35.96, 33.74, 
22.51.  
HR-MS Anal. Calcd for [C32H29F2N5O2S+H]
+ 586.2088; Found 586.2077. 
129 
(S)-N-[4-(6-Benzyl-5,6,7,8-tetrahydroimidazo[2’,1’:2,3]thiazolo[4,5-c]pyridin-2-yl)phenyl]-
2-[2-(3,5-difluorophenyl)acetamido]acetamide - (19)  
 
 
 
 
 
From 2b and 17 using procedure F (pag. 111). Flash chromatography (DCM:MeOH 99:1) to 
give 19 (65 %).  
 
1H-NMR (CDCl3 with drops of CD3OD, 400 MHz): δ 9.40 (1H, s), 7.67 (1H, dt, J = 8.8, 1.6 
Hz), 7.52 (1H, dt, J = 8.8, 1.6), 7.47 (1H, t, J = 5.6 Hz), 7.43 (1H, s), 7.30-7.41 (6H, m), 6.80 
(2H, tt, J = 6.4, 2.4 Hz), 6.67 (1H, tt, J = 11.2, 2.4 Hz), 3.81 (2H, s), 3.59 (2H, s), 3.51 (2H, dt, 
J = 12.4, 6.4 Hz), 3.47 (2H, s), 2.96 (2H, t, J = 5.2 Hz), 2.83 (2H, t, J = 5.2 Hz), 2.55 (2H, t, J = 
6.0 Hz). 
13C-NMR (CDCl3 with drops of CD3OD, 100.6 MHz): δ 170.84, 170.27, 164.05 (2C, d, J = 
241.7 Hz), 148.68, 145.92, 138.47 (t, J = 11.2 Hz), 137.11, 136.98, 129.69, 128.89 (2C), 
128.44, 127.52, 125.36, 124.11; 119.95 (2C), 119.89, 112.01 (2C, d, J = 24.3 Hz), 105.28, 
102.35 (t, J = 25.6 Hz), 61.55, 50.04, 48.94, 42.61, 36.06, 35.92, 24.47.  
HR-MS Anal. calcd for [C32H29F2N5O2S+H]
+ 586.2088; Found 586.2075.
130 
(S)-N-[4-(7-bromoimidazo[2,1-b]benzothiazol-2-yl)phenyl]-2-[2-(3,5-bis(trifluoromethyl) 
phenyl)acetamido]-3-phenylpropanamide - (20 – CF203) 
 
 
 
 
 
Compound 3c (0.201 g, 0.479 mmol) was dissolved in anhydrous THF (15 ml) under 
nitrogen and was added in order: HATU (0.199 g, 0.523 mmol) and DIPEA (152 µl, 0.872 
mmol) and stirred for 15 min. at r.t. The mixture was added 23 (0.150 g, 0.436 mmol) and 
stirred at room temperature overnight. The solvent was removed under reduced pressure 
and the crude was purified by flash chromatography (Hex:AcOEt 1:1) and it was 
crystallized by CH3CN (40 ml) to afford 20. White solid (0.155 g, yield 48 %). 
 
[α]20D = 2.95 (Na, c = 0.28 in DMSO) 
1H NMR (DMSO-d6, 400 MHz): δ 10.26 (1H, s), 8.71 (1H, d, J = 8.7 Hz), 8.70 (1H, s), 8.34 
(1H, d, J = 1.8 Hz), 7.95 (1H, s), 7.93 (1H, d, J = 8.5 Hz), 7.89 (2H, s), 7.81 (2H, d, J = 8.7 Hz), 
7.75 (1H, dd, J = 8.5, 1.8 Hz), 7.66 (2H, d, J = 8.7 Hz), 7.27-7.13 (5H, m), 4.75-4.69 (1H, m), 
3.75 (1H, d, J = 16.4 Hz), 3.70 (1H, d, J = 16.4 Hz), 3.10 (1H, dd, J = 13.8, 4.8 Hz), 2.89 (1H, 
dd, J = 13.8, 9.8 Hz).  
13C NMR (DMSO-d6, 100.6 MHz): δ 170.48, 169.49, 147.42, 146.85, 140.10, 138.44, 
137.86, 131.82, 131.59, 130.58 (2C, q, J = 37 Hz), 130.37 (2C), 129.99, 129.59, 129.50, 
128.40 (2C), 127.86, 126.80 (2C), 125.60 (2C), 123.85 (2C, q, J = 272 Hz), 120.68, 120.11, 
117.12, 115.29, 109.14, 55.42, 41.48, 38.30. 
HR-EIMS Anal. Calcd for [C34H23BrF6N4O2S]
+ 744.0629; Found 744.06134. 
131 
Synthesis of 6-Bromo-2-benzothiazolamines - (21) 
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A solution of 4-bromoaniline (0.500 g, 2.91 mmol) and potassium thiocyanate (1.13 g, 
11.6 mmol) in AcOH (10 ml) was stirred at 20 °C for 10 min. Bromine (150 µl, 2.91 mmol) 
was added over 20 min. to the above solution. The reaction mixture was stirred further at 
room temperature for 90 min. On completion of reaction following a TLC examination, 
the reaction mixture was poured into a solution of NH3 5M and extracted with AcOEt. The 
organic phase was dried over anhydrous Na2SO4 and the solvent was evaporated under 
vacuo. The crude product obtained was purified by flash chromatography (Hex:AcOEt 1:1) 
to afford 21 as white solid (2.67 g, yield 79 %). 
 
1H NMR (DMSO-d6, 400 MHz): δ 7.91 (1H, d, J = 2.5 Hz), 7.63 (2H, s), 7.35 (1H, dd, J = 11.6, 
2.5 Hz), 7.26 (1H, d, J = 11.6 Hz). 
EIMS 228 [M]+. 
132 
2-(4-Nitrophenyl)imidazo[2,1-b]-7-bromobenzothiazole - (22) 
 
 
 
 
 
A mixture of 21 (1.20 g, 5.24 mmol) and 2-Bromo-4’-nitroacetophenone (1.41 g, 5.76 
mmol) was reflux in ethanol for 90 min, the mixture was cooled to 0 °C. The solid was 
collected by filtration and washed with ethanol to afford 22 without any further 
purification. Yellow solid (0.665 g, yield 34 %). 
 
1H NMR (DMSO-d6, 400 MHz) 80 °C: δ 8.92 (1H, s), 8.32 (1H, d, J = 1.9 Hz), 8.28 (2H, d, J = 
8.8 Hz), 8.12 (2H, d. J = 8.8 Hz), 7.96 (1H, d, J = 8.6 Hz), 7.76 (1H, dd, J = 8.6, 1.9 Hz). 
13C NMR (DMSO-d6 100.6 MHz) 80 °C: δ 155.67, 146.92, 145.02, 140.78, 132.15, 131.47, 
130.15, 127.93, 125.93 (2C), 124.62 (2C), 117.76, 115.53, 112.47   
EIMS 373 [M]+. 
133 
2-(4-Aminophenyl)-7-bromoimidazo[2,1-b]benzothiazole - (23) 
 
 
 
 
 
A mixture of 22 (0.225 mg, 0.602 mmol) in ethanol (25 ml), were added in the order: iron 
powder (0.671 g, 12.03 mmol), H2SO4 12N (5 ml). The mixture was refluxed for 30 min. 
and then it was extracted by satured solution of NaHCO3 and AcOEt. The organic phase 
was dried with Na2SO4 anhydrous. The solvent was removed in vacuo. Compound 23 was 
obtained without any further purification. Light brown solid (0.191 g, yield 92 %). 
 
1H NMR (DMSO-d6, 400 MHz): δ 8.46 (1H, s), 8.31 (1H, d, J = 1.9 Hz), 7.89 (1H, d, J = 8.6 
Hz), 7.73 (1H, dd, J = 8.6, 1.9 Hz), 7.53 (2H, d, J = 8.5 Hz), 6.62 (2H, d, J = 8.5 Hz), 5.21 (2H, 
s). 
13C NMR (DMSO-d6, 100.6 MHz): δ 149.41, 149.07, 147.41, 132.39, 132.35, 130.52, 
128.41, 126.94 (2C), 122.78, 117.31, 115.67, 115.08 (2C), 107.58. 
HR-EIMS Anal. Calcd for [C15H10BrN3S]
+ 342.9779; Found 342.9784. 
134 
N-[1-(1-(4-(Imidazo[2,1-b]benzothiazol-2-yl)phenyl)-1H-1,2,3-triazol-4-yl)-2-phenylethyl]-
2-[3,5-bis(trifluoromethyl)phenyl]acetamide - (30 - CF120) 
 
 
 
 
 
A solution of 31 (0.054 g, 0.188 mmol) and 32 (0.075 g, 0.188 mmol) in THF (6 ml) was 
added a solution  of CuSO4
.5H2O (0.001 g, 0.004 mmol) in H2O (1.5 ml) and then a solution 
of sodium ascorbate (0.004 g, 0.019 mmol). The reaction was stirred at r.t. for 6 h and 
then the mixture was extracted with brine and AcOEt. The organic phase was dried over 
anhydrous Na2SO4 and the solvent was removed in vacuo. The crude was purified by flash 
chromatography (Hex:AcOEt 1:1) to afford 30 as white solid (0.090 g, yield 68 %) 
 
1H NMR (DMSO-d6, 400 MHz): δ 8.92 (1H, s), 8.82 (1H, d, J = 8.6 Hz), 8.72 (1H, s), 8.08 (2H, 
d, J = 8.7 Hz), 8.04 (1H, d, J = 7.7 Hz), 8.00 (1H, d, J = 7.7 Hz), 7.97 (2H, d, J = 8.7 Hz), 7.96 
(1, s), 7.87 (2H, s), 7.60 (1H, t, J = 8.4 Hz), 7.46 (1H, t, J = 8.4 Hz), 7.23-7.12 (5H, m), 5.33-
5.27 (1H, m), 3.69 (2H, s), 3.29 (1H, dd, J = 13.7, 6.0 Hz), 3.13 (1H, dd, J = 13.7, 9.2 Hz). 
13C NMR (DMSO-d6, 100.6 MHz): δ 169.38, 150.12, 146.26, 140.73, 139.10, 136.54, 
135.26, 132.87, 131.41 (2C, q, J = 36 Hz), 131.03 (2C), 130.41, 130.24 (2C), 129.04 (2C), 
127.90, 127.27, 127.01 (2C), 126.47, 126.19, 124.43 (2C, q, J = 274 Hz), 121.53, 121.39 
(2C), 121.38, 114.52, 110.98, 47.98, 42.36, 41.38.  
HR-EIMS Anal. Calcd for [C35H24F6N6OS]
+ 690.1637; Found 690.1629. 
135 
2-(4-azido)imidazo[2,1-b]benzothiazole - (31) 
 
 
 
 
 
A solution of 2d (0.300 g, 1.13 mmol) in H2O (10 ml) and H2SO4conc. (1.8 ml) was cooled to 
0 °C with ice bath. A solution of NaNO2 (0.117 g, 1.17 mmol) in H2O (5 ml) was added 
dropwise in 5 min. The mixture was stirred to 0 °C for 30 min. and then a solution of NaN3 
(0.147 g, 2.26 mmol) in H2O (5 ml) was added dropwise in 10 min. constantly at 0 °C. The 
mixture was warmed to rt and was stirred overnight. After complete conversion the pH 
was increased to pH 10 using a satured solution of NaHCO3 and then TEA (2 ml). The 
crude material was extracted with CH2Cl2 and the organic phase was dried over 
anhydrous Na2SO4. The solvent was removed in vacuo and the crude mixture was purified 
by flash chromatography (Hex:AcOEt 3:1) to afford 31 as brown-orange solid (0.258 mg, 
yield 78 %). 
 
1H NMR (DMSO-d6, 400 MHz): δ 8.75 (1H, s), 8.02 (1H, d, J = 8.0 Hz), 7.95 (1H, d, J = 8.0 
Hz), 7.89 (2H, d, J = 8.6 Hz), 7.56 (1H, t, J = 7.5 Hz), 7.42 (1H, t, J = 7.5 Hz), 7.17 (2H, d, J = 
8.6 Hz). 
13C NMR (DMSO-d6 100.6 MHz): δ 148.10, 146.68, 139.09, 132.88, 132.11, 130.32, 127.78, 
127.31 (2C), 126.26, 126.10, 120.60 (2C), 114.40, 110.10.  
HR-EIMS Anal. Calcd for [C15H9N5S]
+ 291.0579; Found 291.0573. 
136 
N-(1-phenylbut-3-yn-2-yl)-2-[3,5-bis(trifluoromethyl)phenyl]acetamide - (32) 
 
 
 
 
 
A solution of 34 (0.190 g, 0.471 mmol) in anhydrous MeOH (20 ml) was cooled to 0 °C and 
then were added in the order: K2CO3 (0.130 g, 0.942 mmol) and Bestmann Ohira Reagent 
35 (0.109 g, 0.566 mmol). The reaction mixture was stirred at rt for 16 h, then the solvent 
was removed under reduced pressure and the crude solid was extracted by AcOEt and 
satured solution of NaHCO3. The organic phase was washed with H2O, it was dried over 
anhydrous Na2SO4 and the solvent was removed in vacuo. The solid was purified by flash 
chromatography (Hex:AcOEt 3:1) to afford 32 as white solid (0.159 mg, yield 84 %).     
 
1H NMR (CDCl3, 400 MHz): δ 7.81 (1H, s), 7.72 (1H, s), 7.31-7.26 (3H, m), 7.20-7.18 (2H, 
m), 5.71 (1H, d, J = 8.0 Hz), 5.09-5.03 (1H, m), 3.63 (1H, d, J = 15.4 Hz), 3.57 (1H, d, J = 15.4 
Hz), 3.01-2.99 (2H, m), 2.34 (1H, s).  
13C NMR (CDCl3, 100.6 MHz): δ 168.33, 137.47, 136.28, 132.67 (2C, q, J = 33 Hz), 130.27 
(2C), 130.13 (2C), 129.02 (2C), 127.85, 123.83 (2C, q, J = 271 Hz), 121.99, 82.67, 73.34, 
43.25, 43.11, 41.50. 
EIMS 399 [M]+. 
137 
(S)-N-(1-hydroxy-3-phenylpropan-2-yl)-2-[3,5-bis(trifluoromethyl)phenyl]acetamide - (33) 
 
 
 
 
 
A solution of 8c (0.800 mg, 1.85 mmol) in anhydrous THF (15 ml) was cooled to 0 °C under 
nitrogen and a second solution of LiBH4 2M in THF (288 µL, 0.577 mmol) was added 
dropwise in 15 min. The solution was stirred for 6 h at r.t. After the complete conversion 
of the ester into the alcohol the mixture was quenched in HCl 0.1M solution, extracted 
with AcOEt, and the organic phase was dried over anhydrous Na2SO4. The solvent was 
removed in vacuo and the crude mixture was purified by flash chromatography 
(CH2Cl2:MeOH 30:1) to afford 33 as white solid (0.692 mg, yield 92 %). 
 
[α]20D = -21.02 (Na, c = 1.04 in MeOH) 
1H NMR (DMSO-d6, 400 MHz): δ 8.09 NH (1H, d, J = 8.6 Hz), 7.95 (1H, s), 7.86 (2H, s), 7.18-
7.09 (5H, m), 4.85 OH (1H, t, J = 5.5 Hz), 3.94-3.88 (1H, m), 3.64 (1H, d, J = 14.4 Hz), 3.60 
(1H, d, J = 14.4 Hz), 3.43-3.32 (2H, m), 2.85 (1H, dd, J = 13.7, 5.2 Hz), 2.61 (1H, dd, J = 13.7, 
8.9 Hz). 
13C NMR (DMSO-d6 100.6 MHz): δ 168.89, 140.36, 139.41, 130.36 (2C, q, J = 33 Hz), 130.30 
(2C), 129.46 (2C), 128.32 (2C), 126.27 (2C), 123.87 (2C, q, J = 271 Hz), 120.58, 63.20, 
52.99, 41.88, 37.09.  
HR-EIMS Anal. Calcd for [C19H17F6NO2]
+ 405.1163; Found 405.1156. 
138 
(S)-N-(1-oxo-3-phenylpropan-2-yl)-2-[3,5-bis(trifluoromethyl)phenyl]acetamide - (34) 
 
 
 
 
 
The alcohol 33 (0.400 g, 0.987 mmol) was dissolved in anhydrous CH2Cl2 (50 ml) under 
nitrogen. Solid DMP (0.502 mg, 1.18 mmol) was added to the solution and the mixture 
was stirred at r.t. After 4 h the reaction mixture was filtered over celite and the solution 
of CH2Cl2 was washed with a satured solution of NaHCO3. The organic phase was dried 
over anhydrous Na2SO4 and the solvent was removed in vacuo. The crude solid was 
purified by flash chromatography (AcOEt:Hex 2:3) to afford 34 as white solid (0.315 g, 
yield 78 %).  
    
[α]20D = +38.18 (Na, c = 0.57 in CHCl3) 
1H NMR (CDCl3, 400 MHz): δ 9.68 (1H, s), 7.84 (1H, s), 7.74 (2H, s), 7.29-7.24 (3H, m), 7.06-
7.03 (2H, m), 6.05 (1H, s), 4.83-4.78 (1H, m), 3.71 (1H, d, J = 15.4 Hz), 3.66 (1H, d, J = 15.4 
Hz), 3.23-3.15 (2H, m).  
13C NMR (CDCl3, 100.6 MHz): δ 198.02, 169.83, 136.71, 134.88, 131.87 (2C, q, J = 36 Hz), 
129.53 (2C), 129.14 (2C), 128.83 (2C), 127.40 (2C), 123.48 (2C, q, J = 274 Hz), 121.41, 
59.90, 42.54, 34.83. 
HR-EIMS Anal. Calcd for [C19H15F6NO2]
+ 403.1007; Found 403.1012.  
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Dimethyl(1-diazo-2-oxopropyl)phosphonate - (35) 
Eur. J. Org. Chem. 2003, 821-832 
 
 
 
 
 
A solution of NaN3 (0.341 g, 5.25 mmol) in acetone (15 ml) and H2O (15 ml) was added 
TsCl (1.00 g, 5.25 mmol). The reaction mixture was stirred at 0 °C for 2 h. Acetone was 
evaporated, the reaction mixture was extracted with diethyl ether, and the organic phase 
was dried over Na2SO4. Evaporation of solvent gave tosyl azide (0.972 g, yield 94 %) as a 
colourless oil.  
 
1H NMR (CDCl3, 300 MHz): δ 7.75 (2H, d, J = 8.1 Hz), 7.33 (2H, d, J = 8.1 Hz), 2.39 (3H, s).  
 
A solution of NaH (80 % dispersion in mineral oil and washed with hexane, 0.150 g, 4.93 
mmol)  in anhydrous THF (20 ml) was cooled to 0 °C under nitrogen. Dimethyl(2-
oxopropyl)phosphonate (0.744 g, 4.48 mmol) in anhydrous THF (10 ml) was added 
dropwise in 20 min. The solution was stirred at 0 °C for 30 min. A solution of Tosyl azide 
(0.972 g, 4.93 mmol) in anhydrous THF (10 ml) was then added in one portion and the 
resulting mixture was stirred at 0 °C for 10 min. The reaction mixture was quickly passed 
through a short column (silica, AcOEt) and the crude mixture was purified by flash 
chromatography (AcOEt) to give dimethyl(1-diazo-2-oxopropyl)phosphonate 35 (0.781 g, 
yield 91 %) as a colourless oil.  
 
1H NMR (CDCl3, 300 MHz): δ 3.75 (3H, s), 3.71 (3H, s), 2.15 (3H, s).  
13C NMR (CHCl3, 75 MHz): δ 189.7, 115.6, 53.6, 53.5, 27.1.  
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Chapter IV: Abl inhibitors 
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4.1  Abl inhibitors: Imatinib 
For the treatment of CML  is very important to develop molecules that can bind 
selectively the Bcr-Abl protein. Among them, Imatinib (Gleevec®), a 2-phenylamino 
pirimidine derivative, seemed to be a promising therapeutic agent. Imatinib mesilate (N-
(4-methyl-3-(4-(pyridin-3-yl)-pyrimidin-2-ylamino) phenyl- 4- ( (4-methyl-piperazin-1-yl) 
methyl) benzamide methanesulfonate) is a known inhibitor of tyrosine kinases targeted 
against platelet derived growth factor receptors (PDGFR), Bcr-Abl and c-Kit.[73] 
Overexpression of these tyrosine kinases can be detected in many types of cancer such as 
meningiomas, melanomas, and cancer of the ovary, prostate, pancreas, and breast. In 
particular our interest was focused to PDGFR for its relationship with angiogenesis, and 
Bcr-Abl for the treatment of chronic myeloid leukemia (CML)[74] and gastrointestinal 
stromal tumors (GISTs).[75] Imatinib was developed by Novartis Pharma AG, Basel, 
Switzerland and approved in November 2001 by FDA for the treatment of affected 
patients with CML. Imatinib targets in a selective way the inactive conformation of 
Abelson Tyrosine Kinase. Binding the protein, the drug is sandwiched between the N- and 
C-lobes of the kinase domain and penetrates through the central region of the kinase, 
from one side to the other (Figure 1). 
 
 
 
     
 
 
Figure 1: Binding mode of Imatinib in Abl protein. 
 
Only the pyridine and pyrimidine rings occlude the region where the adenine ring of ATP 
normally binds. The rest of the compound penetrates into the hydrophobic core of the 
                                                           
[73] M.T. Weigel, I. Meinhold-Heerlein, D.O. Bauerschlag, C. Schem, M. Bauer, W. Jonat, N. Maass, C. 
Mundhenke, Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer 
cells via PDGFR β signaling Cancer Lett. 2009, 273, 70–79. 
[74] I.R. Radford, Imatinib Novartis, Curr. Opin. Invest. Drugs, 2002, 3, 492-499. 
[75] R.L. Jones, I.R. Judson, The development and application of Imatinib, Expert Opin. Drug Saf., 2005, 4, 183-
191. 
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kinase and wedges itself between the activation loop and the helix αC, freezing the kinase 
in its inactive conformation and preventing transphosphorilation (Figure 2) 
 
 
Figure 2: (A) Assembled hydrophobic spine of the active Abl kinase (PDB 2G2l). (B) Dismantled 
hydrophobic spine of the inactive Abl kinase (PDB 1OPJ). 
 
In total, the compound makes six hydrogen bonds with the protein, and the majority of 
contacts are mediated by Van der Waals interactions (Figure 3). 
 
 
Figure 3: The interactions between Abl protein and Imatinib. 
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The adenine group of ATP normally makes two hydrogen bonds with the backbone atoms 
of the peptide chain connecting the N- and C-lobes of kinase domains. The extracyclic 
amino group of ATP donates a hydrogen bond to the carbonyl oxygen of the residue 
corresponding to Glu-316 in Abl, and nitrogen N1 of the purine ring accepts a hydrogen 
bond from the amide nitrogen of residue Met-318. Many small molecules which inhibit  
the protein kinases are anchored to the kinase domain by a pair of hydrogen bonds that 
mimic those which formed from adenine. 
 
4.2  Synthesis of Imatinib 
Imatinib was synthesized for the first time in 1993 by Zimmermann[76] and coworkers, 
following the synthetic pathway represented in Scheme 1. This method involves the use 
of the toxic cyanamide for the synthesis of phenyl-guanidine derivatives 1. Furthermore, 
the enaminone 2 is obtained by a three-step synthesis, in one of which metallic sodium at 
low temperature is employed. 
 
 
 
Scheme 1: Zimmermann’s synthesis of imatinib. 
 
                                                           
[76] J. Zimmermann, E. Buchdunger, H. Mett, T. Meyer, N.B. Lydon, P. Traxler, Phenylamino-pyrimidine 
(PAP)-derivatives: a new classo of potent and highly selective PDGF-receptor autophosphorylation 
inhibitors Bioorg. Med. Chem. Lett. 1996, 11, 1221-1226. 
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Loiseleur[77] and coworkers described a process in which Imatinib is prepared by a 
reductive amination reaction of the methyl 4-formylbenzoate through a Pd/C catalyzed 
hydrogenation (Scheme 2).  
 
 
 
Scheme 2: Loiseleur’s synthesis of imatinib. 
 
A simplier and large-scale applicable pathway is described in Scheme 3[78] and includes the 
reaction of enaminone 3 with guanidine nitrate, which forms the corresponding 
pyrimidinyl amine, followed by the coupling reaction with o-bromo-p-nitro-toluene, using 
CuI as a catalyst and DMEDA as a ligand. This results in the formation of the key 
intermediate 5 that is reduced by N2H4
.H2O/FeCl3/C in an aqueous solvent.  
 
 
 
 
 
                                                           
[77] a) O. Loiseleur, D. Kaufmann, S. Abel, H.M. Buerger, M. Meisenbach, B. Schmitz, G. Sedelmeier, N-
Phenyl-2-pyrimidine-amine derivatives W. O. Patent 03/066613, 2003. b) Z. Szakacs, S. Beni, Z. Varga, 
L. Orfi, G. Keri, B. Noszal, Acid-Base profiling of Imatinib (Gleevec) and its fragments, J. Med. Chem. 
2005, 48, 249-255. 
[78] Y.F. Liu, Y.J. Bai, N. Han, J.P. Jiao, X.L. Gi, A facile total synthesis of Imatinib and its analogues Org. 
Process res. Dev. 2008, 12, 490-495. 
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Compound 6 is then condensed with 4-(chloromethyl)benzoyl chloride to provide compound 
7. Then, via an amination reaction using N-methyl piperazine, Imatinib is obtained.  
 
 
 Scheme 3: Liu synthesis of imatinib. 
   
N,N-Dimethylformamide dimethyl acetal (DMF-DMA) is very useful in organic synthesis as 
a formylating reagent. DMF-DMA is used in the synthesis of enaminones from active 
methylene compounds. Enaminones are useful intermediates in the formation and 
modification of many heterocyclic compounds. In general, enaminone formation is 
conducted in refluxing aromatic hydrocarbons. In this case, the enamination of 
acetylpyridine with DMF-DMA is conducted in xylene and provides enaminone 3 in 92.6 % 
yield. The following reaction with guanidine nitrate is processed in n-butanol for 10 h, to 
give pyrimidinyl amine 4 in 85.5 % yield. In contrast to Zimmermann’s route, in this 
synthetic pathway cyanamide is not involved. In order to obtain formation of the C-N 
coupling product, in the beginning an Ullmann reaction was used, but with the formation 
of the desired product 5 only in 5 % of yield. In recent years, the “classic” Ullmann 
reaction has been transformed into an “Ullmann-type” reaction, in which the use of 
copper salts, a base, and a ligand allow the coupling reaction to go smoothly in mild 
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conditions. The optimal reaction conditions are the use of CuI as catalyst, N,N-
dimethylethylenediamine as ligand, KI as accelerant, and K2CO3 as base, and the reaction 
is processed in dioxane at 100 °C for 20 h. Continuosly, the reduction of the nitro 
compound 5 can be achieved by several reagents in solution-phase reactions, but classical 
reactions with metals like Fe, Sn, Zn, or Al are complicated because of the difficult 
isolation of the product due to emulsions of metallic hydroxides. Fortunately, the 
reduction with hydrazine hydrate results in the formation of the desired amine 6 in 83% 
yield producing harmless byproducts such as nitrogen gas and water. The acylating 
reaction of compound 6 is proceeded in very good yield due to high activity of 4-
(chloromethyl)benzoyl chloride. Finally, the mixture of intermediate 7 and 1-
methylpiperazine was heated to reflux, maintained for 2 h and produced Imatinib base in 
91% yield.  
 
4.3  Synthesis of Imatinib 1,2,3-triazole-based analogues  
Because of the enormous success in treatment of CML-affected patients, in the last few 
years it was observed an increase in the research about Imatinib. On the base of 
bioisosterism of peptide bond and the triazole ring, as showed before in chapter 3.6 , we 
performed the synthesis of a 1,2,3-triazole analogue 8 based on Imatinib scaffold (Figure 
4). 
 
 
Figure 4: Imatinib and its 1,2,3-triazole analogue 8. 
 
The synthetic pathway we decided to follow is presented in Scheme 4. The synthesis 
proceeded with a convergent approach with a final key step based on a cycloaddition in 
Sharpless conditions (as show in paragraph 3.6.2) between azide 9 and alkyne 12 that 
lead only to the desired 1,2,3-triazole derivatives 1,4-disubstituited.  
 
149 
 
The first step is the synthesis of enaminone 3, obtained from the reaction of 3-
acetylpyridine with an excess (4 equivalents) of DMF-DMA in xylene at 140 °C. On the top 
of the flask, a soxhlet containg 4 Å molecular sieves has been put in order to catch MeOH 
molecules that are generated. 
 
 
Scheme 4: Synthesis of 1,2,3-thiazole 8. 
 
After a simple filtration, enaminone 3 was obtained in 81 % yield. Then compound 3 
reacted with guanidine nitrate and sodium hydroxide in n-butanol. After 4 hours the 
product, 4, was collected by filtration in 60 % yield. The following step consists in an 
“Ullmann-type” coupling between compound 4 and o-bromo-p-nitrotoluene. This 
reaction was performed in N2 atmosphere using CuI as a catalyst, DMEDA as a ligand and 
K2CO3 as a base in refluxing dioxane. After 15 hours the reaction was quenched with 
concentrated ammonia solution, then brine was added and extracted with AcOEt. The 
crude was purified by chromatographic column, and the nitro derivative 5 was obtained 
in 41 % yield. The reduction of the nitro group to the corresponding amine 6, achieved via 
a system of hydrazine-monohydrate/FeCl3/active carbon in MeOH and after 4 hours the 
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amine 6 was extracted in 95 % yield. Furthermore, amine 6 was converted in the 
corresponding azide. Firstly, diazonium salt was formed using NaNO2, after 30 min. Then, 
a solution of NaN3 in H2O was added and the reaction mixture was stirred at room 
temperature for 3 h. The desired product, 9, was produced in 81 % yield. Differently the 
synthesis of alkyne 12 proceeded starting from p-ethynyl benzaldehyde. This aldehyde 
was reducted to the corresponding benzyl alcohol 10 using NaBH4 in MeOH at -78 °C in 
order to avoid the reduction of the alkyne moiety (we observed this collateral reaction 
doing the reduction at 0 °C). The crude was purified by chromatographic column leading 
to the desired product 10 in 44 % yield. Alcohol 10 was then converted in the chloride 11 
in presence of an excess of SOCl2 and after chromatographic purification 11 was collected 
in 47 % yield. The reaction of 11 with N-methylpiperazine led to alkyne 12 in 75 % yield 
after chromatographic purification. Finally, azide 9 alkyne 12, through a cycloaddition 
reaction in Sharpless conditions lead only to the desired 1,2,3-triazole derivatives 1,4-
disubstituited 8. In order to give evidence that the 1,4 regioisomer was obtained, we 
recordered the 1H-NMR NOESY spectrum (400 MHz, CDCl3) as showed in Figure 5: 
 
 
 
Figure 5: 
1
H-NMR NOESY spectrum (400 MHz, CDCl3) of compound 8. 
 
151 
The H-12, that in both the regioisomers shows a coupling with H-13, only in the 1,4-
disubstituted triazole can show also a coupling with H-8 e H-9. 
 
4.4  Docking calculations on analogue 8 
In collaboration with Professor Maurizio Botta of the Università degli Studi di Siena 
docking calculations were carried out for analogue 8 on the inactive conformation of Abl. 
From these, it appeared that the binding mode of this analogue perfectly reflects the one 
of Imatinib and also the interactions are the same, making an exception for the hydrogen 
bond with E286, which is missing (Figure 6). Nevertheless, the interaction energy has a 
very similar value to that of Imatinib, which could mean also a similar activity. 
 
 
Figure 6: Doking of Imatinib (light blue) and its 1,2,3-triazole analogue 8 (yellow) in Abl protein. 
 
4.5  Synthesis of compound 8 analogues 
The good results of analogue 8 that brought to light, led us to go deeply in the studies of 
the interactions between these kind of compounds and abl protein. These supplementary 
modeling studies showed that the core of interactions reside in the central portion of the 
compound (Figure 7 in red). For this reason we studied the synthesis of analogues 13 in 
which pyridine ring is substituted with a phenyl ring and with the employment of 
different alkyne portions.  
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In addition the molecular modeling results showed that the two rings, pyridine end 
phenyl, are isosteric, but the presence of the nitrogen atom could be important for an 
optimal interaction with Abl (see Figure 6, M318), so this modification is certainly useful 
in order to make an exhaustive study about Imatinib binding site conformation. 
 
 
Figure 7: Compound 8) in red is highlighted the fundamental portion of the moleculefor the 
interaction with Abl. General structure 13) It is the scaffold of new analogues of 8. In blue are showed 
the portions replaced.  
 
All the compounds synthesized were obtained as the product of a cycloaddition reaction, 
in Sharpless conditions, between azide 18 and different alkynes. The portion of the 
molecule containing the azide moiety has remained unchanged in all the reactions and 
was synthesized following the synthetic pathway described in Scheme 5. 
 
 
 
Scheme 5: Synthesis of key intermediate 18. 
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The synthetic strategy is the same we used to prepare analogue 8 (see Scheme 4), except 
for the fact that, instead of starting from acetyl pyridine, in this case we started from 
acetophenone. In regard to alkyne moieties we employed five different compounds: 
three commercially available and two synthesized in our labs. Alkyne 19 was synthesized 
starting from 2,4-dichloro-benzaldehyde using Bestmann-Ohira reaction (see paragraph 
3.6.5 for the discussion about Bestmann-Ohira). 
 
 
 
The cycloaddition reaction in Sharpless condition of azide 18 and alkyne 19 led to the 
isolation, after chromatographic column, of triazole 20 in 44 % yield:  
 
 
 
 
In addition using azide 18 and alkyne 12 we synthesized 21, the corresponding compound 
of analogue 8 with the replacement of pyridine with phenyl moieties.  
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Three other cycloaddition reactions were performed of azide 18 employing three 
commercially available alkynes: 
- Methyl propiolate: the reaction mixture was stirred at 50 °C for 5 h, then the crude was 
purified by chromatographic column and triazole 22 was collected in 41% yield: 
 
 
 
 
- Dimethylamino propyne: the reaction mixture was stirred at room temperature for 30 
h. Then, after extraction, triazole 23 was obtained in 16% yield: 
 
 
 
 
- Phenyl acetylene: the reaction was performed using a large excess of alkyne (12 
equiv.). The reaction mixture was stirred at room temperature for 28 h and after 
chromatographic purification compound 24 was obtained in 19 % yield: 
 
 
 
 
 
 
155 
General summarizing scheme for the cycloaddition addition step in Sharpless conditions 
(in Table 1 are summarized the conditions for each reaction):   
 
 
 
 
Compound R Temp. (°C) Reaction time (h) Yield % 
20 
 
70 6 44 
21 
 
80 1,5 6 
22 
 
50 5 41 
23 N  r.t. 30 16 
24 
 
r.t. 28 19 
 
Table 1: Summary of different experimental datas employed in cycloaddition in Sharpless conditions. 
 
The values of yield are very far from what we could expected for such click reactions. This 
might be due to the structural complexity of the azide 13 and also to electronic factors 
depending on the substituents of the alkynes: in fact, it is known that alkynes substituted 
with electron withdrawing groups are the most reactive in this kind of reactions. Anyway, 
in the most cases the 1,2,3-triazoles were isolated without the necessity of a 
chromatographic purification.  
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4.6  Biological tests 
To assess the potency of our compounds, their effects on three Bcr-Abl-positive leukemia 
cell lines (K-562, MEG-01, KU-812) were evaluated in proliferation assays, in comparison 
to Imatinib (Gleevec®), which was used as the reference compound. 
 
Inhibition of proliferation 
The decrease in the viability of K-562, MEG-01 and KU-812 cells treated with the 
compounds for 72 hours was assessed using the Resazurin assay. Experiments performed 
to determine the in vitro effects of our compounds displayed a significant antiproliferative 
activity of compound 8. In fact, activity data were in the low micromolar range (Table 2). 
No similar good biological activity was found among the other compounds (20-24), that 
were tested only on K-562 cells. For biological profile in terms of activity toward cell lines, 
compound 8 was selected and submitted to further assays. 
 
Compound K-562 MEG-01 KU-812 
8 0,89 ± 0,003 10,97 ± 0,46 25,42 ± 1,24 
20 > 150 ND ND 
21 54,38 ± 2,08 ND ND 
22 > 100 ND ND 
23 24,4 ± 0,28 ND ND 
24 > 100 ND ND 
 
Table 2: IC50 anti-proliferative values (µM) on K-562, MEG-01, KU-812 cell lines. ND = Not 
determined. IC50 values are means ± SEM of series separate assays, each performed in triplicate. 
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Inhibition of Bcr-Abl phosphorylation 
With the aim of better understanding the antiproliferative activity of the new compound 
8 (FAO30) toward leukemia cells, we decided to check in each cell line a direct link 
between the antiproliferative effects of 8 and the inhibition of Bcr-Abl activity. As showed 
in Figure 8, after 3 hours we observed a significant reduction in the phosphorylation of all 
targets in the presence of 8 when compare to control. The dose dependent inhibition of 8 
is comparable to Imatinib (Gleevec®) effect.  
 
 
Figure 8: Compound 8 (FAO30), used at different concentration, reduces phosphorylation of Bcr-Abl 
in K-562, MEG-01 and in KU-812 incubated for 3 hours, in comparison to Gleevec® used as reference 
compound. Quantification was achieved by chemiluminescence and results represented as the 
percent of the phospho protein.  
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Inhibition of cdc25A expression 
Cell division cycle 25 (cdc25) phosphatases are key regulators of the cell cycle and its 
checkpoints. They are required to dephosphorylate and thus activate the Cdk-cyclin 
complexes that trigger progression through the various cell-cycle phases. Cdc25A is 
required for progression from G1 to the S phase and G2/M in cell cycle and have been 
showed to be overexpressed in a number of cancer cells.[79] For this reason, we examined 
the action of compound 8 (FAO30) on cdc25A expression. Figure 9 shows that 8 
significantly inhibited cdc25A mRNA level after 3 hours in K-562 cells and this inhibition 
was increased after 24 hours exposition in K-562 (Figure 9 A). A similar inhibitory effect at 
24 hours exposition was also observed in MEG-01 cells (Figure 9 B). Of notice, 8 result 
more active at 24 hours than Imatinib in the inhibitory effect on both cell lines.  
 
 
 
Figure 9: Compound 8 (FAO30) inhibits cdc25A expression at 3 and 24 hours in K-562 (A) and in MEG-
01 (B), in comparison to Gleevec® (Imatinib) used as reference compound. Both compounds were 
used at the concentration of 1µM. The results were obtained by qRT-PCR analysis.  
 
 
 
 
 
 
 
 
 
 
 
                                                           
[79] K. Kristjansdottir, J. Rudolph, Cdc25 Phosphatases and cancer, Chem. Biol. 2004, 11, 1043-1051.  
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4.7  Conclusion 
A convenient and versatile synthesis of a new collection of potential Bcr-Abl TK inhibitors 
based on a N-[2-methyl-5-(triazol-1-yl)phenyl]pyrimidin-2-amine scaffold was realized 
using Imatinib (Gleevec®) as inspiring compound.  
Biological evaluation confirmed the importance of the pyridine ring in the interaction of 
the compounds with the target. This is due to a hydrogen bond between the molecule 
and the M318 residue of the protein that is possible only if the pyridine ring is present.  
The evaluation demonstrated that compound 8 (FAO30) is able to inhibit the proliferation 
of three Bcr-Abl-positive leukemia cell lines (IC50 = 0.89 μM ± 0.003). 
The replacement of pyridine ring with phenyl resulted in the obtainment of unreactive 
compounds. We retain this information useful to confirm three-dimensional structure of 
the biological target.  
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4.8  Experimental details 
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4.8.1  Biology 
 
Cell culture 
Human Chronic Myeloid Leukemia (CML) K-562 cells in blast crisis[80], human CML MEG-01 
cell line in megakaryocytic blast crisis[81], and human CML KU-812[82] cell line in myeloid 
blast crisis were obtained from the American Type Culture Collection and were grown in 
RPMI 1640 medium (Euroclone, Devon, UK) containing 10% fetal bovine serum (FBS) or 
20% FBS for KU-812, and antibiotics (100 U/mL penicillin and 100 µg/mL streptomycin). 
The cultures were free of mycoplasma. The compounds were dissolved in DMSO and used 
at the indicated concentrations, same amount of DMSO was used for the control.  
 
Resazurin assay  
The Resazurin assay (Acros Organics, Geel, Belgium) was used to determinate cell 
proliferation[83]. Starved cells (1x104cells/well) were plated in 96 well plate in RPMI 
containing FBS, with or without different concentrations (0,05-150 µM) of the studied 
compounds. Resazurin was dissolved in sterile water and added to the wells, 6 hours 
before the term of 72 hours incubation, in amounts equal to 5% volume and at a 
concentration of 320 µM. The resazurin reduction was determined by measuring the 
fluorescence at 530 nm (excitation) and 590 nm (emission) wavelengths using FLUOstar 
Optima (BMG Labtech, Offenburg, Germany). Data analysis for IC50 calculations was 
performed with the L5W Data Analysis Package plug-in for Excel (Microsoft). Results are 
reported as mean ± SEM.  
 
Western blot analysis  
The inhibitory effect of compounds toward the phosphorylation of Bcr-Abl (Tyr245) and 
STAT-5 (Tyr694) was tested using a PathScan Multiplex Western Detection Kit (Cell 
Signaling Technology, Beverly, MA). This Kit was used to assay the inhibition of multiple 
proteins on membrane without stripping and reprobing.  
                                                           
[80] D. Hudig, M. Djobadze, D. Redelman, J. Mendelsohn, Active tumor cell resistance to human natural 
killer lymphocyte attack. Cancer Res. 1981, 41, 2803-2808.  
[81] M. Ogura, Y. Morishima, R. Ohno, Y. Kato, N. Hirabayashi, H. Nagura, H. Saito, Establishment of a novel 
human megakaryoblastic leukemia cell line, MEG-01, with positive Philadelphia chromosome. Blood 
1985 66, 1384-1392.  
[82] K. Kishi, A new leukemia cell line with Philadelphia chromosome characterized as basophil precursors, 
Leuk. Res. 1985, 9, 381-390.  
[83] M.K. McMillian, L. Li, J.B. Parker, L. Patel, Z. Zhong, J.W. Gunnett, W.J. Powers, M.D. Johnson, An 
improved resazurin-based cytotoxicity assay for hepatic cells. Cell Biol. Toxicol 2002, 18, 157-173.  
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The inhibitory effect toward the phosphorilation of Src (Tyr416) was assessed using 
specific antibody (Cell signaling Technology). Cells were cultured at a concentration of 
1x106cells/well and challenged with the compound (FAO30 50µM, 10µM, 1µM and 
reference compound Gleevec 1µM). After 3 hours, cells were harvested and lysed in an 
appropriate buffer containing 1% Triton X-100. Filters were additionally reprobed with β-
actin (control loading, Cell Signaling Technology). The proapoptic activity of the selected 
compounds was also tested, using immunoblot analysis with Poly-ADP-Ribose-Polymerase 
(PARP)-specific antibody that reveals both the uncleaved (113 kDa) and cleaved (89 kDa) 
forms of PARP (Cell Signaling Technology). Cell lines were cultured at a concentration of 
14x105cells/well and challenged with different concentrations of the studied compound 
or control compound for 72 hours. Proteins were quantitated by BCA method (Pierce, 
Rockford, IL). Equal amounts of total cellular protein were resolved by SDS-
polyacrylamide gel electrophoresis, transferred to PVDF filters, and subjected to 
immunoblot. Non saturated, immunoreactive bands were detected with a CCD camera 
gel documentation system (ChemiDocXRS, Bio-Rad Laboratories, Hercules, CA) and than 
quantitated with Quantity One (Bio-Rad Laboratories).  
165 
4.8.2  Chemistry 
 
General 
All non-aqueous reactions were performed under inert atmosphere with dry, freshly 
distilled solvents using standard procedures. Drying of organic extracts during the work-
up of reactions was performed over anhydrous Na2SO4 or MgSO4. Evaporation of solvents 
was accomplished with a rotatory evaporator. Thin-layer chromatography (TLC) was 
performed on Merck precoated 60F254 plates. Reactions were monitored by TLC on silica 
gel, with detection by UV light (254 nm) or by charring with 1 % permanganate solution. 
Flash chromatography was performed using Silica gel (240–400 mesh, Merck). NMR 
spectra were recorded with Brucker 300 and 400 MHz spectrometers using chloroform-d 
(CDCl3), dimethylsolfoxide-d6 (DMSO-d6) and methanol-d4 (CD3OD). Chemical shifts are 
reported in parts per million (δ) downfield from tetramethylsilane (TMS). EI mass spectra 
were recorded at an ionizing voltage of 6Kev on a VG 70-70 EQ. ESI mass spectra were 
recorded on FT-ICR APEXII (Bruker Daltonics). All reactions were carried out in dry 
solvents. Specific rotations were misured by a polarimeter “P-1030 Jasco” with 10 cm of 
Optical path cells and 1 ml of capacity. The mesures were done between 18 and 22 °C at 
589 nm Wavelength (Na lamp). The melting point was determined  by “Digital Melting 
Point IA9100 series - Electrothermal”.  
166 
(E)-3-(dimethylamino)-1-(pyridine-3-yl)prop-2-en-1-one - (3) 
Org. Process Res. Dev. 2008, 12, 490-495. 
 
 
 
 
A solution of 3-acetyl-pyridine (6.06 g, 50 mmol) and N,N-dimethylformamide 
dimethylacetal (11.90 g, 100 mmol) in xylene (50 ml) was refluxed  at 140 °C for 20 h. The 
solvent was removed in vacuo and hexane (200 ml) was added with consequent 
formation of yellow crystals. After complete crystallization, the product 3 was collected 
by filtration in 81 % yield. No further purification was needed. 
 
1H-NMR (CDCl3, 300 MHz): δ 9.02 (1H, s), 8.61 (1H, dd, J = 5.3, 2.7 Hz), 8.15 (1H, dd, J = 8.0, 
2.7 Hz), 7.80 (1H, d, J = 12 Hz), 7.31 (1H, dd, J = 8.0, 5.3 Hz), 5.67 (1H, d), 3.16 (3H, s), 2.94 
(3H, s).  
13C-NMR (CDCl3, 300 MHz): δ 186.30, 154.68, 151.38, 148.85, 135.62, 135.03, 123.25, 
91.79, 45.18, 37.35. 
167 
4-(pyridine-3-yl)pyrimidin-2-amine - (4) 
Org. Process Res. Dev. 2008, 12, 490-495. 
 
 
 
 
Guanidine nitrate (4.92 g, 40.3 mmol) and sodium hydroxide (1.25 g, 40.3 mmol) were 
added to a solution of Compound 3 (7.10 g, 40.3 mmol) in n-BuOH (45 ml). The reaction 
mixture was refluxed at 120 °C for 4 h, then cooled to room temperature. The precipitate 
was collected by filtration and washed with water (70 ml), then dried in the oven at 75-80 
°C. No further purification was needed and the desired product 4 was obtained as white 
crystals in 60 % yield. 
 
1H-NMR (CDCl3, 300 MHz): δ 9.21 (1H, d, J = 2.6 Hz), 8.63 (1H, d, J = 3.3 Hz), 8.47 (1H, dt, J 
= 8.3, 1.7 Hz), 8.33 (1H, d, J = 5.9 Hz), 7.55 (1H, dd, J = 8.3, 3.3 Hz), 7.19 (1H, d, J = 5.9 Hz), 
4.86 (1H, s). 
13C-NMR (CDCl3, 300 MHz): δ 160.4, 161.1, 154.4, 147.9, 147.5, 134.0, 133.0, 124.0, 103.3. 
168 
N-(2-methyl-5-nitrophenyl)-4-(pyridin-3-yl)pyrimidin-2-amine - (5) 
Org. Process Res. Dev. 2008, 12, 490-495. 
 
 
 
 
To a solution of Compound 4 (0.19 g, 1.1 mmol) in dry dioxane (5 ml) under nitrogen 
atmosphere, o-bromo-p-nitrotoluene (0.22 g, 1.0 mmol), CuI (0.05 g, 0.25 mmol), DMEDA 
(0.270 ml, 0.25 mmol),  and K2CO3 (0.28 g, 2.0 mmol) were added and the reaction 
mixture was refluxed at 120 °C for 15 h, then cooled to room temperature. Concentrated 
ammonia (4 ml) and brine (20 ml) were added and extracted with ethyl acetate. The 
organic layers were dried over Na2SO4 and concentrated in vacuo. The crude was purified 
by column chromatography on silica gel (MeOH:CH2Cl2 1:80) to give the desired product 5 
as yellowish powder in 40 % yield. 
 
1H-NMR (CDCl3, 300 MHz): δ 9.47 (1H, d, J = 1.8 Hz), 9.28 (1H, bs), 8.76 (1H, d, J = 4.3 Hz), 
8.59 (1H, d, J = 6.5 Hz), 7.87 (1H, dd, J = 7.2, 1.8 Hz), 7.54 (1H, dd, J = 7.2, 4.3 Hz), 7.38 (1H, 
s), 7.32 (1H, d, J = 6.5 Hz), 7.23 (1H, bs), 2.44 (3H, s). 
13C-NMR (CDCl3, 400 MHz): δ 159.32, 158.76, 147.19, 146.94, 144.44, 139.02, 137.65, 
134.58, 132.09, 131.03, 125.68, 118.14, 115.48, 109.03, 29.71, 18.42. 
169 
6-Methyl-N-(4-(pyridine-3-yl)pyrimidin-2-yl)benzene-1,3-diamine - (6) 
Org. Process Res. Dev. 2008, 12, 490-495. 
 
 
 
 
To a solution of compound 5 (0.300 g, 0.98 mmol) in MeOH (10 ml) hydrazine 
monohydrate (0.223 ml, 3.91 mmol), FeCl3 (0.003 g, 0.02 mmol) and active carbon (0.001 
g) were added and the reaction mixture was refluxed at 80 °C for 6 h. The solvent was 
removed in vacuo, water (30 ml) was added and extracted with CH2Cl2 (3x10 ml). The 
organic layers were dried over Na2SO4 and concentrated in vacuo. No further purification 
was needed and the desired product 6 was collected as yellow powder in 99% yield. 
 
1H-NMR (DMSO-d6, 300 MHz): δ 9.22 (1H, s), 8.67 (1H, d, J = 4.4 Hz), 8.63 (1H, s), 8.44 (1H, 
d, J = 5.1 Hz), 8.39 (1H, d, J = 8.0 Hz), 7.51 (1H, dd, J = 7.9, 4.4 Hz), 6.85 (1H, d, J = 8.0 Hz), 
6.77 (1H, d, J = 1.4 Hz), 6.32 (1H, dd, J = 8.0, 2.0 Hz), 4.80 (2H, s), 2.04 (3H, s). 
13C-NMR (DMSO-d6, 300 MHz): δ 168.6, 161.1, 154.4, 147.9, 147.8, 147.5, 144.8, 134.0, 
133.0, 130.6, 124.0, 119.0, 105.1, 103.3, 102.6, 17.6. 
170 
N-(2-methyl-5-(4-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-1,2,3-triazol-1-
yl)phenyl)-4-(pyridine-3-yl)pyrimidin-2-amine - (8) 
 
 
 
 
To a solution of compound 9 (0.07 g, 0.23 mmol) and compound 12 (0.05 g, 0.23 mmol) in 
H2O:t-BuOH 1:1 (5 ml) sodium ascorbate (0.004 g, 0.02 mmol) and copper(II)sulfate 
pentahydrate (0.001 g) were added and the reaction mixture was stirred at room 
temperature for 24 h. The reaction mixture was filtered and the solid was washed with 
water and dried in the oven at 80 °C. The crude was purified by column chromatography 
on silica gel (MeOH:CH2Cl2  1:10) and the desired product 8 was obtained as a yellow solid 
in 76 % yield. 
 
1H-NMR (CDCl3, 400 MHz): δ 9.32 (1H, s), 9.05 (1H, s), 8.88 (1H, s), 8.58 ( 1H, d, J = 5.0 Hz), 
9.39 (1H, d, J = 7.9 Hz), 8.22 (1H, s), 7.90 (2H, d, J = 7.8 Hz), 7.51 (1H, m), 7.44 (3H, d, J = 
7.8 Hz), 7.38 (1H, d, J = 8.2 Hz), 7.29 (1H, d, J = 5.3 Hz), 3.60 (2H, s), 2.63 (8H, s), 2.42 (3H, 
s), 2.36 (3H, s). 
13C-NMR (CDCl3, 400 MHz): δ 163.44, 160.94, 159.84, 152.41, 149.16, 148.80, 139.43, 
138.94, 136.48, 135.32, 133.19, 131.94, 130.27 (2C), 130.08, 127.86, 126.49 (2C), 124.48, 
118.07, 115.00, 113.14, 109.58, 63.22, 55.61 (2C), 53.22 (2C), 46.25, 18.34. 
EIMS 517 [M]+ 
171 
N-(5-azido-2-methylphenyl)-4-(pyridine-3-yl)pyrimidin-2-amine - (9) 
 
 
 
 
Compound 6 (0.29 g, 1.06 mmol) was suspended in water (15 ml) and was cooled to 0 °C, 
then concentrated H2SO4 was added until compound 19 was completely dissolved. A 
solution of sodium nitrite (0.11 g, 1.59 mmol) in water (2 ml) was added and the reaction 
mixture was stirred at 0 °C for 30 min. Then a solution of sodium azide (0.14 g, 2.12 
mmol) in water (2 ml) was added at 0 °C and the reaction mixture was stirred at room 
temperature for 3 h. Potassium carbonate was added until pH 8 and the reaction mixture 
was extracted with CH2Cl2. The organic layers were dried over Na2SO4 and concentrated in 
vacuo. No further purification was needed and the desired product 9 were collected as 
orange crystals in 81 % yield. 
 
1H-NMR (CDCl3, 300 MHz): δ 9.12 (1H, s), 8.79 (1H, d, J = 4.5 Hz), 8.62 (1H, d, J = 7.8 Hz), 
8.54 (1H, d, J = 5.0 Hz), 8.06 (1H, s), 7.55-7.67 (2H, m), 7.27 (1H, s), 7.19 (1H, d, J = 8.1 Hz), 
6.37 (1H, dd, J = 8.1, 2.3 Hz), 2.30 (3H, s).  
13C-NMR (CDCl3, 400 MHz): δ 163.32, 160.99, 159.71, 152.20, 149.07, 139.38, 139.13, 
135.25, 133.23, 132.03, 124.36, 114.29, 111.62, 109.28, 30.32, 18.13. 
EIMS 303 [M]+
172 
(4-ethynylphenyl) methanol - (10) 
 
 
 
 
A solution of 4-ethynylbenzaldehyde (0.20 g, 1.5 mmol) in MeOH (10 ml) was cooled to -
78 °C and sodium borohydride (0.02 g, 0.4 mmol) was added in little amounts. The 
reaction mixture was stirred at -78°C for 30 min and then warmed to room temperature. 
Hydrochloric acid 1N was added in order to quench sodium borohydride not reacted and 
the solvent was removed in vacuo. Water (50 ml) was added and extracted with ethyl 
acetate (3x15 ml). The organic layers were dried over Na2SO4 and concentrated in vacuo. 
The crude was purified by column chromatography on silica gel (AcOEt:Hex 3:7) and the 
desired product 10 were obtained as a white solid in 44 % yield. 
 
1H-NMR (CDCl3, 300 MHz): δ 7.47 (2H, d, J = 8,4 Hz), 7.33 (2H, d, J = 8.4 Hz), 4.57 (2H, s), 
3.09 (1H, s). 
EIMS 132 [M]+
173 
1-(chloromethyl)-4-ethynylbenzene - (11) 
 
 
 
 
To a solution of compound 10 (0.09 g, 0.7 mmol) in CH2Cl2 (2 ml) thionyl chloride (2 ml) 
was added and the reaction mixture was refluxed at 60 °C for 4 h. Then the volatiles were 
removed in vacuo and the crude was purified by column chromatography on silica gel 
(Hex). The desired product 11 was obtained as a yellow oil in 47 % yield. 
 
1H-NMR (CDCl3, 300 MHz): δ 7.42 (2H, d, J = 8.3 Hz), 7.26 (2H, d, J = 8.3Hz), 3.49 (2H, s), 
3.04 (1H, s), 2.49 (8H, bs), 2.31 (3H, s). 
EIMS 150 [M]+
174 
1-(4-ethynylbenzyl)-4-methylpiperazine - (12) 
 
 
 
 
A solution of compound 11 (0.05 g, 0.3 mmol) and N-methylpiperazine was refluxed at 
140 °C for 40 min. Water (30 ml) was added and extracted with CH2Cl2 (3x10 ml). The 
organic layers were dried over Na2SO4 and concentrated in vacuo. The crude was purified 
by column chromatography on silica gel (CH2Cl2:MeOH 20:1) and the desired product 12 
was obtained as a colourless oil in 75 % yield. 
 
1H-NMR (CDCl3, 300 MHz): δ 7.42 (2H, d, J = 8.3 Hz), 7.26 (2H, d, J = 8.3Hz), 3.49 (2H, s), 
3.04 (1H, s), 2.49 (8H, bs), 2.31 (3H, s). 
EIMS 214 [M]+
175 
(E)-3-(dimethylamino)-1-phenylprop-2-en-1-one - (14) 
Org. Process Res. Dev. 2008, 12, 490-495. 
 
 
 
 
A solution of acetophenone (3.00 g, 25 mmol) and N,N-dimethylformamide 
dimethylacetal (11.90 g, 100 mmol) in xylene (50 ml) was refluxed  at 180 °C for 11 h. The 
solvent was removed in vacuo and hexane (200 ml) was added with consequent 
formation of yellow crystals. After complete crystallization, the product was collected by 
filtration in 32 % yield. No further purification was needed. 
 
1H-NMR (CDCl3, 300 MHz): δ 7.88 (2H, d, J = 6.3 Hz), 7.79 (1H, d, J = 12.4 Hz), 7.46-7.36 
(3H, m), 3.14 (3H, bs), 2.92 (3H, bs). 
176 
4-phenylpyrimidin-2-amine - (15) 
Org. Process Res. Dev. 2008, 12, 490-495. 
 
 
 
 
Guanidine nitrate (0.87 g, 7.1 mmol) and sodium hydroxide (0.22 g, 7.1 mmol) were 
added to a solution of compound 14 (1.26 g, 7.1 mmol) in n-BuOH (70 ml). The reaction 
mixture was refluxed at 130 °C for 15 h, then cooled to room temperature. The 
precipitate was collected by filtration, washed with water (70 ml) and dried in the oven at 
75-80 °C. No further purification was needed and the desired product 15 was obtained as 
white crystals in 49 % yield. 
 
1H-NMR (CDCl3, 300 MHz): δ 8.30 (1H, d, J = 5.6 Hz), 8.00-7.97 (2H, m), 7.48-7.46 (3H, m), 
7.04 (1H, d, J = 5.6 Hz), 5.27 (2H, bs). 
177 
N-(2-methyl-5-nitrophenyl)-4-phenylpyrimidin-2-amine - (16) 
Org. Process Res. Dev. 2008, 12, 490-495. 
 
 
 
 
To a solution of compound 15 (0.89 g, 5.2 mmol) in dry dioxane (23 ml) under nitrogen 
atmosphere, o-Bromo-p-nitro toluene (1.02 g, 4.7 mmol), CuI (0.25 g, 1.3 mmol), DMEDA 
(0.14 ml, 1.3 mmol),  and K2CO3 (1.44 g, 10.5 mmol) were added and the reaction mixture 
was refluxed at 120 °C for 15 h, then cooled to room temperature. Concentrated 
ammonia (12 ml) and brine (60 ml) were added and extracted with ethyl acetate. The 
organic layers were dried over Na2SO4 and concentrated in vacuo. The crude was purified 
by column chromatography on silica gel (AcOEt:Hex 1:1) to give the desired product 16 as 
yellowish powder in 31 % yield. 
 
1H-NMR (DMSO-d6, 300 MHz): δ 9.16 (1H, s), 8.89 (1H, d, J = 2.6 Hz), 8.60 (1H, d, J = 5.0 
Hz), 8.20-8.17 (2H, m), 7.92-7.89 (1H, m), 7.56-7.51 (5H, m), 4.46 (3H, s). 
178 
6-Methyl-N-(4-phenylpyrimidin-2-yl)benzene-1,3-diamine - (17) 
Org. Process Res. Dev. 2008, 12, 490-495. 
 
 
 
 
To a solution of compound 16 (0.49 g, 1.6 mmol) in MeOH (20 ml), hydrazine 
monohydrate (2.00 g, 25.6 mmol), FeCl3 (0.005 g, 0.03 mmol) and active carbon (0.01 g) 
were added and the reaction mixture was refluxed at 100 °C for 4 h. The solvent was 
removed in vacuo, water (100 ml) was added and extracted with CH2Cl2 (3x30 ml). The 
organic layers were dried over Na2SO4 and concentrated in vacuo. No further purification 
was needed and the desired product 17 was collected as yellow powder in 93 % yield. 
 
1H-NMR (CDCl3, 300 MHz): δ 8.41 (1H, d, J = 5.0 Hz), 8.06-8.02 (2H, m), 7.65 (1H, d, J = 2.3 
Hz), 7.52-7.48 (3H, m), 7.41 (1H, bs), 7.14 (1H, d, J = 5.8 Hz), 7.00 (1H, d, J = 8.0 Hz), 6.46 
(1H, dd, J = 7.9, 2.1 Hz), 4.0-3.1 (2H, bs), 2.26 (3H, s). 
179 
N-(5-azido-2-methylphenyl)-4-phenylpyrimidin-2-amine - (18) 
 
 
 
 
Compound 17 (0.41 g, 1.5 mmol) was suspended in water (70 ml) and cooled to 0 °C, then 
concentrated H2SO4 was added until compound 17 was completely dissolved. A solution 
of sodium nitrite (0.51 g, 2.2 mmol) in water (9 ml) was added and the reaction mixture 
was stirred at 0°C for 30 min. Then a solution of sodium azide (0.19 g, 2.9 mmol) in water 
(9 ml) was added at 0 °C and the reaction mixture was stirred at room temperature for 3 
h. Potassium carbonate was added until pH=8 and the reaction mixture was extracted 
with CH2Cl2 (4x30 ml). The organic layers were dried over Na2SO4 and concentrated in 
vacuo. No further purification was needed and the desired product 18 was collected as 
orange crystals in 92 % yield. 
 
1H-NMR (CDCl3, 300 MHz): δ 8.46 (2H, d, J = 5.2 Hz), 8.32 (1H, d, J = 2.1 Hz), 8.10-8.05 (2H, 
m), 7.51-7.49 (2H, m), 7.21-7.13 (3H, m), 6.64 (1H, dd, J = 7.9 Hz, J = 2.7 Hz), 2.33 (3H, s). 
EIMS 302 [M]+
180 
2,4-dichloro-ethynylbenzene - (19) 
 
 
 
 
A solution of 2,4-dichloro-benzaldehyde (0.10 g, 0.6 mmol) in dry MeOH (20 ml) was 
cooled to 0°C and then potassium carbonate (0.16 g, 1.2 mmol) and dimethyl-1-diazo-2-
oxopropylphosphonate (0.21 g, 0.7 mmol) were added. The reaction mixture was stirred 
at room temperature for 20 h. The solvent was removed in vacuo, saturated NaHCO3 (70 
ml) was added and extracted with ethyl acetate (3x20 ml). The organic layers were dried 
over Na2SO4 and the solvent was removed in vacuo. The crude was purified by column 
chromatography on silica gel (AcOEt:Hex 1:1) and the desired product 19 was obtained as 
a white solid in 41 % yield. 
 
1H-NMR (CDCl3, 300 MHz): δ 7.46-7.42 (2H, m), 7.20 (1H, dd, J = 8.6, 1.7 Hz), 3.39 (1H, s). 
EIMS 170 [M]+
181 
N-[2-methyl-5-(4-(2,4-dichlorophenyl)-1H-1,2,3-triazol-1-yl)phenyl]-4-phenylpyrimidin-2-
amine - (20) 
 
 
 
 
To a solution of compound 18 (0.05 g, 0.16 mmol) and 2,4-dichloro-ethynylbenzene 19 
(0.04 mg, 2.4 mmol) in H2O:tBuOH 1:1 (4 ml) sodium ascorbate (0.003 g, 0.016 mmol) and 
copper(II)sulfate pentahydrate (0.001 g) were added and the reaction mixture was stirred 
at 70 °C for 6 h. The solvent was removed in vacuo, water (50 ml) was added and 
extracted with CH2Cl2 (4x20 ml). The organic layers were dried over Na2SO4 and 
concentrated in vacuo. The crude was purified by column chromatography on silica gel 
(AcOEt:Hex 2:3) and the desired product 20 was obtained as a yellow solid in 44 % yield. 
 
1H-NMR (CDCl3, 400 MHz): δ 9.07 (1H, d, J = 2.1 Hz), 8.62 (1H, s), 8.53 (1H, d, J = 5.1 Hz), 
8.33 (1H, d, J = 8.5 Hz), 8.14-8.16 (2H, m), 7.51-7.85 (4H, m), 7.45 (1H, dd, J = 8.1, 2.1 Hz), 
7.42 (1H, dd, J = 8.5, 2.1 Hz), 7.39 (1H, d, J = 8.18 Hz), 7.26-7.28 (2H, m), 2.49 (3H, s). 
13C-NMR (CDCl3, 400 MHz): δ 165.36, 159.90, 158.44, 143.56, 138.98, 136.68, 135.62, 
134.29, 131.78, 131.31, 131.15, 130.75, 129.98, 129.03 (2C), 127.87, 127.64, 127.21 (2C), 
121.23, 114.38, 112.35, 109.13, 29.70, 17.86.  
HR-EIMS Anal. Calcd for [C25H18Cl2N6]
+ 472.0970, Found 472.0972. 
182 
N-(2-methyl-5-(4-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-1,2,3-triazol-1-yl)phenyl)-4-
phenylpyrimidin-2-amine - (21) 
 
 
 
 
To a solution of compound 18 (0.02 g, 0.07 mmol) and compound 12 (0.014 g, 0.07 mmol) 
in H2O:tBuOH 1:1 (2.5 ml) sodium ascorbate (0.002 g, 0.007 mmol) and copper(II)sulfate 
pentahydrate (0.001 g) were added and the reaction mixture was stirred at 80 °C for 1.5 
h. The solvent was removed in vacuo, water (10 ml) and brine (10 ml) were added and 
extracted with DCM (5x5 ml). The organic layers were dried over Na2SO4 and 
concentrated in vacuo. The crude was purified by column chromatography on silica gel 
(AcOEt:Hex 1:2) and the desired product 21 was obtained as a yellow powder in 6 % yield. 
 
1H-NMR (CDCl3, 300 MHz): δ 9.08 (1H, d, J = 2.0 Hz), 8.54 (1H, bs), 8.21 (1H, s), 8.12-8.15 
(2H, m), 7.85 (2H, d, J = 7.8 Hz), 7.51-7.53 (3H, m), 7.34-7.48 (5H, m), 7.16 (1H, bs), 3.63 
(2H, s), 2.77 (8H, bs), 2.56 (3H, s), 2.44 (3H, s). 
EIMS 516 [M]+
183 
Methyl 1-(4-methyl-3-(4-phenylpyrimidin-2-ylamino)phenyl)-1H-1,2,3-triazole-4-
carboxylate - (22) 
 
 
 
 
To a solution of compound 18 (0.050 g, 0.16 mmol) and methyl propiolate (0.015 ml, 0.16 
mmol) in H2O:tBuOH 1:1 (3 ml) sodium ascorbate (0.003 g, 0.016 mmol) and 
copper(II)sulfate pentahydrate (0.001 g) were added and the reaction mixture was stirred 
at 50 °C for 5 h. The solvent was removed in vacuo, water (30 ml) was added and 
extracted with DCM (4x10 ml). The organic layers were dried over Na2SO4 and 
concentrated in vacuo. The crude was purified by column chromatography on silica gel 
(AcOEt:Hex 1:1) and the desired product 22 was obtained as an orange solid in 41 % yield. 
 
1H-NMR (CDCl3, 400 MHz): δ 9.14 (1H, bs), 8.58 (1H, s), 8.51 (1H, d, J = 5.1 Hz), 8.13-8.15 
(2H, m), 7.53-7.60 (3H, m), 7.40 (1H, dd, J = 8.3, 1.9 Hz), 7.36 (1H, d, J = 8.3 Hz), 7.31 (1H, 
bs), 7.26-7.28 (2H, m), 4.03 (3H, s), 2.46 (3H, s). 
13C-NMR (CDCl3, 400 MHz): δ 165.97, 161.83, 160.37, 159.03, 141.00, 139.80, 137.22, 
135.68, 132.03, 131.90, 129.73(2C), 127.97, 127.85 (2C), 126.15, 114.71, 112.52, 109.82. 
HR-EIMS Anal. Calcd for [C21H18N6O2]
+ 386.1491, Found 386.1492. 
184 
N-[2-methyl-5-(4-((dimethylamino)methyl)-1H-1,2,3-triazol-1-yl)phenyl]-4-
phenylpyrimidin-2-amine - (23) 
 
 
 
 
To a solution of compound 18 (0.050 g, 0.16 mmol) and 3-dimethylamino-1-propyne 
(0.018 ml, 0.16 mmol) in H2O:tBuOH 1:1 (3 ml) sodium ascorbate (0.003 g, 0.016 mmol) 
and copper(II)sulfate pentahydrate (0.001 g) were added and the reaction mixture was 
stirred at room temperature for 30 h. The solvent was removed in vacuo, water (30 ml) 
was added and extracted with CH2Cl2 (4x10 ml). The organic layers were dried over 
Na2SO4 and concentrated in vacuo. No further purification was needed and the desired 
product 23 was obtained as yellow solid in 16 % yield. 
 
1H-NMR (CDCl3, 400 MHz): δ 9.06 (1H, d, J = 1.8 Hz), 8.58 (1H, bs), 8.31 (1H, s), 8.13-8.15 
(2H, m), 7.52-7.56 (3H, m), 7.40 (1H, dd, J = 8.2, 1.8 Hz), 7.34 (1H, d, J = 8.2 Hz), 7.18 (1H, 
bs), 3.99 (2H, bs), 2.55 (6H, bs), 2.45 (3H, s). 
HR-EIMS Anal. Calcd for [C22H23N7]
+ 385.2015; Found 385.2005. 
185 
N-[2-methyl-5-(4-phenyl-1H-1,2,3-triazol-1-yl)phenyl]-4-phenylpyrimidin-2-amine - (24) 
 
 
 
 
To a solution of compound 19 (0.050 g, 0.16 mmol) and phenylacetylene (0.260 ml, 2,4 
mmol) in H2O:tBuOH 1:1 (3.5 ml) sodium ascorbate (0.003 g, 0.016 mmol) and 
copper(II)sulfate pentahydrate (0.001 g) were added and the reaction mixture was stirred 
at room temperature for 28 h. The solvent was removed in vacuo, water (60 ml) was 
added and extracted with CH2Cl2 (4x20 ml). The organic layers were dried over Na2SO4 
and concentrated in vacuo. The crude was purified by column chromatography on silica 
gel (AcOEt:Hex 1:2) and the desired product 24 was obtained as yellow solid in 19 % yield. 
 
1H-NMR (CDCl3, 400 MHz): δ 9.10 (1H, d, J = 2.1 Hz), 8.53 (1H, d, J = 5.2 Hz), 8.25 (1H, s), 
8.14-8.17 (2H, m), 7.92 (2H, dd, J = 8.4, 1.3 Hz), 7.53-7.56 (3H, m), 7.46-7.50 (3H, m), 7.36-
7.41 (3H, m), 7.26 (1H, d, J = 5.2 Hz), 2.47 (3H, s). 
13C-NMR (CDCl3, 400 MHz): δ 166.04, 160.44, 158.90, 148.85, 139.52, 137.43, 136.40, 
131.96, 11.83, 131.17, 129.70 (2C), 129.51 (2C), 128.94, 127.92 (2C), 127.52, 126.53, 
118.25, 114.82, 112.64, 109.68, 18.46. 
HR-EIMS Anal. Calcd for [C25H20N6]
+ 404.1749; Found 404.1763. 
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A solution of NaN3 (0.341 g, 5.25 mmol) in acetone (15 ml) and H2O (15 ml) was added 
TsCl (1.00 g, 5.25 mmol). The reaction mixture was stirred at 0 °C for 2 h. Acetone was 
evaporated, the reaction mixture was extracted with diethyl ether, and the organic phase 
was dried over Na2SO4. Evaporation of solvent gave tosyl azide (0.972 g, yield 94 %) as a 
colourless oil.  
 
1H NMR (CDCl3, 300 MHz): δ 7.75 (2H, d, J = 8.1 Hz), 7.33 (2H, d, J = 8.1 Hz), 2.39 (3H, s).  
 
A solution of NaH (80 % dispersion in mineral oil and washed with hexane, 0.150 g, 4.93 
mmol)  in anhydrous THF (20 ml) was cooled to 0 °C under nitrogen. Dimethyl(2-
oxopropyl)phosphonate (0.744 g, 4.48 mmol) in anhydrous THF (10 ml) was added 
dropwise in 20 min. The solution was stirred at 0 °C for 30 min. A solution of Tosyl azide 
(0.972 g, 4.93 mmol) in anhydrous THF (10 ml) was then added in one portion and the 
resulting mixture was stirred at 0 °C for 10 min. The reaction mixture was quickly passed 
through a short column (silica, AcOEt) and the crude mixture was purified by flash 
chromatography (AcOEt) to give dimethyl(1-diazo-2-oxopropyl)phosphonate 35 (0.781 g, 
yield 91 %) as a colourless oil.  
 
1H NMR (CDCl3, 300 MHz): δ 3.75 (3H, s), 3.71 (3H, s), 2.15 (3H, s).  
13C NMR (CHCl3, 75 MHz): δ 189.7, 115.6, 53.6, 53.5, 27.1.  
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